```
=> fil reg
FILE 'REGISTRY' ENTERED AT 13:08:12 ON 11 FEB 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   10 FEB 2003  HIGHEST RN 488699-93-0
DICTIONARY FILE UPDATES:  10 FEB 2003  HIGHEST RN 488699-93-0

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available.  See HELP
PROPERTIES for more information.  See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> d sta que l7
L5                STR
```




```
REP G1=(0-1) AK
NODE ATTRIBUTES:
NSPEC   IS RC     AT  19
CONNECT IS M1  RC AT  10
CONNECT IS M1  RC AT  14
CONNECT IS M1  RC AT  19
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC   2
NUMBER OF NODES IS  16

STEREO ATTRIBUTES: NONE
L7          146 SEA FILE=REGISTRY CSS FUL L5

100.0% PROCESSED   2387 ITERATIONS                    146 ANSWERS
SEARCH TIME: 00.00.02


=> d his l7-

     (FILE 'REGISTRY' ENTERED AT 12:58:36 ON 11 FEB 2003)
```

```
L7          146 S L5 CSS FUL
                SAV L7 GERSTL893/A

     FILE 'HCAOLD' ENTERED AT 13:03:21 ON 11 FEB 2003
L8            0 S L7

     FILE 'HCAPLUS' ENTERED AT 13:03:29 ON 11 FEB 2003
L9           15 S L7
L10           6 S L9 AND (BARBER ? OR COOK ? OR MAW ? OR PRYDE ? OR STOBIE ?)/A
L11           8 S L9 AND PFIZ?/PA,CS
L12           8 S L10,L11
L13           9 S L9 AND ?ENDOPEPTIDASE?
L14           9 S L9 AND ?ENDOPEPTIDASE?(L)NEUTRAL
L15           9 S L13,L14

     FILE 'REGISTRY' ENTERED AT 13:05:41 ON 11 FEB 2003
L16           1 S 82707-54-8

     FILE 'HCAPLUS' ENTERED AT 13:06:42 ON 11 FEB 2003
L17        1908 S L16
L18        1688 S NEPRILYSIN OR ENKEPHALINASE OR VASOPEPTIDASE OR ATRIOPEPTIDAS
L19          10 S L9 AND L17,L18
L20          10 S L15,L19
L21          15 S L9,L20

     FILE 'USPATFULL, USPAT2' ENTERED AT 13:07:53 ON 11 FEB 2003
L22           8 S L7

     FILE 'REGISTRY' ENTERED AT 13:08:12 ON 11 FEB 2003

=> d ide can l16

L16  ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2003 ACS
RN   82707-54-8  REGISTRY
CN   Neprilysin (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   Antigens, CALLA (common acute lymphoblastic leukemia-assocd.)
CN   Atriopeptidase
CN   CALLA antigens
CN   CD antigens, CD10
CN   CD10 antigen
CN   Common acute lymphoblastic leukemia-assocd. antigens
CN   E.C. 3.4.24.11
CN   Endopeptidase-24.11
CN   Enkephalinase
CN   Glycoproteins, CALLA
CN   Kell glycoprotein
CN   Kidney brush border neutral proteinase
CN   Kidney brush-border neutral endopeptidase
CN   Membrane metalloendopeptidase
CN   Neutral endopeptidase
CN   Neutral endopeptidase 24.11
CN   Neutral metalloendopeptidase
CN   Peptidase, membrane metalloendo-
CN   Proteinase, kidney brush border neutral
CN   Vasopeptidase
DR   88201-55-2
MF   Unspecified
CI   MAN
LC   STN Files:   ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS,
       BIOSIS, BIOTECHNO, CA, CAPLUS, CIN, CSNB, EMBASE, PROMT, TOXCENTER,
       USPAT2, USPATFULL
```

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
1877 REFERENCES IN FILE CA (1962 TO DATE)
7 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1882 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 138:83797

REFERENCE 2: 138:82977

REFERENCE 3: 138:73273

REFERENCE 4: 138:70882

REFERENCE 5: 138:70749

REFERENCE 6: 138:69475

REFERENCE 7: 138:66064

REFERENCE 8: 138:53625

REFERENCE 9: 138:53445

REFERENCE 10: 138:53331

=> fil uspatall
FILE 'USPATFULL' ENTERED AT 13:08:29 ON 11 FEB 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 13:08:29 ON 11 FEB 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs hitrn fhitstr tot l22

L22 ANSWER 1 OF 8 USPATFULL
AN 2002:301556 USPATFULL
TI Treatment of sexual dysfunction
IN Gonzalez, Maria Isabel, Cambridge, UNITED KINGDOM
Higginbottom, Michael, Cambridge, UNITED KINGDOM
Stock, Herman Thijs, Wijchen, NETHERLANDS
Pritchard, Martyn Clive, Huntingdon, UNITED KINGDOM
Pinnock, Robert Denham, Cambridgshire, UNITED KINGDOM
Van Der Graaf, Pieter Hadewijn, Kent, UNITED KINGDOM
Naylor, Alisdair Mark, Kent, UNITED KINGDOM
Wayman, Christopher Peter, Kent, UNITED KINGDOM
PI US 2002169101 A1 20021114
AI US 2001-999284 A1 20011115 (9)
RLI Continuation-in-part of Ser. No. US 2001-759777, filed on 12 Jan 2001, PENDING Continuation-in-part of Ser. No. US 2000-700165, filed on 9 Nov 2000, PENDING A 371 of International Ser. No. WO 2000-GB1787, filed on 10 May 2000, UNKNOWN
PRAI GB 2001-9910 20010423
GB 2001-11037 20010504
US 1999-133355P 19990510 (60)
DT Utility
FS APPLICATION
LREP WARNER-LAMBERT COMPANY, 2800 PLYMOUTH ROAD, ANN ARBOR, MI, 48107
CLMN Number of Claims: 67
ECL Exemplary Claim: 1
DRWN 24 Drawing Page(s)
LN.CNT 5522
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Bombesin receptor antagonists have been found to be useful in the treatment of sexual dysfunction in both males and females. They may be selective BB1 antagonists or mixed BB1/BB2 antagonists. Combinations are disclosed of bombesin receptor antagonists with a range of other active compounds, for example PDE5 inhibitors, NEP inhibitors and lasofoxifene.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **388630-83-9P**
(prepn. and reaction of in the prepn. of bombesin receptor antagonists for treatment of sexual dysfunction)
IT **337962-93-3P**
(prepn. of as bombesin receptor antagonists for treatment of sexual dysfunction)
IT **337962-74-0P 388630-36-2P**
(prepn. of as bombesin receptor antagonists for treatment of sexual dysfunction)
IT **388630-83-9P**
(prepn. and reaction of in the prepn. of bombesin receptor antagonists for treatment of sexual dysfunction)
RN 388630-83-9 USPATFULL
CN Cyclopentanepropanoic acid, 1-[[(5-ethyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]-.alpha.-propyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L22 ANSWER 2 OF 8 USPATFULL
AN 2002:191642 USPATFULL
TI Compounds for the treatment of sexual dysfunction
IN Harrow, Ian Dennis, County of Kent, UNITED KINGDOM
Stacey, Peter, County of Kent, UNITED KINGDOM
Walsh, Roderick Thomas, County of Kent, UNITED KINGDOM
Wayman, Christopher Peter, County of Kent, UNITED KINGDOM
Phillips, Stephen Charles, County of Kent, UNITED KINGDOM
PI US 2002102707 A1 20020801
AI US 2001-905846 A1 20010713 (9)
PRAI GB 2000-17387 20000714
US 2000-220908P 20000726 (60)
DT Utility
FS APPLICATION
LREP Gregg C. Benson, Pfizer Inc., Patent Department, Eastern Point Road, MS 4159, Groton, CT, 06340
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 26 Drawing Page(s)
LN.CNT 4919
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Polynucleotide and polypeptide sequences are described. The polypeptide sequences comprise one or more of: (a) a polypeptide having the deduced amino acid sequence translated from the polynucleotide sequence in SEQ

ID NO: 1 or SEQ ID NO: 5 and variants, fragments, homologues, analogues and derivatives thereof; (b) a polypeptide of SEQ ID NO: 2 and variants, fragments, homologues, analogues and derivatives thereof (c) a polypeptide encoded by the cDNA of NCIMB 41110 and variants, fragments, homologues, analogues and derivatives thereof; or (d) a polypeptide which has at least 78% identity to (i) the polypeptide encoded by the polynucleotide of SEQ ID NO: 1 or SEQ ID NO: 5, (ii) the polypeptide of SEQ ID NO: 2, or (iii) the polypeptide encoded by the cDNA of NCIMB 41110. Such polypeptide sequences are, inter alia, useful in the prophylaxis and/or treatment of sexual dysfunction, in particular male erectile dysfunction (MED) or female sexual dysfunction (FSD), preferably female sexual arousal disorder (FSAD).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **337962-68-2P 337962-69-3P 337962-71-7P**
337962-74-0P 388630-36-2P
(treatment of male sexual dysfunction using neutral endopeptidase inhibitors and their combination with phosphodiesterase type 5 inhibitors and other agents in relation to inhibition of angiotensin converting enzyme)
IT **337962-78-4P 337962-80-8P 337962-81-9P**
337962-93-3P 388630-83-9P
(treatment of male sexual dysfunction using neutral endopeptidase inhibitors and their combination with phosphodiesterase type 5 inhibitors and other agents in relation to inhibition of angiotensin converting enzyme)
IT **337962-68-2P**
(treatment of male sexual dysfunction using neutral endopeptidase inhibitors and their combination with phosphodiesterase type 5 inhibitors and other agents in relation to inhibition of angiotensin converting enzyme)
RN 337962-68-2 USPATFULL
CN Cyclopentanepropanoic acid, 1-[[[1,6-dihydro-6-oxo-1-(phenylmethyl)-3-pyridinyl]amino]carbonyl]-.alpha.-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



L22 ANSWER 3 OF 8 USPATFULL
AN 2002:99469 USPATFULL
TI Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase
IN Barber, Christopher Gordon, Kent, UNITED KINGDOM
Cook, Andrew Simon, Kent, UNITED KINGDOM
Maw, Graham Nigel, Kent, UNITED KINGDOM
Pryde, David Cameron, Kent, UNITED KINGDOM
Stobie, Alan, Kent, UNITED KINGDOM
PI US 2002052370 A1 20020502
AI US 2001-893585 A1 20010628 (9)
PRAI GB 2000-16684 20000706
GB 2001-1584 20010122
US 2000-219100P 20000718 (60)
US 2001-274957P 20010312 (60)
DT Utility

FS APPLICATION
LREP Gregg C. Benson, Pfizer Inc., Patent Department, MS 4159, Eastern Point Road, Groton, CT, 06340
CLMN Number of Claims: 37
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 5141
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compounds of formula I wherein R.sup.1 is optionally substituted C.sub.1-6alkyl, optionally substituted C.sub.3-7cycloalkyl, optionally substituted aryl or optionally substituted heterocyclyl; n is 0, 1 or 2; and Y is -- NR.sup.18S(O).sub.uR.sup.19 or a group shown below. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **337962-68-2P 337962-69-3P 337962-71-7P 337962-74-0P 388630-36-2P**
(treatment of male sexual dysfunction using neutral endopeptidase inhibitors and their combination with phosphodiesterase type 5 inhibitors and other agents in relation to inhibition of angiotensin converting enzyme)
IT **337962-78-4P 337962-80-8P 337962-81-9P 337962-93-3P 388630-83-9P**
(treatment of male sexual dysfunction using neutral endopeptidase inhibitors and their combination with phosphodiesterase type 5 inhibitors and other agents in relation to inhibition of angiotensin converting enzyme)
IT **337962-68-2P**
(treatment of male sexual dysfunction using neutral endopeptidase inhibitors and their combination with phosphodiesterase type 5 inhibitors and other agents in relation to inhibition of angiotensin converting enzyme)
RN 337962-68-2 USPATFULL
CN Cyclopentanepropanoic acid, 1-[[[1,6-dihydro-6-oxo-1-(phenylmethyl)-3-pyridinyl]amino]carbonyl]-.alpha.-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



L22 ANSWER 4 OF 8 USPATFULL
AN 2002:99460 USPATFULL
TI Pharmaceutical compositions and method for the treatment of hypertension
IN Wilkins, Martin R., Buckinghamshire, UNITED KINGDOM
Thormaehlen, Dirk, Rheden, GERMANY, FEDERAL REPUBLIC OF
Waldeck, Harald, Isernhagen, GERMANY, FEDERAL REPUBLIC OF
PI US 2002052361 A1 20020502
US 6482820 B2 20021119
AI US 2001-930186 A1 20010816 (9)
RLI Continuation of Ser. No. WO 2000-EP1068, filed on 10 Feb 2000, UNKNOWN
PRAI DE 1999-19906310 19990216
DT Utility
FS APPLICATION
LREP CROWELL & MORING LLP, INTELLECTUAL PROPERTY GROUP, P.O. BOX 14300, WASHINGTON, DC, 20044-4300

CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 516
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to the use of benzazepine-N-acetic acid derivatives which contain an oxo-group in the .alpha.-position to the nitrogen atom and are substituted in position 3 by a 1-(carboxyalkyl)cyclo-entylcarbonylamino radical, and their salts and biolabile esters for the treatment of hypertension, particularly for the treatment of certain forms of secondary hypertension, in larger mammals and particularly humans, and for the production of pharmaceutical compositions suitable for this treatment. The cause of the hypertension to be treated may have a wide variety of origins. The invention particularly relates to the treatment of those forms of secondary hypertension which may occur as a result of various non-cardiac diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **182821-27-8 182821-29-0**
(medicament for treatment of high blood pressure)
IT **182821-27-8**
(medicament for treatment of high blood pressure)
RN 182821-27-8 USPATFULL
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[(2R)-2-(ethoxycarbonyl)-4-phenylbutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L22 ANSWER 5 OF 8 USPATFULL
AN 2002:48607 USPATFULL
TI Treatment of male sexual dysfunction
IN Naylor, Alasdair Mark, Sandwich, UNITED KINGDOM
Graaf, Pieter Hadewijn Van Der, Sandwich, UNITED KINGDOM
Wayman, Christopher peter, Sandwich, UNITED KINGDOM
PI US 2002028799 A1 20020307
AI US 2001-895367 A1 20010629 (9)
PRAI GB 2000-16684 20000706
GB 2000-30647 20001215
GB 2001-6167 20010313
GB 2001-8483 20010404
US 2000-219100P 20000718 (60)
US 2001-265358P 20010131 (60)
DT Utility
FS APPLICATION
LREP Gregg C. Benson, Pfizer Inc., Patent Department, MS 4159, Eastern Point Road, Groton, CT, 06340
CLMN Number of Claims: 18
ECL Exemplary Claim: 1

DRWN No Drawings
LN.CNT 3839
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to the use of neutral endopeptidase inhibitors (NEPi) and a combination of NEPi and phosphodiesterase type 5 (PDE5) inhibitor for the treatment of male sexual dysfunction, in particular MED.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **337962-68-2P 337962-69-3P 337962-71-7P 337962-74-0P 388630-36-2P**
(treatment of male sexual dysfunction using neutral endopeptidase inhibitors and their combination with phosphodiesterase type 5 inhibitors and other agents in relation to inhibition of angiotensin converting enzyme)
IT **337962-78-4P 337962-80-8P 337962-81-9P 337962-93-3P 388630-83-9P**
(treatment of male sexual dysfunction using neutral endopeptidase inhibitors and their combination with phosphodiesterase type 5 inhibitors and other agents in relation to inhibition of angiotensin converting enzyme)
IT **337962-68-2P**
(treatment of male sexual dysfunction using neutral endopeptidase inhibitors and their combination with phosphodiesterase type 5 inhibitors and other agents in relation to inhibition of angiotensin converting enzyme)
RN 337962-68-2 USPATFULL
CN Cyclopentanepropanoic acid, 1-[[[1,6-dihydro-6-oxo-1-(phenylmethyl)-3-pyridinyl]amino]carbonyl]-.alpha.-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



L22 ANSWER 6 OF 8 USPATFULL
AN 1998:85948 USPATFULL
TI Pharmaceuticals which promote gastrointestinal blood circulation
IN Rozsa, Susanna, Szeged, Hungary
Papp, Julius Gy., Szeged, Hungary
Thormaehlen, Dirk, Rheden, Germany, Federal Republic of
Waldeck, Harald, Isernhagen, Germany, Federal Republic of
PA Solvay Pharmaceuticals GmbH, Hanover, Germany, Federal Republic of (non-U.S. corporation)
PI US 5783573 19980721
AI US 1997-929114 19970915 (8)
PRAI DE 1996-19638020 19960918
DT Utility
FS Granted
EXNAM Primary Examiner: Jarvis, William R. A.
LREP Evenson, McKeown, Edwards & Lenahan P.L.L.C.
CLMN Number of Claims: 6
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1138
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The use is described of compounds of the general formula I ##STR1## wherein R.sup.1 represents a phenyl-lower alkyl group which can optionally be substituted in the phenyl ring by lower alkyl, lower alkoxy or halogen, or represents a naphthyl-lower alkyl group,

R.sup.2 denotes hydrogen or a biolabile ester-forming group, and

R.sup.3 denotes hydrogen or a biolabile ester-forming group,

and physiologically acceptable salts of the acids of formula I for preparing pharmaceutical compositions for the treatment and/or prophylaxis of gastrointestinal blood circulation disturbances.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **182560-83-4P 182560-84-5P 182560-85-6P**
182560-86-7P 182560-96-9P 182560-97-0P
182560-98-1P 182560-99-2P 182561-11-1P
182561-14-4P 182821-26-7P 182821-27-8P
182821-33-6P 204781-61-3P 204781-62-4P
204781-63-5P 204781-64-6P 204781-65-7P
204781-66-8P 204781-67-9P 204781-68-0P
204781-69-1P 204781-70-4P
(benzazepineacetic acid derivs. promoting gastrointestinal blood circulation)
IT **182560-83-4P**
(benzazepineacetic acid derivs. promoting gastrointestinal blood circulation)
RN 182560-83-4 USPATFULL
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-(ethoxycarbonyl)-4-phenylbutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L22 ANSWER 7 OF 8 USPATFULL
AN 97:94229 USPATFULL
TI Benzazepine-, benzoxazepine- and benzothiazepine-n-acetic acid derivatives, process for their preparation and pharmaceutical compositions containing them
IN Waldeck, Harald, Isernhagen, Germany, Federal Republic of
Hoeltje, Dagmar, Gehrden, Germany, Federal Republic of
Messinger, Josef, Sehnde, Germany, Federal Republic of
Antel, Jochen, Bad Muender, Germany, Federal Republic of
Wurl, Michael, Garbsen, Germany, Federal Republic of
Thormaehlen, Dirk, Rheden, Germany, Federal Republic of
PA Solvay Pharmaceuticals GmbH, Hanover, Germany, Federal Republic of (non-U.S. corporation)
PI US 5677297 19971014
AI US 1996-620213 19960322 (8)
PRAI DE 1995-19510566 19950323
DT Utility

FS Granted
EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Coleman, Brenda
LREP Evenson, McKeown, Edwards & Lenahan P.L.L.C.
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1975
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds with neutral endopeptidase (NEP) inhibitory activity corresponding to the formula I ##STR1## in which R.sup.1 is a lower alkoxy-lower-alkyl group whose lower alkoxy radical is substituted by a lower alkoxy group, or a phenyl-lower-alkyl or phenyloxy-lower-alkyl group which can optionally be substituted in the phenyl ring by lower alkyl, lower alkoxy or halogen, or a naphthyl-lower-alkyl group,

A is CH.sub.2, O or S,

R.sup.2 is hydrogen or halogen,

R.sup.3 is hydrogen or halogen,

R.sup.4 is hydrogen or a group forming a biolabile ester, and

R.sup.5 is hydrogen or a group forming a biolabile ester, and the physiologically acceptable acid addition salts thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **182560-83-4P 182560-84-5P 182560-85-6P**
182560-86-7P 182560-89-0P 182560-90-3P
182560-91-4P 182560-92-5P 182560-93-6P
182560-94-7P 182560-95-8P 182560-96-9P
182560-97-0P 182560-98-1P 182560-99-2P
182561-00-8P 182561-01-9P 182561-02-0P
182561-03-1P 182561-04-2P 182561-05-3P
182561-06-4P 182561-07-5P 182561-08-6P
182561-09-7P 182561-10-0P 182561-11-1P
182561-12-2P 182561-13-3P 182561-14-4P
182561-29-1P 182561-30-4P 182561-31-5P
182561-32-6P 182561-33-7P 182561-34-8P
182561-35-9P 182561-36-0P 182561-38-2P
182561-39-3P 182561-40-6P 182704-04-7P
182821-26-7P 182821-27-8P 182821-28-9P
182821-29-0P 182821-30-3P 182821-31-4P
182821-32-5P 182821-33-6P 182821-36-9P
182821-37-0P 182824-17-5P
(prepn. of 3-[[(1-carboxyalkyl)cyclopentyl]carbonylamino]benzazepin-1-acetates and analogs as neutral endopeptidase inhibitors)
IT **182560-83-4P**
(prepn. of 3-[[(1-carboxyalkyl)cyclopentyl]carbonylamino]benzazepin-1-acetates and analogs as neutral endopeptidase inhibitors)
RN 182560-83-4 USPATFULL
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-(ethoxycarbonyl)-4-phenylbutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L22 ANSWER 8 OF 8 USPAT2
AN 2002:99460 USPAT2
TI Pharmaceutical compositions and method for the inhibition and treatment of secondary hypertension
IN Wilkins, Martin R., Buckinghamshire, UNITED KINGDOM
Thormaehlen, Dirk, Rheden, GERMANY, FEDERAL REPUBLIC OF
Waldeck, Harald, Isernhagen, GERMANY, FEDERAL REPUBLIC OF
PA Solvay Pharmaceuticals GmbH, Hannover, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
PI US 6482820 B2 20021119
AI US 2001-930186 20010816 (9)
RLI Continuation of Ser. No. WO 2000-EP1068, filed on 10 Feb 2000
PRAI DE 1999-19906310 19990216
DT Utility
FS GRANTED
EXNAM Primary Examiner: Spivack, Phyllis G.
LREP Crowell & Moring LLP
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 494
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to the use of benzazepine-N-acetic acid derivatives which contain an oxo-group in the .alpha.-position to the nitrogen atom and are substituted in position 3 by a 1-(carboxyalkyl)cyclo-entylcarbonylamino radical, and their salts and biolabile esters for the treatment of hypertension, particularly for the treatment of certain forms of secondary hypertension, in larger mammals and particularly humans, and for the production of pharmaceutical compositions suitable for this treatment. The cause of the hypertension to be treated may have a wide variety of origins. The invention particularly relates to the treatment of those forms of secondary hypertension which may occur as a result of various non-cardiac diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **182821-27-8 182821-29-0**
(medicament for treatment of high blood pressure)
IT **182821-27-8**
(medicament for treatment of high blood pressure)
RN 182821-27-8 USPAT2
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[(2R)-2-(ethoxycarbonyl)-4-phenylbutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



```
=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 13:08:58 ON 11 FEB 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 11 Feb 2003  VOL 138 ISS 7
FILE LAST UPDATED: 10 Feb 2003  (20030210/ED)

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> d all tot fhitstr 121

L21  ANSWER 1 OF 15  HCAPLUS  COPYRIGHT 2003 ACS
AN   2002:869567  HCAPLUS
DN   137:370356
TI   Preparation and use of bombesin receptor antagonists for treatment of
     sexual dysfunction in males and females
IN   Gonzalez, Maria Isabel; Higginbottom, Michael; Stock, Herman Thijs;
     Pritchard, Martyn Clive; Pinnock, Robert Denham; Van der Graaf, Pieter
     Hadewijn; Naylor, Alisdair Mark; Wayman, Christopher Peter
PA   UK
SO   U.S. Pat. Appl. Publ., 105 pp., Cont.-in-part of U.S. Pat. Appl. 2002
     58,606.
     CODEN: USXXCO
DT   Patent
LA   English
IC   ICM  A61K031-00
NCL  514001000
CC   34-2 (Amino Acids, Peptides, and Proteins)
     Section cross-reference(s): 1, 63
FAN.CNT 9
     PATENT NO.        KIND  DATE          APPLICATION NO.  DATE
     ---------------   ----  --------      ---------------  --------
PI   US 2002169101      A1   20021114      US 2001-999284   20011115
```

	US 2002058606	A1	20020516	US 2001-759777	20010112
PRAI	US 1999-133355P	P	19990510		
	WO 2000-GB1787	W	20000510		
	US 2000-700165	A2	20001109		
	US 2001-759777	A2	20010112		
	GB 2001-9910	A	20010423		
	GB 2001-11037	A	20010504		

OS MARPAT 137:370356

GI



I

AB Bombesin receptor antagonists have been found to be useful in the treatment of sexual dysfunction in both males and females. They may be selective BB1 antagonists or mixed BB1/BB2 antagonists. Combinations are disclosed of bombesin receptor antagonists with a range of other active compds., for example PDE5 inhibitors, NEP inhibitors and lasofoxifene. Prepn. of bombesin receptor antagonists consisting of .alpha.-Me tryptophane (e.g., I) or .alpha.-methylphenylalanine derivs. was given. In tests on sexually-dysfunctional male rats, it was concluded that I had a stimulatory effect, at the level of sexual desire, performance, and anorgasmy. In tests on sexually-dysfunctional female rats, it was concluded that I had a stimulatory effect on proceptivity, which was unaffected by repeated administration.

ST bombesin receptor antagonist amino acid prepn sexual dysfunction

IT Behavior
(arousal; prepn. and use of bombesin receptor antagonists for treatment of sexual dysfunction in males and females)

IT Sexual behavior
(disorder; prepn. and use of bombesin receptor antagonists for treatment of sexual dysfunction in males and females)

IT Human
(prepn. and use of bombesin receptor antagonists for treatment of sexual dysfunction in males and females)

IT Bombesin receptors
RL: PAC (Pharmacological activity); BIOL (Biological study)
(prepn. and use of bombesin receptor antagonists for treatment of sexual dysfunction in males and females)

IT Amino acids, preparation
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and use of bombesin receptor antagonists for treatment of sexual dysfunction in males and females)

IT Drugs
(sexual dysfunction induced by; prepn. and use of bombesin receptor antagonists for treatment of sexual dysfunction in males and females)

IT 105754-24-3P 204067-15-2P 204067-16-3P 204067-17-4P 337962-91-1P
388630-83-9P 425641-31-2P 425641-32-3P 425641-34-5P
425641-40-3P 425641-41-4P 425641-42-5P 425641-43-6P 425641-45-8P

425641-46-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction of in the prepn. of bombesin receptor antagonists for treatment of sexual dysfunction)

IT **337962-93-3P** 425638-88-6P 425638-90-0P 425638-92-2P
425638-94-4P 425638-96-6P 425638-98-8P 425639-00-5P 425639-02-7P
425639-04-9P 425639-07-2P 425639-13-0P 425639-16-3P 425639-19-6P
425639-22-1P 425639-25-4P 425639-28-7P 425639-31-2P 425639-33-4P
425639-35-6P 425639-37-8P 425639-39-0P 425639-41-4P 425639-43-6P
425639-45-8P 425639-47-0P 425639-48-1P 425639-49-2P 425639-50-5P
425639-52-7P 425639-53-8P 425639-55-0P 425639-57-2P 425639-59-4P
425639-61-8P 425639-63-0P 425639-65-2P 425639-68-5P 425639-70-9P
425639-72-1P 425639-74-3P 425639-76-5P 425639-77-6P 425639-79-8P
425639-81-2P 425639-83-4P 425639-85-6P 425639-87-8P 425639-89-0P
425639-91-4P 425639-93-6P 425639-95-8P 425639-96-9P 425639-97-0P
425639-98-1P 425639-99-2P 425640-00-2P 425640-01-3P 425640-02-4P
425640-03-5P 425640-04-6P 425640-06-8P 425640-08-0P 425640-09-1P
425640-10-4P 425640-11-5P 425640-12-6P 425640-14-8P 425640-15-9P
425640-17-1P 425640-18-2P 425640-20-6P 425640-21-7P 425640-23-9P
425640-24-0P 425640-26-2P 425640-28-4P 425640-30-8P 425640-32-0P
425640-34-2P 425640-36-4P 425640-38-6P 425640-39-7P 425640-40-0P
425640-41-1P 425640-43-3P 425640-45-5P 425640-47-7P 425640-49-9P
425640-51-3P 425640-53-5P 425640-55-7P 425640-57-9P 425640-59-1P
425640-60-4P 425640-62-6P 425640-64-8P 425640-66-0P 425640-68-2P
425640-70-6P 425640-72-8P 425640-74-0P 425640-76-2P 425640-78-4P
425640-80-8P 425640-82-0P 425640-83-1P 425640-84-2P 425640-85-3P
425640-86-4P 425640-87-5P 425640-88-6P 425640-89-7P 425640-90-0P
425640-91-1P 425640-92-2P 425640-93-3P 425640-94-4P 425640-95-5P
425640-96-6P 425640-97-7P 425640-98-8P 425640-99-9P 425641-00-5P
425641-01-6P 425641-02-7P 425641-03-8P 425641-04-9P 425641-05-0P
425641-06-1P 425641-07-2P 425641-08-3P 425641-09-4P 425641-10-7P
425641-11-8P 425641-12-9P 425641-13-0P 425641-14-1P 425641-15-2P
425641-16-3P 425641-17-4P 425641-18-5P 425641-19-6P 425641-20-9P
425641-21-0P 425641-22-1P 425641-23-2P 425641-24-3P 425641-25-4P
425641-26-5P 425641-27-6P 425641-28-7P 425641-29-8P 425641-30-1P
425641-39-0P 426213-31-2P 426213-32-3P 426267-06-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of as bombesin receptor antagonists for treatment of sexual dysfunction)

IT 204067-01-6 428864-38-4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prepn. of as bombesin receptor antagonists for treatment of sexual dysfunction)

IT **337962-74-0P 388630-36-2P**
RL: PUR (Purification or recovery); PREP (Preparation)
(prepn. of as bombesin receptor antagonists for treatment of sexual dysfunction)

IT 425641-33-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of as bombesin receptor antagonists for treatment of sexual dysfunction)

IT 187609-88-7 204066-72-8 204066-73-9 204066-75-1 204066-76-2
204066-78-4 204066-79-5 204066-80-8 204066-82-0 204066-83-1
204066-84-2 204066-86-4 204066-89-7 204066-95-5 204067-38-9
425639-10-7 428864-39-5 428864-40-8 428864-41-9 428864-42-0
428864-43-1 428864-45-3 428864-47-5 428864-48-6 428864-49-7
428864-50-0 428864-51-1 428864-52-2 428864-53-3 428864-54-4
428864-55-5 428864-56-6 428864-57-7 428864-58-8 428864-59-9

428864-63-5 428864-64-6 428864-66-8 428864-67-9 429657-44-3
475247-11-1 475247-13-3 475247-25-7 475249-13-9
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prepn. of as bombesin receptor antagonists for treatment of sexual dysfunction)

IT 55-22-1, Isonicotinic acid, reactions 62-23-7, 4-Nitrobenzoic acid 65-85-0, Benzoic acid, reactions 74-11-3, 4-Chlorobenzoic acid 85-46-1, Naphthalene-1-sulfonyl chloride 86-59-9, Quinoline-8-carboxylic acid 88-13-1, Thiophene-3-carboxylic acid 88-14-2, Furan-2-carboxylic acid 89-95-2, o-Tolylmethanol 93-03-8, (3,4-Dimethoxyphenyl)methanol 93-11-8, Naphthalene-2-sulfonyl chloride 93-25-4, (2-Methoxyphenyl)acetic acid 98-31-7, 3,4-Dichlorobenzenesulfonyl chloride 98-59-9, 4-Methylbenzenesulfonyl chloride 98-60-2, 4-Chlorobenzenesulfonyl chloride 98-74-8, 4-Nitrobenzenesulfonyl chloride 98-98-6, Pyridine-2-carboxylic acid 99-04-7, 3-Methylbenzoic acid 99-64-9, 3-Dimethylaminobenzoic acid 99-81-0, 2-Bromo-1-(4-nitrophenyl)-ethanone 99-94-5, 4-Methylbenzoic acid 100-09-4, 4-Methoxybenzoic acid 104-01-8, (4-Methoxyphenyl)acetic acid 105-13-5, (4-Methoxyphenyl)methanol 108-86-1, Bromobenzene, reactions 118-90-1, 2-Methylbenzoic acid 118-91-2, 2-Chlorobenzoic acid 121-51-7, 3-Nitrobenzenesulfonyl chloride 122-78-1, Phenylacetaldehyde 156-38-7, (4-Hydroxyphenyl)acetic acid 349-75-7, (3-Trifluoromethylphenyl)methanol 349-88-2, 4-Fluorobenzenesulfonyl chloride 349-95-1, (4-Trifluoromethylphenyl)methanol 445-29-4, 2-Fluorobenzoic acid 446-51-5, (2-Fluorophenyl)methanol 451-82-1, (2-Fluorophenyl)acetic acid 488-93-7, Furan-3-carboxylic acid 527-72-0, Thiophene-2-carboxylic acid 535-80-8, 3-Chlorobenzoic acid 552-16-9, 2-Nitrobenzoic acid 555-16-8, 4-Nitrobenzaldehyde, reactions 579-75-9, 2-Methoxybenzoic acid 586-38-9, 3-Methoxybenzoic acid 587-03-1, m-Tolylmethanol 589-18-4, p-Tolylmethanol 591-17-3, 1-Bromo-3-methylbenzene 605-65-2, 5-DimethylaminoNaphthalene-1-sulfonyl chloride 610-16-2, 2-Dimethylaminobenzoic acid 612-16-8, (2-Methoxyphenyl)methanol 613-89-8, 2-Amino-1-phenylethanone 615-18-9, 2-Chlorobenzoxazole 619-25-0, (3-Nitrophenyl)methanol 619-73-8, (4-Nitrophenyl)methanol 621-36-3, m-Tolylacetic acid 621-37-4, (3-Hydroxyphenyl)acetic acid 622-47-9, p-Tolylacetic acid 644-36-0, o-Tolylacetic acid 673-06-3, D-Phenylalanine 701-27-9, 3-Fluorobenzenesulfonyl chloride 776-04-5, 2-Trifluoromethylbenzenesulfonyl chloride 777-44-6, 3-Trifluoromethylbenzenesulfonyl chloride 873-76-7, (4-Chlorophenyl)methanol 874-97-5, 3-Hydroxymethylbenzonitrile 877-65-6, (4-tert-Butylphenyl)methanol 879-65-2, Quinoxaline-2-carboxylic acid 931-97-5, 1-Hydroxycyclohexanecarbonitrile 934-60-1, 6-Methylpyridine-2-carboxylic acid 1477-50-5, 1H-Indole-2-carboxylic acid 1532-97-4, 4-Bromoisoquinoline 1592-38-7, Naphthalen-2-ylmethanol 1656-44-6, 2,4-Dinitrobenzenesulfonyl chloride 1670-81-1, 1H-Indole-5-carboxylic acid 1670-82-2, 1H-Indole-6-carboxylic acid 1670-83-3, 1H-Indole-7-carboxylic acid 1777-82-8, (2,4-Dichlorophenyl)methanol 1805-32-9, (3,4-Dichlorophenyl)methanol 1877-72-1, 3-Cyanobenzoic acid 1899-93-0, 3-Methylbenzenesulfonyl chloride 1918-79-2, 5-Methylthiophene-2-carboxylic acid 1939-99-7, Phenylmethanesulfonyl chloride 2052-07-5, 2-Bromobiphenyl 2104-06-5 2124-55-2, 1H-Indole-4-carboxylic acid 2688-90-6, Biphenyl-2-sulfonyl chloride 2766-74-7, 5-Chlorothiophene-2-sulfonyl chloride 2888-06-4, 3-Chlorobenzenesulfonyl chloride 2905-21-7, 2-Fluorobenzenesulfonyl chloride 2905-23-9, 2-Chlorobenzenesulfonyl chloride 2991-42-6, 4-Trifluoromethylbenzenesulfonyl chloride 3405-77-4, 5-Methylisoxazole-3-carboxylic acid 3622-35-3, Benzothiazole-6-carboxylic acid 3740-52-1, (2-Nitrophenyl)acetic acid 4052-30-6, 4-Methanesulfonylbenzoic acid 4254-29-9, Indan-2-ol 4265-16-1, Benzofuran-2-carbaldehyde 4533-95-3, 2-Chloro-5-nitrobenzenesulfonyl chloride 4533-96-4, 4-Chloro-2-nitrobenzenesulfonyl chloride 4595-59-9, 5-Bromopyrimidine 4780-79-4, Naphthalen-1-ylmethanol 5345-27-7, 3-Methanesulfonylbenzoic acid 6314-28-9, Benzo[b]thiophene-2-

carboxylic acid 6624-49-3, Isoquinoline-3-carboxylic acid 6964-21-2, Thiophen-3-ylacetic acid 6973-60-0, 1-Methyl-1H-pyrrole-2-carboxylic acid 7693-46-1, 4-Nitrophenylchloroformate 10130-74-2, 3-Methoxybenzenesulfonyl chloride 10333-68-3, 2-Pyrrol-1-ylbenzoic acid 13826-35-2, (3-Phenoxyphenyl)methanol 15084-51-2, 4-tert-Butylbenzenesulfonyl chloride 16136-58-6, 1-Methyl-1H-Indole-2-carboxylic acid 16629-19-9, Thiophene-2-sulfonyl chloride 16709-25-4 17078-28-3, (4-Dimethylaminophenyl)acetic acid 17849-38-6, (2-Chlorophenyl)methanol 18704-37-5, Quinoline-8-sulfonyl chloride 19524-06-2, 4-Bromopyridine hydrochloride 23095-31-0, 3,4-Dimethoxybenzenesulfonyl chloride 23806-24-8, 3-Methylthiophene-2-carboxylic acid 23814-12-2, 1H-Benzotriazole-5-carboxylic acid 24974-75-2, (2-Nitrophenyl)methanesulfonyl chloride 25952-53-8, 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride 26638-43-7, 2-Chlorosulfonylbenzoic acid methyl ester 28286-86-4, 2,4-Dichloro-5-methylbenzenesulfonyl chloride 28385-45-7 38594-42-2, (2,3-Dichlorophenyl)methanol 39774-26-0, 2-Bromo-6-phenylpyridine 42413-03-6, 3-Chloro-4-methylbenzenesulfonyl chloride 49584-26-1, 4-Cyanobenzenesulfonyl chloride 51527-73-2, 2,4,6-Trichlorobenzenesulfonyl chloride 54997-92-1, 4-Butylbenzenesulfonyl chloride 56542-67-7, 3-Cyanobenzenesulfonyl chloride 56946-83-9, 2,5-Dichlorothiophene-3-sulfonyl chloride 59337-92-7, 3-Chlorosulfonylthiophene-2-carboxylic acid, methyl ester 69360-26-5, 2-Cyanobenzenesulfonyl chloride 71648-21-0, (3-Ethoxyphenyl)methanol 73713-79-8 80466-79-1, 3,5-Dimethylisoxazole-4-sulfonyl chloride 82964-91-8, 4-Methanesulfonylbenzenesulfonyl chloride 88398-93-0, 5-Chloro-1,3-dimethyl-1H-pyrazole-4-sulfonyl chloride 91170-93-3, 3-Chloro-4-fluorobenzensulfonyl chloride 94108-56-2, 4-Trifluoromethoxybenzenesulfonyl chloride 99924-18-2, 5-Phenyloxazole-4-carboxylic acid 100516-88-9, Quinolin-6-ylmethanol 114322-14-4, Benzo[c]1,2,5-oxadiazole-4-sulfonyl chloride 118783-85-0 137049-00-4, 1-Methyl-1H-imidazole-4-sulfonyl chloride 137049-02-6, 1,2-Dimethyl-1H-imidazole-4-sulfonyl chloride 142854-50-0 151858-64-9, 5-Pyridin-2-ylthiophene-2-sulfonyl chloride 160233-27-2, 5-Isoxazol-3-ylthiophene-2-sulfonyl chloride 166964-37-0, 5-Benzenesulfonylthiophene-2-sulfonyl chloride 185908-35-4, 8-Nitronaphthalene-1-sulfonyl chloride 204067-12-9 206262-15-9, 2-p-Tolyloxybenzenesulfonyl chloride 206262-83-1, 5-Methyl-2-phenoxybenzenesulfonyl chloride 216394-05-7, 5-Bromo-6-chloropyridine-3-sulfonyl chloride 216394-11-5, 2-Methoxy-4-methylbenzenesulfonyl chloride 425641-36-7 425641-37-8 425641-38-9 425641-47-0 426213-33-4 426213-34-5 475250-18-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of in the prepn. of bombesin receptor antagonists for treatment of sexual dysfunction)

IT 180916-16-9, Lasofoxifene
RL: MSC (Miscellaneous)
(treatment of sexual dysfunction with bombesin receptor antagonists and)

IT **388630-83-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction of in the prepn. of bombesin receptor antagonists for treatment of sexual dysfunction)

RN 388630-83-9 HCAPLUS

CN Cyclopentanepropanoic acid, 1-[[(5-ethyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]-.alpha.-propyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L21 ANSWER 2 OF 15 HCAPLUS COPYRIGHT 2003 ACS
AN 2002:777881 HCAPLUS
DN 137:278918
TI Preparation of cyclopentyl-substituted glutaric acid monoamides as **neutral endopeptidase** inhibitors for treating female sexual arousal disorder and related conditions
IN Challenger, Stephen; Cook, Andrew Simon; Gillmore, Adam Thomas; Middleton, Donald Stuart; Pryde, David Cameron; Stobie, Alan
PA Pfizer Limited, UK; Pfizer Inc.
SO PCT Int. Appl., 130 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07C235-82
ICS C07C255-60; C07D231-56; C07D311-74; C07C323-40; C07D307-79; C07D213-40; C07D215-12; C07D319-20; C07D317-52; A61K031-195; A61K031-335; A61K031-41; A61K031-435; A61P015-00
CC 24-4 (Alicyclic Compounds)
Section cross-reference(s): 1, 63
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002079143	A1	20021010	WO 2002-IB807	20020318

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI GB 2001-7750 A 20010328
GB 2001-13112 A 20010530
GB 2001-20152 A 20010817
OS MARPAT 137:278918
GI



AB The invention relates to cyclopentyl-substituted glutaric acid monoamides (shown as I; e.g. (2S)-2-[[1-[[[3-(4-chlorophenyl)propyl]amino]carbonyl]cyclopentyl]methyl]-4-methoxybutanoic acid), inhibition of **neutral endopeptidase** (NEP) enzyme, methods of prepn. and uses, e.g. treating female sexual arousal disorder. In I, R1 is optionally substituted C1-6alkyl, carbocyclyl, heterocyclyl, H, C1-6alkoxy, amino, or sulfonylamino. X is the linkage -(CH2)n- or -(CH2)q-O- (wherein Y is attached to the O); wherein one or more H atoms in linkage X may be replaced independently by C1-4alkoxy; hydroxy; hydroxyC1-3alkyl; C3-7cycloalkyl; carbocyclyl; heterocyclyl; or by C1-4alkyl optionally substituted by one or more fluoro or Ph groups; n is 3-7; and q is 2-6; and Y is optionally substituted Ph or pyridyl. One process for prepg. I involves reacting II (Prot = protecting group) with Y-X-NH2 to give protected I, which is then deprotected and later optionally converted to a salt; other methods involve asym. hydrogenation of an alkene precursor to II. More than 100 example prepns. of intermediates and claimed compds. are included; most of the claimed compds. are N-phenpropyl amides. IC50 values against **neutral endopeptidase** and selectivity against **neutral endopeptidase** vs. ACE are given for some of the claimed compds.; for example, 3-[1-[[[3-(2,3-dihydrobenzofuran-5-yl)propyl]amino]carbonyl]cyclopentyl]propanoic acid showed an IC50 against NEP of 3 nM and a >300 selectivity against ACE. Test results for use of (2S)-2-[[1-[[[3-(4-chlorophenyl)propyl]amino]carbonyl]cyclopentyl]methyl]-4-methoxybutanoic acid in rabbit models of female sexual arousal response and male erectile response are included.

ST cyclopentyl glutaric acid amide prepn **neutral endopeptidase** inhibition; sexual disorder treatment cyclopentyl glutaric acid amide

IT 5-HT receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(5-HT2C, agonists, antagonists or modulators; in combination with cyclopentyl-substituted glutaric acid monoamide **neutral endopeptidase** inhibitors for treating female sexual arousal disorder and related conditions)

IT Dopamine agonists
(D2, selective; in combination with cyclopentyl-substituted glutaric acid monoamide **neutral endopeptidase** inhibitors for treating female sexual arousal disorder and related conditions)

IT Dopamine agonists
(D3, selective; in combination with cyclopentyl-substituted glutaric acid monoamide **neutral endopeptidase** inhibitors for treating female sexual arousal disorder and related conditions)

IT Neuropeptide Y receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Y1, inhibitors; in combination with cyclopentyl-substituted glutaric acid monoamide **neutral endopeptidase** inhibitors for treating female sexual arousal disorder and related conditions)

IT Estrogen receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(agonists, antagonists or modulators; in combination with cyclopentyl-substituted glutaric acid monoamide **neutral endopeptidase** inhibitors for treating female sexual arousal disorder and related conditions)

IT Sexual behavior
(disorder, female; prepn. of cyclopentyl-substituted glutaric acid monoamides as **neutral endopeptidase** inhibitors for treating female sexual arousal disorder and related conditions)

IT Drug delivery systems
(for cyclopentyl-substituted glutaric acid monoamides as **neutral endopeptidase** inhibitors for treating female sexual arousal disorder and related conditions)

IT Sexual behavior
(impotence; prepn. of cyclopentyl-substituted glutaric acid monoamides as **neutral endopeptidase** inhibitors for treating female sexual arousal disorder and related conditions)

IT Dopamine agonists
(in combination with cyclopentyl-substituted glutaric acid monoamide **neutral endopeptidase** inhibitors for treating female sexual arousal disorder and related conditions)

IT Androgens
Estrogens
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(in combination with cyclopentyl-substituted glutaric acid monoamide **neutral endopeptidase** inhibitors for treating female sexual arousal disorder and related conditions)

IT Pituitary hormone receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(melanocortin, agonists or modulators; in combination with cyclopentyl-substituted glutaric acid monoamide **neutral endopeptidase** inhibitors for treating female sexual arousal disorder and related conditions)

IT Human
(prepn. of cyclopentyl-substituted glutaric acid monoamides as **neutral endopeptidase** inhibitors for treating female sexual arousal disorder and related conditions)

IT 128908-32-7, Melanocortin
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(enhancer; in combination with cyclopentyl-substituted glutaric acid monoamide **neutral endopeptidase** inhibitors for treating female sexual arousal disorder and related conditions)

IT 139755-83-2, 5-[2-Ethoxy-5-(4-methyl-1-piperazinylsulfonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one 171596-29-5, (6R,12AR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione 215297-27-1, 3-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulfonyl)-2-propoxyphenyl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one 224785-90-4, 2-[2-Ethoxy-5-(4-ethylpiperazin-1-yl-1-sulfonyl)phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one 334826-98-1, 5-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulfonyl)pyridin-3-yl]-3-ethyl-2-(2-methoxyethyl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one 335077-70-8, 5-(5-Acetyl-2-butoxy-3-pyridinyl)-3-ethyl-2-(1-ethyl-3-azetidinyl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(in combination with cyclopentyl-substituted glutaric acid monoamide **neutral endopeptidase** inhibitors for treating female sexual arousal disorder and related conditions)

IT 50-27-1, Oestriol 50-28-2, Oestradiol, biological studies 53-16-7, Oestrone, biological studies 53-41-8, Androsterone 58-00-4, Apomorphine 58-22-0, Testosterone 846-46-8 2283-82-1,

Dehydroandrosterone 5630-53-5, Tibolone 84449-90-1, Raloxifene 91374-21-9, Ropinirole 104632-26-0, Pramipexole 121062-08-6, Melanotan II 180916-16-9, Lasofoxifene
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(in combination with cyclopentyl-substituted glutaric acid monoamide **neutral endopeptidase** inhibitors for treating female sexual arousal disorder and related conditions)

IT 9068-52-4, Phosphodiesterase type 5
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; in combination with cyclopentyl-substituted glutaric acid monoamide **neutral endopeptidase** inhibitors for treating female sexual arousal disorder and related conditions)

IT 465529-13-9P, Sodium (2S)-2-[[1-[[[3-(4-chlorophenyl)propyl]amino]carbonyl]cyclopentyl]methyl]-4-methoxybutanoate
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate, x-ray powder diffraction pattern; prepn. of cyclopentyl-substituted glutaric acid monoamides as **neutral endopeptidase** inhibitors for treating female sexual arousal disorder and related conditions)

IT 493-08-3P, Chroman 698-27-1P, 2-Hydroxy-4-methylbenzaldehyde 2222-15-3P, 4-(4-Methoxyphenyl)butyramide 3875-78-3P, 6-Bromochroman 4113-04-6P, Quinoline-6-carboxaldehyde 5337-94-0P, 5-Bromo-2,2-dimethyl-2,3-dihydrobenzo[b]furan 13198-21-5P, 3-(2-Naphthyl)-1-propanamine 13436-50-5P, 2-Acetyl-2H-indazole 15583-16-1P, 3-(2-Pyridinyl)-1-propanamine 17359-45-4P, 7-Methyl-2,3-Dihydro-1-benzofuran 18655-50-0P, 3-(4-Chlorophenyl)propylamine 18655-51-1P, 3-(2-Methoxyphenyl)-1-propanamine 18655-52-2P, 3-(3-Methoxyphenyl)-1-propanamine 22205-09-0P, 4-(4-Hydroxyphenyl)butyramine 23291-98-7P, 3-(2,3-Dihydro-1H-inden-5-yl)propanoic acid 23471-44-5P, 1-(2-Chlorophenoxy)-2-propanamine 24781-50-8P, 3-(1-Naphthyl)-1-propanamine 27404-31-5P, 2-(1-Benzofuran-3-yl)ethylamine 28446-68-6P, 3-(4-Methoxyphenyl)-2-propenenitrile 33155-59-8P, tert-Butyl (4-chlorophenyl)acetate 35549-47-4P, 2-(2-Cyanoethyl)pyridine 36397-23-6P, 3-(4-Methoxyphenyl)-1-propanamine 43154-25-2P, 3-(3,4-(Ethylenedioxy)phenyl)-2-propenenitrile 50561-69-8P, Methyl 3-(4-chlorophenyl)propanoate 52204-89-4P, 7-Methyl-2,3-dihydro-1-benzofuran-3-ol 52407-43-9P, 1-Benzofuran-3-ylacetonitrile 53857-57-1P, 5-Bromo-1H-indazole 54930-39-1P, 3-(4-Methylphenyl)-1-propanamine 55260-45-2P, 3-(3-(Benzyloxy)phenyl)-1-propanamine 63996-36-1P, 2-(4-Bromophenyl)pyridine 65984-53-4P, 3-(4-Bromophenyl)-1-propanamine 72457-26-2P, 4-(4-Methoxyphenyl)butylamine 76386-57-7P, 3-(4-Bromophenyl)-2-propenenitrile 83987-53-5P, 3-(4-(Methylthio)phenyl)-1-propanamine 99839-78-8P, 3-(4-Chlorophenyl)propanamide 102292-30-8P, 5-Bromo-2-methyl-2,3-dihydro-1-benzo[b]furan 180144-72-3P, 3-(2,3-Dihydro-1H-inden-5-yl)propylamine 196799-45-8P, 2,3-Dihydrobenzo[b]furan-7-carboxaldehyde 219736-07-9P, 5-Bromo-6-methyl-2,3-dihydrobenzo[b]furan 341011-30-1P, 3-(4-Methoxy-3-chlorophenyl)-1-propylamine 377084-64-5P, 3-(2,4-Difluorophenyl)-1-propanamine 388630-61-3P, 1-[(2R)-2-(tert-Butoxycarbonyl)pentyl]cyclopentanecarboxylic acid 388631-29-6P, 1-[2-(tert-Butoxycarbonyl)-4-methoxybutyl]cyclopentanecarboxylic acid 401940-05-4P, 3-(2,6-Difluorophenyl)-1-propanamine 465528-47-6P, tert-Butyl 4-methoxy-2-[[1-[[[3-(4-methoxyphenyl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoate 465528-48-7P, tert-Butyl 4-methoxy-2-[[1-[[[3-(4-methoxyphenyl)-1-methylpropyl]amino]carbonyl]cyclopentyl]methyl]butanoate 465528-49-8P, tert-Butyl 4-methoxy-2-[[1-[[[2-(2-chlorophenoxy)-1-methylethyl]amino]carbonyl]cyclopentyl]methyl]butanoate 465528-50-1P, tert-Butyl 4-methoxy-2-[[1-[[[3-(4-fluorophenyl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoate 465528-51-2P, tert-Butyl 4-methoxy-2-[[1-[[[4-phenylbutyl]amino]carbonyl]cyclopentyl]methyl]butanoate 465528-52-3P, tert-Butyl 4-methoxy-2-[[1-[[[3-phenylpropyl]amino]carbonyl]cyclopentyl]methyl]butanoate 465528-53-4P, tert-Butyl 4-methoxy-2-[[1-[[[3-(4-

hydroxyphenyl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoate
465528-54-5P, tert-Butyl 4-methoxy-2-[[1-[[[3-(4-
(trifluoromethyl)phenyl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoate
465528-55-6P, tert-Butyl 4-methoxy-2-[[1-[[[3-(4-
ethylphenyl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoate
465528-56-7P, tert-Butyl 4-methoxy-2-[[1-[[[3-(4-methoxy-2-
methylphenyl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoate
465528-57-8P, tert-Butyl 4-methoxy-2-[[1-[[[3-(2,3-
dihydrobenzofuran-5-yl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoate
465528-58-9P, tert-Butyl 4-methoxy-2-[[1-[[[3-(2-
hydroxyphenyl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoate
465528-59-0P, tert-Butyl 4-methoxy-2-[[1-[[[3-(3-
chlorophenyl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoate
465528-60-3P, tert-Butyl 4-methoxy-2-[[1-[[[3-(2-
chlorophenyl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoate
465528-61-4P, tert-Butyl 4-methoxy-2-[[1-[[[3-(4-
chlorophenyl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoate
465528-62-5P, tert-Butyl (2R)-2-propyl-3-[1-[[[3-(4-
methoxyphenyl)propyl]amino]carbonyl]cyclopentyl]propanoate 465528-63-6P,
tert-Butyl (2R)-2-methyl-3-[1-[[[3-(4-methoxyphenyl)propyl]amino]carbonyl]
cyclopentyl]propanoate 465528-64-7P, tert-Butyl 3-[1-[[[3-(4-
methoxyphenyl)propyl]amino]carbonyl]cyclopentyl]propanoate 465528-65-8P,
tert-Butyl 3-[1-[[[3-(3-chlorophenyl)propyl]amino]carbonyl]cyclopentyl]pro
panoate 465528-66-9P, tert-Butyl 3-[1-[[[3-(4-
chlorophenyl)propyl]amino]carbonyl]cyclopentyl]propanoate 465528-67-0P,
tert-Butyl 3-[1-[[[3-(2,3-dihydrobenzofuran-5-
yl)propyl]amino]carbonyl]cyclopentyl]propanoate 465528-68-1P, tert-Butyl
(2S)-4-methoxy-2-[[1-[[[3-(4-chlorophenyl)propyl]amino]carbonyl]cyclopenty
l]methyl]butanoate 465528-69-2P, tert-Butyl (2S)-4-methoxy-2-[[1-[[[3-(4-
fluorophenyl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoate
465528-70-5P, tert-Butyl (2S)-4-methoxy-2-[[1-[[[3-(4-
methoxyphenyl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoate
465528-71-6P, tert-Butyl (2S)-4-methoxy-2-[[1-[[[3-(2,3-
dihydrobenzofuran-5-yl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoate
465528-72-7P, tert-Butyl 3-[1-[[[3-(6-quinolinyl)propyl]amino]carbonyl]cyc
lopentyl]propanoate 465528-73-8P, tert-Butyl 4-methoxy-2-[[1-[[[3-(2-
methoxyphenyl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoate
465528-74-9P, tert-Butyl 4-methoxy-2-[[1-[[[3-(4-
methylphenyl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoate
465528-75-0P, tert-Butyl 4-methoxy-2-[[1-[[[3-(3-
(benzyloxy)phenyl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoate
465528-76-1P, tert-Butyl 4-methoxy-2-[[1-[[[3-(3-
methoxyphenyl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoate
465528-77-2P, tert-Butyl 4-methoxy-2-[[1-[[[3-(2,4-
dimethoxyphenyl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoate
465528-78-3P, tert-Butyl (2S)-4-methoxy-2-[[1-[[[4-(4-
methoxyphenyl)butyl]amino]carbonyl]cyclopentyl]methyl]butanoate
465528-79-4P, tert-Butyl 3-[1-[[[3-(1-naphthyl)propyl]amino]carbonyl]cyclo
pentyl]propanoate 465528-80-7P, tert-Butyl 3-[1-[[[3-(2-
naphthyl)propyl]amino]carbonyl]cyclopentyl]propanoate 465528-81-8P,
tert-Butyl (2S)-4-methoxy-2-[[1-[[[3-(3-chloro-4-
fluorophenyl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoate
465528-82-9P, tert-Butyl (2S)-4-methoxy-2-[[1-[[[3-(4-chloro-3-
fluorophenyl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoate
465528-83-0P, tert-Butyl (2S)-4-methoxy-2-[[1-[[[3-(2,4-
difluorophenyl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoate
465528-84-1P, tert-Butyl 3-[1-[[[3-(2,6-difluorophenyl)propyl]amino]carbon
yl]cyclopentyl]propanoate 465528-85-2P, tert-Butyl 3-[1-[[[3-(2,3-
difluorophenyl)propyl]amino]carbonyl]cyclopentyl]propanoate
465528-86-3P, tert-Butyl 3-[1-[[[3-(4-(trifluoromethoxy)phenyl)propyl]amin
o]carbonyl]cyclopentyl]propanoate **465528-87-4P**, tert-Butyl
(2S)-4-methoxy-2-[[1-[[[3-(2-pyridyl)propyl]amino]carbonyl]cyclopentyl]met
hyl]butanoate 465528-88-5P, tert-Butyl 3-[1-[[[3-(5-

indanyl)propyl]amino]carbonyl]cyclopentyl]propanoate **465528-89-6P**, tert-Butyl (2S)-4-methoxy-2-[[1-[[[3-(3,4-(ethylenedioxy)phenyl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoate 465528-90-9P, tert-Butyl (2S)-4-methoxy-2-[[1-[[[3-(4-(2-pyridyl)phenyl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoate 465528-91-0P, tert-Butyl 3-[1-[[[3-(4-bromophenyl)propyl]amino]carbonyl]cyclopentyl]propanoate 465528-92-1P, tert-Butyl 3-[1-[[[3-(1-methyl-5-indazolyl)propyl]amino]carbonyl]cyclopentyl]propanoate 465528-93-2P, tert-Butyl 3-[1-[[[3-(2-methyl-2H-indazol-5-yl)propyl]amino]carbonyl]cyclopentyl]propanoate 465528-94-3P, tert-Butyl 3-[1-[[[3-(3,4-dihydro-2H-1-benzopyran-6-yl)propyl]amino]carbonyl]cyclopentyl]propanoate 465528-95-4P, tert-Butyl 3-[1-[[[3-(4-(methylthio)phenyl)propyl]amino]carbonyl]cyclopentyl]propanoate 465528-96-5P, tert-Butyl 3-[1-[[[3-(2,3-dihydrobenzofuran-5-yl)butyl]amino]carbonyl]cyclopentyl]propanoate 465528-97-6P, tert-Butyl 3-[1-[[[3-(2,3-dihydrobenzofuran-5-yl)-1-methylpropyl]amino]carbonyl]cyclopentyl]propanoate 465528-98-7P, tert-Butyl (2S)-4-methoxy-2-[[1-[[[3-(4-(methylthio)phenyl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoate 465528-99-8P, tert-Butyl 3-[1-[[[2-(2,3-dihydro-3-benzofuranyl)ethyl]amino]carbonyl]cyclopentyl]propanoate **465529-00-4P**, tert-Butyl (2S)-4-methoxy-2-[[1-[[[3-(2,3-dihydro-7-benzofuranyl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoate **465529-01-5P**, tert-Butyl (2S)-4-methoxy-2-[[1-[[[3-(2,3-dihydro-7-methylbenzofuran-5-yl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoate **465529-02-6P**, tert-Butyl (2S)-2-((2-methoxyethoxy)methyl)-3-[1-[[[3-(2,3-dihydrobenzofuran-5-yl)propyl]amino]carbonyl]cyclopentyl]propanoate **465529-03-7P**, tert-Butyl (2S)-2-((2-methoxyethoxy)methyl)-3-[1-[[[3-(2,3-dihydro-2,2-dimethylbenzofuran-5-yl)propyl]amino]carbonyl]cyclopentyl]propanoate **465529-04-8P**,. tert-Butyl (2R)-2-methyl-3-[1-[[[3-(2,2-difluoro-1,3-benzodioxol-5-yl)propyl]amino]carbonyl]cyclopentyl]propanoate **465529-05-9P**, tert-Butyl (2S)-4-methoxy-2-[[1-[[[3-(2,3-dihydrobenzofuran-5-yl)butyl]amino]carbonyl]cyclopentyl]methyl]butanoate **465529-06-0P**, tert-Butyl (2S)-4-methoxy-2-[[1-[[[3-(2,3-dihydro-6-methylbenzofuran-5-yl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoate 465529-07-1P, tert-Butyl (2S)-2-((2-methoxyethoxy)methyl)-3-[1-[[[3-(4-chlorophenyl)propyl]amino]carbonyl]cyclopentyl]propanoate **465529-08-2P**, tert-Butyl (2S)-4-methoxy-2-[[1-[[[3-(2,3-dihydrobenzofuran-5-yl)-3-methylbutyl]amino]carbonyl]cyclopentyl]methyl]butanoate 465529-09-3P, tert-Butyl (2S)-4-methoxy-2-[[1-[[[3-(4-chlorophenyl)-4-hydroxybutyl]amino]carbonyl]cyclopentyl]methyl]butanoate 465529-10-6P, tert-Butyl (2S)-4-methoxy-2-[[1-[[[3-(4-chlorophenyl)-4-hydroxy-3-methylbutyl]amino]carbonyl]cyclopentyl]methyl]butanoate 465529-11-7P, tert-Butyl (2S)-4-methoxy-2-[[1-[[[3-(3-chloro-4-methoxyphenyl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoate **465529-12-8P**, tert-Butyl (2S)-4-methoxy-2-[[1-[[[3-(2,3-dihydro-2-methylbenzofuran-5-yl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoate 465529-15-1P, tert-Butyl 3-[1-[[[3-(4-cyanophenyl)propyl]amino]carbonyl]cyclopentyl]propanoate 465529-16-2P, Cyclohexanaminium 1-[2-(tert-butoxycarbonyl)-4-methoxybutyl]cyclopentanecarboxylate 465529-17-3P, 1-[(2S)-2-(tert-Butoxycarbonyl)-4-methoxybutyl]cyclopentanecarboxylic acid 465529-18-4P, (1S,2S)-1-Hydroxy-N-methyl-1-phenyl-2-propanaminium 1-[(2S)-2-(tert-butoxycarbonyl)-4-methoxybutyl]cyclopentanecarboxylate 465529-19-5P, 1-(2-tert-Butoxycarbonyl-4-methoxy-3-oxobutyl)cyclopentanecarboxylic acid 465529-20-8P, 8-Methoxymethyl-6-oxo-7-oxaspiro[4.5]decane-9-carboxylic acid tert-butyl ester 465529-21-9P, 1-((2E)-2-tert-Butoxycarbonyl-4-methoxy-2-butenyl)cyclopentanecarboxylic acid 465529-22-0P, 1-((2Z)-2-tert-Butoxycarbonyl-4-methoxy-2-butenyl)cyclopentanecarboxylic acid 465529-24-2P, 1-Benzyl 3-tert-butyl 2-(2-methoxyethyl)malonate 465529-25-3P, 2-(tert-Butoxycarbonyl)-4-methoxybutanoic acid 465529-26-4P, tert-Butyl 2-(2-methoxyethyl)acrylate 465529-27-5P, tert-Butyl (2E)-2-(2-methoxyethyl)-3-[(4-methylphenyl)sulfonyl]-2-propenoate 465529-28-6P, 1-[(1E)-2-(tert-Butoxycarbonyl)-4-methoxy-1-

butenyl]cyclopentanecarboxylic acid 465529-29-7P, Sodium 1-[(1E)-2-(tert-butoxycarbonyl)-4-methoxy-1-butenyl]cyclopentanecarboxylate 465529-31-1P, 1-((2R)-3-tert-Butoxy-2-methyl-3-oxopropyl)cyclopentanecarboxylic acid (+)-pseudoephedrine salt 465529-32-2P, 3-(4-Ethylphenyl)-1-propanamine 465529-33-3P, 3-(4-Methoxy-2-methylphenyl)-1-propanamine 465529-34-4P, 3-(2,3-Dihydrobenzofuran-5-yl)-1-propanamine 465529-35-5P, 3-(4-(2-Pyridyl)phenyl)-1-propanamine 465529-36-6P, 3-(3,4-(Ethylenedioxy)phenyl)-1-propanamine 465529-37-7P, 3-(2,4-Dimethoxyphenyl)-1-propanamine 465529-38-8P, 3-(2,3-Dihydro-2,2-dimethylbenzofuran-5-yl)-1-propanamine 465529-39-9P, 3-(3,4-Dihydro-2H-1-benzopyran-6-yl)-1-propanamine 465529-40-2P, 3-(2,2-Difluoro-1,3-benzodioxol-5-yl)-1-propanamine 465529-41-3P, 3-(2,3-Dihydro-7-methylbenzofuran-5-yl)-1-propanamine 465529-42-4P, 3-(2,3-Dihydro-6-methylbenzofuran-5-yl)-1-propanamine 465529-43-5P, 3-(2,3-Dihydro-2-methylbenzofuran-5-yl)-1-propanamine 465529-45-7P, 5-Bromo-7-methyl-2,3-dihydro-1-benzofuran 465529-46-8P, 3-(4-Chloro-3-fluorophenyl)-2-propenenitrile 465529-47-9P, 3-(4-Chloro-3-fluorophenyl)-1-propylamine 465529-48-0P, 3-(3-Chloro-4-fluorophenyl)-1-propanamine 465529-49-1P, 3-(2,3-Difluorophenyl)-1-propanamine 465529-50-4P, 3-(4-(Trifluoromethoxy)phenyl)-1-propanamine 465529-51-5P, 3-(6-Quinolinyl)-1-propanamine 465529-52-6P, 3-(2,3-Dihydro-7-benzofuranyl)-1-propanamine 465529-53-7P, tert-Butyl 4-(4-hydroxyphenyl)butylcarbamate 465529-54-8P, tert-Butyl 4-(4-methoxyphenyl)butylcarbamate 465529-55-9P, 5-Bromo-2H-indazole 465529-56-0P, 2-Methyl-5-bromo-2H-indazole 465529-57-1P, 1-Methyl-5-bromo-1H-indazole 465529-58-2P, 3-(1-Methyl-1H-indazol-5-yl)-2-propenenitrile 465529-59-3P, 3-(1-Methyl-1H-indazol-5-yl)-1-propanamine 465529-60-6P, 3-(2,3-Dihydro-1H-inden-5-yl)propanamide 465529-61-7P, 1-(2-Chlorophenoxy)-2-propanone oxime 465529-62-8P, 2-(2,3-Dihydro-1-benzofuran-3-yl)ethylamine 465529-63-9P, 3-(2,3-Dihydro-1-benzofuran-5-yl)-2-butenenitrile 465529-64-0P, 3-(2,3-Dihydro-1-benzofuran-5-yl)butylamine 465529-65-1P, (3E)-4-(2,3-Dihydro-1-benzofuran-5-yl)-3-buten-2-one 465529-66-2P, 4-(2,3-Dihydro-1-benzofuran-5-yl)-2-butanone 465529-67-3P, 4-(2,3-Dihydro-1-benzofuran-5-yl)-2-butanamine 465529-68-4P, Methyl (2E)-2-cyano-3-(2,3-dihydro-1-benzofuran-5-yl)-2-butenoate 465529-69-5P, Methyl 2-cyano-3-(2,3-dihydro-1-benzofuran-5-yl)-3-methylbutanoate 465529-70-8P, 3-(2,3-Dihydro-1-benzofuran-5-yl)-3-methylbutanenitrile 465529-71-9P, tert-Butyl 3-(2,3-dihydro-1-benzofuran-5-yl)-3-methylbutylcarbamate 465529-72-0P, 3-(2,3-Dihydro-1-benzofuran-5-yl)-3-methylbutylamine 465529-73-1P, Methyl 2-(4-chlorophenyl)-3-cyanopropanoate 465529-74-2P, 4-Amino-2-(4-chlorophenyl)butanol 465529-75-3P, tert-Butyl 2-(4-chlorophenyl)propanoate 465529-76-4P, 4-Amino-2-(4-chlorophenyl)-2-methylbutanol
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of cyclopentyl-substituted glutaric acid monoamides as **neutral endopeptidase** inhibitors for treating female sexual arousal disorder and related conditions)

IT 465529-14-0P, Sodium (2S)-2-[[1-[[[3-(4-chlorophenyl)propyl]amino]carbonyl]cyclopentyl]methyl]-4-methoxybutanoate monohydrate
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and x-ray powder diffraction pattern; prepn. of cyclopentyl-substituted glutaric acid monoamides as **neutral endopeptidase** inhibitors for treating female sexual arousal disorder and related conditions)

IT **82707-54-8, Neutral endopeptidase**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(prepn. of cyclopentyl-substituted glutaric acid monoamides as **neutral endopeptidase** inhibitors for treating female sexual arousal disorder and related conditions)

IT 465527-76-8P, 4-Methoxy-2-[[1-[[[3-(4-methoxyphenyl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoic acid 465527-77-9P, 4-Methoxy-2-[[1-[[[3-(4-methoxyphenyl)-1-methylpropyl]amino]carbonyl]cyclopentyl]methyl]butanoic acid 465527-78-0P, 4-Methoxy-2-[[1-[[[2-(2-chlorophenoxy)-1-methylethyl]amino]carbonyl]cyclopentyl]methyl]butanoic acid 465527-80-4P, 2-[[1-[[[3-(4-Fluorophenyl)propyl]amino]carbonyl]cyclopentyl]methyl]-4-methoxybutanoic acid 465527-82-6P, 4-Methoxy-2-[[1-[[[4-phenylbutyl]amino]carbonyl]cyclopentyl]methyl]butanoic acid 465527-83-7P, 4-Methoxy-2-[[1-[[[3-phenylpropyl]amino]carbonyl]cyclopentyl]methyl]butanoic acid 465527-85-9P, 4-Methoxy-2-[[1-[[[3-(4-hydroxyphenyl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoic acid 465527-87-1P, 4-Methoxy-2-[[1-[[[3-(4-(trifluoromethyl)phenyl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoic acid 465527-88-2P, 4-Methoxy-2-[[1-[[[3-(4-ethylphenyl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoic acid 465527-89-3P, 4-Methoxy-2-[[1-[[[3-(4-methoxy-2-methylphenyl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoic acid **465527-90-6P**, 4-Methoxy-2-[[1-[[[3-(2,3-dihydrobenzofuran-5-yl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoic acid 465527-91-7P, 4-Methoxy-2-[[1-[[[3-(2-hydroxyphenyl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoic acid 465527-92-8P, 4-Methoxy-2-[[1-[[[3-(3-chlorophenyl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoic acid 465527-93-9P, 4-Methoxy-2-[[1-[[[3-(2-chlorophenyl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoic acid 465527-94-0P, 2-[[1-[[[3-(4-Chlorophenyl)propyl]amino]carbonyl]cyclopentyl]methyl]-4-methoxybutanoic acid 465527-95-1P, (2R)-2-Propyl-3-[1-[[[3-(4-methoxyphenyl)propyl]amino]carbonyl]cyclopentyl]propanoic acid 465527-96-2P, (2R)-2-Methyl-3-[1-[[[3-(4-methoxyphenyl)propyl]amino]carbonyl]cyclopentyl]propanoic acid 465527-97-3P, 3-[1-[[[3-(4-Methoxyphenyl)propyl]amino]carbonyl]cyclopentyl]propanoic acid 465527-98-4P, 3-[1-[[[3-(3-Chlorophenyl)propyl]amino]carbonyl]cyclopentyl]propanoic acid 465527-99-5P, 3-[1-[[[3-(4-Chlorophenyl)propyl]amino]carbonyl]cyclopentyl]propanoic acid 465528-00-1P, 3-[1-[[[3-(2,3-Dihydrobenzofuran-5-yl)propyl]amino]carbonyl]cyclopentyl]propanoic acid 465528-01-2P, (2S)-2-[[1-[[[3-(4-Chlorophenyl)propyl]amino]carbonyl]cyclopentyl]methyl]-4-methoxybutanoic acid 465528-02-3P, (2S)-4-Methoxy-2-[[1-[[[3-(4-fluorophenyl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoic acid 465528-03-4P, (2S)-4-Methoxy-2-[[1-[[[3-(4-methoxyphenyl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoic acid **465528-04-5P**, (2S)-4-Methoxy-2-[[1-[[[3-(2,3-dihydrobenzofuran-5-yl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoic acid 465528-05-6P, 3-[1-[[[3-(6-Quinolinyl)propyl]amino]carbonyl]cyclopentyl]propanoic acid 465528-06-7P, 4-Methoxy-2-[[1-[[[3-(2-methoxyphenyl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoic acid 465528-07-8P, 4-Methoxy-2-[[1-[[[3-(4-methylphenyl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoic acid 465528-08-9P, 4-Methoxy-2-[[1-[[[3-(3-(benzyloxy)phenyl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoic acid 465528-09-0P, 4-Methoxy-2-[[1-[[[3-(3-methoxyphenyl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoic acid 465528-10-3P, 4-Methoxy-2-[[1-[[[3-(2,4-dimethoxyphenyl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoic acid 465528-11-4P, (2S)-4-Methoxy-2-[[1-[[[4-(4-methoxyphenyl)butyl]amino]carbonyl]cyclopentyl]methyl]butanoic acid 465528-12-5P, 3-[1-[[[3-(1-Naphthyl)propyl]amino]carbonyl]cyclopentyl]propanoic acid 465528-13-6P, 3-[1-[[[3-(2-Naphthyl)propyl]amino]carbonyl]cyclopentyl]propanoic acid 465528-14-7P, (2S)-4-Methoxy-2-[[1-[[[3-(3-chloro-4-fluorophenyl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoic acid 465528-15-8P, (2S)-4-Methoxy-2-[[1-[[[3-(4-chloro-3-fluorophenyl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoic acid 465528-16-9P, (2S)-4-Methoxy-2-[[1-[[[3-(2,4-difluorophenyl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoic acid 465528-17-0P, 3-[1-[[[3-(2,6-Difluorophenyl)propyl]amino]carbonyl]cyclopentyl]propanoic acid 465528-18-1P, 3-[1-[[[3-(2,3-Difluorophenyl)propyl]amino]carbonyl]cyclopentyl]propanoic acid 465528-19-2P, 3-[1-[[[3-(4-(Trifluoromethoxy)phenyl)propyl]amino]carbonyl]cyclopentyl]propanoic acid **465528-20-5P**, (2S)-4-Methoxy-2-[[1-

[[[3-(2-pyridyl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoic acid 465528-21-6P, 3-[1-[[[3-(5-Indanyl)propyl]amino]carbonyl]cyclopentyl]propanoic acid **465528-22-7P** 465528-23-8P, (2S)-4-Methoxy-2-[[1-[[[3-(4-(2-pyridyl)phenyl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoic acid 465528-24-9P, 3-[1-[[[3-(4-Bromophenyl)propyl]amino]carbonyl]cyclopentyl]propanoic acid 465528-25-0P, 3-[1-[[[3-(1-Methyl-5-indazolyl)propyl]amino]carbonyl]cyclopentyl]propanoic acid 465528-26-1P, 3-[1-[[[3-(4-Cyanophenyl)propyl]amino]carbonyl]cyclopentyl]propanoic acid 465528-27-2P, 3-[1-[[[3-(2-Methyl-2H-indazol-5-yl)propyl]amino]carbonyl]cyclopentyl]propanoic acid 465528-28-3P, 3-[1-[[[3-(3,4-Dihydro-2H-1-benzopyran-6-yl)propyl]amino]carbonyl]cyclopentyl]propanoic acid 465528-29-4P, 3-[1-[[[3-(4-(Methylthio)phenyl)propyl]amino]carbonyl]cyclopentyl]propanoic acid 465528-30-7P, 3-[1-[[[3-(2,3-Dihydrobenzofuran-5-yl)butyl]amino]carbonyl]cyclopentyl]propanoic acid 465528-31-8P, 3-[1-[[[3-(2,3-Dihydrobenzofuran-5-yl)-1-methylpropyl]amino]carbonyl]cyclopentyl]propanoic acid 465528-32-9P, (2S)-4-Methoxy-2-[[1-[[[3-(4-(methylthio)phenyl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoic acid 465528-33-0P, 3-[1-[[[2-(2,3-Dihydro-3-benzofuranyl)ethyl]amino]carbonyl]cyclopentyl]propanoic acid **465528-34-1P**, (2S)-4-Methoxy-2-[[1-[[[3-(2,3-dihydro-7-benzofuranyl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoic acid **465528-35-2P**, (2S)-4-Methoxy-2-[[1-[[[3-(2,3-dihydro-7-methyl-5-benzofuranyl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoic acid **465528-36-3P**, (2S)-2-((2-Methoxyethoxy)methyl)-3-[1-[[[3-(2,3-dihydro-5-benzofuranyl)propyl]amino]carbonyl]cyclopentyl]propanoic acid **465528-37-4P**, (2S)-2-((2-Methoxyethoxy)methyl)-3-[1-[[[3-(2,3-dihydro-2,2-dimethyl-5-benzofuranyl)propyl]amino]carbonyl]cyclopentyl]propanoic acid **465528-38-5P**, (2R)-2-Methyl-3-[1-[[[3-(2,2-difluoro-1,3-benzodioxol-5-yl)propyl]amino]carbonyl]cyclopentyl]propanoic acid **465528-39-6P**, (2S)-4-Methoxy-2-[[1-[[[3-(2,3-dihydro-5-benzofuranyl)butyl]amino]carbonyl]cyclopentyl]methyl]butanoic acid **465528-40-9P**, (2S)-4-Methoxy-2-[[1-[[[3-(2,3-dihydro-6-methyl-5-benzofuranyl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoic acid 465528-41-0P, (2S)-2-((2-Methoxyethoxy)methyl)-3-[1-[[[3-(4-chlorophenyl)propyl]amino]carbonyl]cyclopentyl]propanoic acid **465528-42-1P**, (2S)-4-Methoxy-2-[[1-[[[3-(2,3-dihydrobenzofuran-5-yl)-3-methylbutyl]amino]carbonyl]cyclopentyl]methyl]butanoic acid 465528-43-2P, (2S)-4-Methoxy-2-[[1-[[[3-(4-chlorophenyl)-4-hydroxybutyl]amino]carbonyl]cyclopentyl]methyl]butanoic acid 465528-44-3P, (2S)-4-Methoxy-2-[[1-[[[3-(4-chlorophenyl)-4-hydroxy-3-methylbutyl]amino]carbonyl]cyclopentyl]methyl]butanoic acid 465528-45-4P, (2S)-4-Methoxy-2-[[1-[[[3-(3-chloro-4-methoxyphenyl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoic acid **465528-46-5P**, (2S)-4-Methoxy-2-[[1-[[[3-(2,3-dihydro-2-methylbenzofuran-5-yl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoic acid

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of cyclopentyl-substituted glutaric acid monoamides as **neutral endopeptidase** inhibitors for treating female sexual arousal disorder and related conditions)

IT 465529-23-1P, 1-[(3E)-2-(tert-Butoxycarbonyl)-4-methoxy-3-butenyl]cyclopentanecarboxylic acid

RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. of cyclopentyl-substituted glutaric acid monoamides as **neutral endopeptidase** inhibitors for treating female sexual arousal disorder and related conditions)

IT 67-64-1, Acetone, reactions 90-11-9, 1-Bromonaphthalene 90-82-4, (+)-Pseudoephedrine 91-62-3, 6-Methylquinoline 100-69-6, 2-Vinylpyridine 105-34-0, Methyl cyanoacetate 106-37-6, 1,4-Dibromobenzene 106-38-7, 4-Bromotoluene 107-13-1, Acrylonitrile, reactions 108-39-4, 3-Methylphenol, reactions 108-91-8,

Cyclohexylamine, reactions 109-04-6, 2-Bromopyridine 123-11-5, 4-Methoxybenzaldehyde, reactions 271-44-3, Indazole 437-81-0, 2,6-Difluorobenzaldehyde 496-16-2, 2,3-Dihydrobenzo[b]furan 578-57-4, 2-Bromoanisole 580-13-2, 2-Bromonaphthalene 659-28-9, 4-Trifluoromethoxybenzaldehyde 696-62-8, 4-Iodoanisole 824-42-0, 2-Hydroxy-3-methylbenzaldehyde 1122-91-4, 4-Bromobenzaldehyde 1481-93-2, 4-Chromanol 1585-07-5, 1-Bromo-4-ethylbenzene 1746-11-8, 2-Methyl-2,3-dihydro-1-benzo[b]furan 1878-66-6, p-Chlorophenylacetic acid 1950-78-3, Para-toluenesulfonyl iodide 2019-34-3, 3-(4-Chlorophenyl)propanoic acid 2265-93-2, 2,4-Difluoroiodobenzene 2398-37-0, 3-Bromoanisole 2646-91-5, 2,3-Difluorobenzaldehyde 3400-45-1, Cyclopentanecarboxylic acid 3446-89-7, 4-(Methylthio)benzaldehyde 4296-15-5, 2-Iodoethyl methyl ether 4521-28-2, 4-(4-Methoxyphenyl)butyric acid 5527-95-7, 4-Chloro-3-fluorobenzaldehyde 6290-49-9, Methyl methoxyacetate 6337-33-3, 2,2-Dimethyl-2,3-dihydrobenzo[b]furan 6482-24-2, 2-Bromoethyl methyl ether 7169-34-8, 3-Coumaranone 17715-69-4, 2,4-Dimethoxybromobenzene 18800-42-5, 1-(2-Chlorophenoxy)acetone 27060-75-9, 4-Bromo-3-methylanisole 33070-32-5, 5-Bromo-2,2-difluorobenzodioxolane 34328-61-5, 3-Chloro-4-fluorobenzaldehyde 36805-97-7, N,N-Dimethylformamide di-tert-butyl acetal 52287-51-1, 3,4-Ethylenedioxybromobenzene 52449-43-1, Methyl 2-(4-chlorophenyl)acetate 55745-70-5, 2,3-Dihydrobenzo[b]furan-5-carboxaldehyde 56635-88-2, 3-(2,3-Dihydro-1H-inden-5-yl)propenoic acid 72594-86-6 90843-31-5, 5-Acetyl-2,3-dihydrobenzo[b]furan 118756-03-9, 1-(3-tert-Butoxy-3-oxopropyl)cyclopentanecarboxylic acid 132464-84-7, 5-Iodo-2,3-dihydrobenzofuran 139084-39-2, (R)-1-[2-(tert-Butoxycarbonyl)-4-pentenyl]cyclopentanecarboxylic acid 377084-66-7, 3-(4-Chlorophenyl)propylamine hydrochloride 465529-44-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; prepn. of cyclopentyl-substituted glutaric acid monoamides as **neutral endopeptidase** inhibitors for treating female sexual arousal disorder and related conditions)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Pfizer; WO 9110644 A 1991 HCAPLUS
(2) Pfizer; WO 9113054 A 1991 HCAPLUS
(3) Pfizer; WO 0202513 A 2002 HCAPLUS
(4) Schering; WO 9406756 A 1994 HCAPLUS

IT **465528-57-8P**, tert-Butyl 4-methoxy-2-[[1-[[[3-(2,3-dihydrobenzofuran-5-yl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of cyclopentyl-substituted glutaric acid monoamides as **neutral endopeptidase** inhibitors for treating female sexual arousal disorder and related conditions)

RN 465528-57-8 HCAPLUS

CN Cyclopentanepropanoic acid, 1-[[[3-(2,3-dihydro-5-benzofuranyl)propyl]amino]carbonyl]-.alpha.-(2-methoxyethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L21 ANSWER 3 OF 15 HCAPLUS COPYRIGHT 2003 ACS
AN 2002:391522 HCAPLUS
DN 136:395983
TI Bombesin receptor antagonists, and combinations with other agents, for the treatment of sexual dysfunction
IN Gonzalez, Maria Isabel; Stock, Herman Thijs; Pinnock, Robert Denham; Pritchard, Martyn Clive; Wayman, Christopher Peter; Van der Graaf, Pieter Hadewijn; Naylor, Alisdair Mark; Higginbottom, Michael
PA Warner-Lambert Company, USA
SO PCT Int. Appl., 225 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K031-165
ICS A61K031-395; A61K031-17; A61K031-18; A61P015-10
CC 1-12 (Pharmacology)
Section cross-reference(s): 28, 34
FAN.CNT 9

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002040008	A2	20020523	WO 2001-GB5018	20011114
	WO 2002040008	A3	20020822		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	WO 2002040022	A1	20020523	WO 2000-GB4380	20001117
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2002023802	A5	20020527	AU 2002-23802	20011114
PRAI	WO 2000-GB4380	W	20001117		
	GB 2001-9910	A	20010423		
	GB 2001-11037	A	20010504		
	WO 2001-GB5018	W	20011114		

OS MARPAT 136:395983
AB Bombesin receptor antagonists have been found to be useful in the treatment of sexual dysfunction in both males and females. They may be selective BB1 antagonists or mixed BB1/BB2 antagonists. Combinations are disclosed of bombesin receptor antagonists with a range of other active compds., for example phosphodiesterase V inhibitors, **neutral endopeptidase** inhibitors, and lasofoxifene. Prepn. of compds. of the invention is described.
ST bombesin receptor antagonist sexual dysfunction treatment; phosphodiesterase inhibitor bombesin antagonist sexual dysfunction treatment; **neutral endopeptidase** inhibitor bombesin antagonist prepn sexual dysfunction treatment; lasofoxifene bombesin antagonist sexual dysfunction treatment
IT Nervous system agents
(CNS-active; bombesin receptor antagonists, and combinations with other agents, for treatment of sexual dysfunction)

IT Oxytocin receptors
Vasopressin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(agonists and modulators; bombesin receptor antagonists, and combinations with other agents, for treatment of sexual dysfunction)
IT VIP receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(agonists; bombesin receptor antagonists, and combinations with other agents, for treatment of sexual dysfunction)
IT Estrogens
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(and agonists and antagonists; bombesin receptor antagonists, and combinations with other agents, for treatment of sexual dysfunction)
IT Prostaglandins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(and prostaglandin esters; bombesin receptor antagonists, and combinations with other agents, for treatment of sexual dysfunction)
IT Gastrin-releasing peptide receptors
Tachykinin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonists; bombesin receptor antagonists, and combinations with other agents, for treatment of sexual dysfunction)
IT Steroids, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antiinflammatory; bombesin receptor antagonists, and combinations with other agents, for treatment of sexual dysfunction)
IT Behavior
(arousal, sexual arousal disorders; bombesin receptor antagonists, and combinations with other agents, for treatment of sexual dysfunction)
IT 5-HT agonists
5-HT antagonists
Angiotensin receptor antagonists
Anti-inflammatory agents
Anticholesteremic agents
Anticoagulants
Antidiabetic agents
Dopamine agonists
Drug delivery systems
Drug interactions
Hormone replacement therapy
Human
Opioid antagonists
Platelet aggregation inhibitors
Purinoceptor agonists
Vasodilators
(bombesin receptor antagonists, and combinations with other agents, for treatment of sexual dysfunction)
IT Bombesin receptors
Sex hormones
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(bombesin receptor antagonists, and combinations with other agents, for treatment of sexual dysfunction)
IT Opioids
Peptides, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bombesin receptor antagonists, and combinations with other agents, for treatment of sexual dysfunction)
IT Ion channel blockers
(calcium; bombesin receptor antagonists, and combinations with other

agents, for treatment of sexual dysfunction)
IT Resolution (separation)
(chromatog.; bombesin receptor antagonists, and combinations with other agents, for treatment of sexual dysfunction)
IT Sexual behavior
(disorder; bombesin receptor antagonists, and combinations with other agents, for treatment of sexual dysfunction)
IT Transport proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(dopamine-transporting, modulators; bombesin receptor antagonists, and combinations with other agents, for treatment of sexual dysfunction)
IT Drugs
(drug-induced sexual dysfunction; bombesin receptor antagonists, and combinations with other agents, for treatment of sexual dysfunction)
IT Alkaloids, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ergot; bombesin receptor antagonists, and combinations with other agents, for treatment of sexual dysfunction)
IT Drug delivery systems
(implants, testosterone; bombesin receptor antagonists, and combinations with other agents, for treatment of sexual dysfunction)
IT Sexual behavior
(impotence; bombesin receptor antagonists, and combinations with other agents, for treatment of sexual dysfunction)
IT Pituitary hormone receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(melanocortin, agonists and modulators; bombesin receptor antagonists, and combinations with other agents, for treatment of sexual dysfunction)
IT 5-HT receptors
Cannabinoid receptors
Estrogen receptors
Opioid receptors
Potassium channel
Purinoceptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(modulators; bombesin receptor antagonists, and combinations with other agents, for treatment of sexual dysfunction)
IT Anti-inflammatory agents
(nonsteroidal; bombesin receptor antagonists, and combinations with other agents, for treatment of sexual dysfunction)
IT Transport proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(norepinephrine-transporting, modulators; bombesin receptor antagonists, and combinations with other agents, for treatment of sexual dysfunction)
IT Drug delivery systems
(oral; bombesin receptor antagonists, and combinations with other agents, for treatment of sexual dysfunction)
IT Ion channel openers
(potassium; bombesin receptor antagonists, and combinations with other agents, for treatment of sexual dysfunction)
IT Transport proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(serotonin-transporting, modulators; bombesin receptor antagonists, and combinations with other agents, for treatment of sexual dysfunction)
IT Antidepressants
(sexual dysfunction induced by; bombesin receptor antagonists, and combinations with other agents, for treatment of sexual dysfunction)
IT Analgesics
(sexual pain disorders; bombesin receptor antagonists, and combinations with other agents, for treatment of sexual dysfunction)

IT Bombesin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(type BB1, antagonists; bombesin receptor antagonists, and combinations with other agents, for treatment of sexual dysfunction)
IT Bombesin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(type BB2, antagonists; bombesin receptor antagonists, and combinations with other agents, for treatment of sexual dysfunction)
IT Adrenoceptor antagonists
(.alpha.-; bombesin receptor antagonists, and combinations with other agents, for treatment of sexual dysfunction)
IT 57576-52-0, Thromboxane A2
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(agonists; bombesin receptor antagonists, and combinations with other agents, for treatment of sexual dysfunction)
IT 58-22-0, Testosterone
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(and replacement agents; bombesin receptor antagonists, and combinations with other agents, for treatment of sexual dysfunction)
IT 50-28-2, Estradiol, biological studies 9002-62-4, Prolactin, biological studies 9002-67-9, Luteinizing hormone 9002-68-0, Follicle-stimulating hormone
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(bombesin receptor antagonists, and combinations with other agents, for treatment of sexual dysfunction)
IT 57-83-0, Progesterone, biological studies
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); BIOL (Biological study)
(bombesin receptor antagonists, and combinations with other agents, for treatment of sexual dysfunction)
IT 425638-88-6P 425638-90-0P 425638-92-2P 425638-94-4P 425638-96-6P
425638-98-8P 425639-00-5P 425639-02-7P 425639-04-9P 425639-07-2P
425639-10-7P 425639-13-0P 425639-16-3P 425639-19-6P 425639-22-1P
425639-25-4P 425639-28-7P 425639-31-2P 425639-33-4P 425639-35-6P
425639-37-8P 425639-39-0P 425639-41-4P 425639-43-6P 425639-45-8P
425639-47-0P 425639-48-1P 425639-49-2P 425639-50-5P 425639-53-8P
425639-55-0P 425639-57-2P 425639-59-4P 425639-61-8P 425639-65-2P
425639-68-5P 425639-70-9P 425639-72-1P 425639-74-3P 425639-76-5P
425639-77-6P 425639-79-8P 425639-81-2P 425639-83-4P 425639-85-6P
425639-87-8P 425639-89-0P 425639-91-4P 425639-93-6P 425639-95-8P
425639-96-9P 425639-97-0P 425639-98-1P 425639-99-2P 425640-00-2P
425640-01-3P 425640-02-4P 425640-03-5P 425640-15-9P 425640-23-9P
425641-28-7P 429657-44-3P
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(bombesin receptor antagonists, and combinations with other agents, for treatment of sexual dysfunction)
IT 50-50-0, Estradiol benzoate 102577-19-5, Neuromedin B
RL: PAC (Pharmacological activity); BIOL (Biological study)
(bombesin receptor antagonists, and combinations with other agents, for treatment of sexual dysfunction)
IT 426213-31-2P 426213-32-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(bombesin receptor antagonists, and combinations with other agents, for treatment of sexual dysfunction)
IT 58-18-4, Methyl testosterone 59-92-7, biological studies 71-58-9, Medroxyprogesterone acetate 520-85-4, Medroxyprogesterone 521-18-6, Dihydrotestosterone 28860-95-9, Carbidopa 37221-79-7, Vasoactive intestinal polypeptide 37221-79-7D, Vasoactive intestinal polypeptide,

analogs 114798-26-4, Losartan 204066-72-8 204066-73-9 204066-75-1
204066-76-2 204066-78-4 204066-79-5 204066-80-8 204066-82-0
204066-83-1 204066-84-2 204066-86-4 204066-87-5 204066-89-7
204066-93-3 204066-95-5 204067-01-6 204067-38-9 215297-27-1
425640-04-6 425640-06-8 425640-08-0 425640-09-1 425640-10-4
425640-11-5 425640-12-6 425640-14-8 425640-17-1 425640-18-2
425640-20-6 425640-21-7 425640-24-0 425640-26-2 425640-28-4
425640-30-8 425640-32-0 425640-34-2 425640-36-4 425640-38-6
425640-39-7 425640-40-0 425640-41-1 425640-43-3 425640-45-5
425640-47-7 425640-49-9 425640-51-3 425640-53-5 425640-55-7
425640-57-9 425640-59-1 425640-60-4 425640-62-6 425640-66-0
425640-68-2 425640-70-6 425640-72-8 425640-74-0 425640-76-2
425640-78-4 425640-80-8 425640-82-0 425640-83-1 425640-84-2
425640-85-3 425640-86-4 425640-87-5 425640-88-6 425640-89-7
425640-90-0 425640-91-1 425640-92-2 425640-93-3 425640-94-4
425640-95-5 425640-96-6 425640-97-7 425640-98-8 425640-99-9
425641-00-5 425641-01-6 425641-02-7 425641-03-8 425641-04-9
425641-05-0 425641-06-1 425641-07-2 425641-08-3 425641-09-4
425641-10-7 425641-11-8 425641-12-9 425641-13-0 425641-14-1
425641-15-2 425641-16-3 425641-17-4 425641-18-5 425641-19-6
425641-20-9 425641-21-0 425641-22-1 425641-23-2 425641-24-3
425641-25-4 425641-26-5 425641-27-6 425641-29-8 425641-30-1
428864-38-4 428864-39-5 428864-40-8 428864-41-9 428864-42-0
428864-43-1 428864-44-2 428864-45-3 428864-46-4 428864-47-5
428864-48-6 428864-49-7 428864-50-0 428864-51-1 428864-52-2
428864-53-3 428864-54-4 428864-55-5 428864-56-6 428864-57-7
428864-58-8 428864-59-9 428864-63-5 428864-64-6 428864-66-8
428864-67-9
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bombesin receptor antagonists, and combinations with other agents, for treatment of sexual dysfunction)

IT **388630-36-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(bombesin receptor antagonists, and combinations with other agents, for treatment of sexual dysfunction)

IT **337962-74-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(bombesin receptor antagonists, and combinations with other agents, for treatment of sexual dysfunction)

IT 10102-43-9, Nitric oxide, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(donors; bombesin receptor antagonists, and combinations with other agents, for treatment of sexual dysfunction)

IT 128908-32-7, Melanocortin
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(enhancers; bombesin receptor antagonists, and combinations with other agents, for treatment of sexual dysfunction)

IT 9000-81-1, Acetylcholinesterase 9025-82-5, Phosphodiesterase
9068-52-4, Phosphodiesterase V **82707-54-8, Neutral endopeptidase** 82785-45-3, Neuropeptide Y
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; bombesin receptor antagonists, and combinations with other agents, for treatment of sexual dysfunction)

IT 9088-07-7, Natriuretic factor
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(modulators; bombesin receptor antagonists, and combinations with other agents, for treatment of sexual dysfunction)

IT 25506-37-0P 31558-54-0P 63430-65-9P 73717-05-2P 97534-88-8P
97557-59-0P 105754-24-3P 137140-98-8P 158556-65-1P 158951-86-1P
159672-85-2P 159672-86-3P 160233-08-9P 172154-13-1P 172154-15-3P
172154-17-5P 172154-18-6P 204067-15-2P 204067-16-3P 204067-17-4P

291761-10-9P 337962-91-1P **388630-99-7P** 425641-31-2P
425641-32-3P 425641-33-4P 425641-34-5P 425641-39-0P 425641-46-9P
425641-47-0P 425641-48-1P 425641-49-2P 425641-50-5P 425641-51-6P
425641-52-7P 425641-53-8P 428864-72-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction; bombesin receptor antagonists, and combinations with other agents, for treatment of sexual dysfunction)

IT 55-22-1, Isonicotinic acid, reactions 62-23-7, 4-Nitrobenzoic acid 65-85-0, Benzoic acid, reactions 74-11-3, 4-Chlorobenzoic acid 85-46-1, 1-Naphthalenesulfonyl chloride 86-59-9, Quinoline-8-carboxylic acid 88-13-1, Thiophene-3-carboxylic acid 88-14-2, Furan-2-carboxylic acid 89-95-2 93-03-8 93-11-8, 2-Naphthalenesulfonyl chloride 93-25-4, (2-Methoxyphenyl)acetic acid 98-31-7 98-59-9 98-60-2 98-74-8 98-98-6, Pyridine-2-carboxylic acid 99-04-7, 3-Methylbenzoic acid 99-64-9, 3-Dimethylaminobenzoic acid 99-81-0 99-94-5, 4-Methylbenzoic acid 100-09-4, 4-Methoxybenzoic acid 104-01-8, (4-Methoxyphenyl)acetic acid 104-03-0, (4-Nitrophenyl)acetic acid 105-13-5 108-86-1, Bromobenzene, reactions 118-90-1, 2-Methylbenzoic acid 118-91-2, 2-Chlorobenzoic acid 121-51-7 122-78-1, Benzeneacetaldehyde 156-38-7, (4-Hydroxyphenyl)acetic acid 349-75-7 349-88-2 349-95-1 445-29-4, 2-Fluorobenzoic acid 446-51-5 451-82-1, (2-Fluorophenyl)acetic acid 488-93-7, Furan-3-carboxylic acid 527-72-0, Thiophene-2-carboxylic acid 535-80-8, 3-Chlorobenzoic acid 552-16-9, 2-Nitrobenzoic acid 555-16-8, 4-Nitrobenzaldehyde, reactions 579-75-9, 2-Methoxybenzoic acid 586-38-9, 3-Methoxybenzoic acid 587-03-1 589-18-4 591-17-3, 1-Bromo-3-methylbenzene 605-65-2 610-16-2, 2-Dimethylaminobenzoic acid 612-16-8 613-89-8 615-18-9, 2-Chlorobenzoxazole 619-25-0 619-73-8 621-36-3, m-Tolylacetic acid 621-37-4, (3-Hydroxyphenyl)acetic acid 622-47-9, p-Tolylacetic acid 644-36-0, o-Tolylacetic acid 673-06-3, D-Phenylalanine 701-27-9 776-04-5 777-44-6 873-76-7 874-97-5 877-65-6 879-65-2, Quinoxaline-2-carboxylic acid 931-97-5, 1-Hydroxycyclohexanecarbonitrile 934-60-1, 6-Methylpyridine-2-carboxylic acid 1477-50-5, 1H-Indole-2-carboxylic acid 1592-38-7, 2-Naphthalenemethanol 1656-44-6 1670-81-1, 1H-Indole-5-carboxylic acid 1670-82-2, 1H-Indole-6-carboxylic acid 1670-83-3, 1H-Indole-7-carboxylic acid 1777-82-8 1805-32-9 1877-72-1, 3-Cyanobenzoic acid 1899-93-0 1918-79-2, 5-Methylthiophene-2-carboxylic acid 1939-99-7, Benzenemethanesulfonyl chloride 2104-06-5 2124-55-2, 1H-Indole-4-carboxylic acid 2688-90-6, [1,1'-Biphenyl]-2-sulfonyl chloride 2766-74-7 2888-06-4 2905-21-7 2905-23-9 2991-42-6 3405-77-4, 5-Methylisoxazole-3-carboxylic acid 3622-35-3, Benzothiazole-6-carboxylic acid 4052-30-6, 4-Methanesulfonylbenzoic acid 4254-29-9 4265-16-1, Benzofuran-2-carbaldehyde 4533-95-3 4533-96-4 4780-79-4, 1-Naphthalenemethanol 5345-27-7 6314-28-9, Benzo[b]thiophene-2-carboxylic acid 6624-49-3, Isoquinoline-3-carboxylic acid 6964-21-2, 3-Thiopheneacetic acid 6973-60-0 7693-46-1, p-Nitrophenyl chloroformate 10130-74-2 10333-68-3, 2-Pyrrol-1-ylbenzoic acid 13826-35-2 14068-53-2, 2-Amino-5-ethyl-1,3,4-thiadiazole 15084-51-2 16136-58-6, 1-Methyl-1H-indole-2-carboxylic acid 16629-19-9, 2-Thiophenesulfonyl chloride 16709-25-4 17078-28-3, (4-Dimethylaminophenyl)acetic acid 17849-38-6 18704-37-5, 8-Quinolinesulfonyl chloride 23095-31-0 23806-24-8, 3-Methylthiophene-2-carboxylic acid 23814-12-2, 1H-Benzotriazole-5-carboxylic acid 24424-99-5, Di-tert-butyl dicarbonate 24974-75-2 26638-43-7 28286-86-4 38594-42-2 39774-26-0, 2-Bromo-6-phenylpyridine 42413-03-6 49584-26-1 51527-73-2 54997-92-1 56542-67-7 56946-83-9 59337-92-7 69360-26-5 71648-21-0 73713-79-8 80466-79-1 82964-91-8 88398-93-0 91170-93-3 94108-56-2 99924-18-2 100516-88-9, 6-Quinolinemethanol 114322-14-4, 2,1,3-Benzoxadiazole-4-sulfonyl chloride 118783-85-0 137049-00-4 137049-02-6 142854-50-0 151858-64-9 160233-27-2 166964-37-0

185908-35-4 204067-08-3 204067-12-9 206262-15-9 206262-83-1
216394-05-7 216394-11-5 425641-35-6 425641-36-7 425641-37-8
425641-38-9 425641-40-3 425641-41-4 425641-42-5 425641-43-6
425641-45-8 426213-33-4 426213-34-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction; bombesin receptor antagonists, and combinations with other agents, for treatment of sexual dysfunction)

IT 9004-10-8, Insulin, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(sensitizing agents; bombesin receptor antagonists, and combinations with other agents, for treatment of sexual dysfunction)

IT 125978-95-2, Nitric oxide synthase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(substrates; bombesin receptor antagonists, and combinations with other agents, for treatment of sexual dysfunction)

IT **388630-36-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(bombesin receptor antagonists, and combinations with other agents, for treatment of sexual dysfunction)

RN 388630-36-2 HCAPLUS
CN Cyclopentanepropanoic acid, 1-[[(5-ethyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]-.alpha.-propyl-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L21 ANSWER 4 OF 15 HCAPLUS COPYRIGHT 2003 ACS
AN 2002:304371 HCAPLUS
DN 138:49186
TI SLV-306
AU Sorbera, L. A.; Leeson, P. A.; Castaner, J.
CS Prous Science, Barcelona, 08080, Spain
SO Drugs of the Future (2002), 27(1), 27-31
CODEN: DRFUD4; ISSN: 0377-8282
PB Prous Science
DT Journal; General Review
LA English
CC 1-0 (Pharmacology)
AB A review. The synthesis, pharmacol. actions, and clin. studies of SLV-306, a new drug for treating hypertension, is described. SLV-306 is synthesized by acylation of 3(S)-amino-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepine-1-acetic acid tert-Bu ester with 1-[2-(R)-(ethoxycarbony)-4-phenyl-butyl]cyclopentanecarboxylic acid by methanesulfonyl chloride and triethylamine in dichloromethane to yield the amide (III), which is then treated with trifluoroacetic acid to eliminate the tert Bu ester group.
ST review antihypertensive **neprilysin** inhibitor SLV306 synthesis heart failure
IT Antihypertensives
Hypertension
(antihypertensive SLV-306)
IT Heart, disease
(failure; antihypertensive SLV-306)

IT **182821-27-8P**, SLV 306
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antihypertensive SLV-306)
IT **82707-54-8, Neprilysin** 138238-81-0, Endothelin converting enzyme
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; antihypertensive SLV-306)
RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Anon; DailyDrugNews com 2001
(2) Anon; Pipeline 2002
(3) Meil, J; Naunyn-Schmied Arch Pharmacol, Abst P 52.22 1998, V358(1, Suppl 2)
(4) Meil, J; Naunyn-Schmied Arch Pharmacol, Abst P 52.25 1998, V358(1, Suppl 2)
(5) Prous Science Drug R&d Backgrounders; Arterial hypertensior (online publication) 2001
(6) Prous Science Drug R&d Backgrounders; Heart failure (online publication) 2002
(7) Seed, A; J Am Coll Cardiol 2001, V37(2, Suppl A), P237A
(8) Thormahlen, D; 6th Int Conf Endothelin, Abst 180 1999
(9) Waldeck, H; EP 0733642 HCAPLUS
(10) Waldeck, H; JP 1996269011
(11) Waldeck, H; CA 2172354 HCAPLUS
(12) Waldeck, H; US 5677297 HCAPLUS
IT **182821-27-8P**, SLV 306
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antihypertensive SLV-306)
RN 182821-27-8 HCAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[(2R)-2-(ethoxycarbonyl)-4-phenylbutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L21 ANSWER 5 OF 15 HCAPLUS COPYRIGHT 2003 ACS
AN 2002:51273 HCAPLUS
DN 136:96099
TI Treatment of male sexual dysfunction
IN Naylor, Alasdair Mark; Van der Graaf, Pieter Hadewijn; Wayman, Christopher Peter
PA Pfizer Limited, UK; Pfizer Inc.
SO PCT Int. Appl., 124 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K031-55
ICS A61K031-401; A61K031-4166; A61K031-41; A61K031-421; A61K031-4365;

A61K031-17; A61K031-16
CC 1-12 (Pharmacology)
Section cross-reference(s): 24, 25, 27, 28
FAN.CNT 9

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002003995	A2	20020117	WO 2001-IB1187	20010702
	WO 2002003995	A3	20020418		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2002052370	A1	20020502	US 2001-893585	20010628
PRAI	GB 2000-16684	A	20000706		
	GB 2000-30647	A	20001215		
	GB 2001-6167	A	20010313		
	GB 2001-8483	A	20010404		
	US 2000-219100P	P	20000718		
	GB 2001-1584	A	20010122		
	US 2001-274957P	P	20010312		

OS MARPAT 136:96099
AB The present invention relates to the use of **neutral endopeptidase** inhibitors (NEPi) and a combination of NEPi and phosphodiesterase type (PDE5) inhibitor for the treatment of male sexual dysfunction, in particular MED.
ST male sexual dysfunction **neutral endopeptidase** inhibitor
IT Opioid receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study) (ORL1 (opioid receptor-like 1), modulators; treatment of male sexual dysfunction using **neutral endopeptidase** inhibitors and their combination with phosphodiesterase type 5 inhibitors and other agents in relation to inhibition of angiotensin converting enzyme)
IT Neuropeptide Y receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study) (Y5, antagonists; treatment of male sexual dysfunction using **neutral endopeptidase** inhibitors and their combination with phosphodiesterase type 5 inhibitors and other agents in relation to inhibition of angiotensin converting enzyme)
IT Neuropeptide Y receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study) (Y1, antagonists; treatment of male sexual dysfunction using **neutral endopeptidase** inhibitors and their combination with phosphodiesterase type 5 inhibitors and other agents in relation to inhibition of angiotensin converting enzyme)
IT VIP receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study) (agonists; treatment of male sexual dysfunction using **neutral endopeptidase** inhibitors and their combination with phosphodiesterase type 5 inhibitors and other agents in relation to inhibition of angiotensin converting enzyme)
IT Endothelin receptors
Tachykinin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study) (antagonists; treatment of male sexual dysfunction using **neutral endopeptidase** inhibitors and their combination with phosphodiesterase type 5 inhibitors and other agents

in relation to inhibition of angiotensin converting enzyme)
IT Estrogens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antiestrogens; treatment of male sexual dysfunction using **neutral endopeptidase** inhibitors and their combination with phosphodiesterase type 5 inhibitors and other agents in relation to inhibition of angiotensin converting enzyme)
IT Ion channel blockers
(calcium; treatment of male sexual dysfunction using **neutral endopeptidase** inhibitors and their combination with phosphodiesterase type 5 inhibitors and other agents in relation to inhibition of angiotensin converting enzyme)
IT Sexual behavior
(disorder, male; treatment of male sexual dysfunction using **neutral endopeptidase** inhibitors and their combination with phosphodiesterase type 5 inhibitors and other agents in relation to inhibition of angiotensin converting enzyme)
IT Transport proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(dopamine-transporting, modulators; treatment of male sexual dysfunction using **neutral endopeptidase** inhibitors and their combination with phosphodiesterase type 5 inhibitors and other agents in relation to inhibition of angiotensin converting enzyme)
IT Sexual behavior
(ejaculation, disorder; treatment of male sexual dysfunction using **neutral endopeptidase** inhibitors and their combination with phosphodiesterase type 5 inhibitors and other agents in relation to inhibition of angiotensin converting enzyme)
IT Alkaloids, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ergot; treatment of male sexual dysfunction using **neutral endopeptidase** inhibitors and their combination with phosphodiesterase type 5 inhibitors and other agents in relation to inhibition of angiotensin converting enzyme)
IT Anticholesteremic agents
(fibrates and statins; treatment of male sexual dysfunction using **neutral endopeptidase** inhibitors and their combination with phosphodiesterase type 5 inhibitors and other agents in relation to inhibition of angiotensin converting enzyme)
IT Sexual behavior
(impotence; treatment of male sexual dysfunction using **neutral endopeptidase** inhibitors and their combination with phosphodiesterase type 5 inhibitors and other agents in relation to inhibition of angiotensin converting enzyme)
IT Pituitary hormone receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(melanocortin, agonists; treatment of male sexual dysfunction using **neutral endopeptidase** inhibitors and their combination with phosphodiesterase type 5 inhibitors and other agents in relation to inhibition of angiotensin converting enzyme)
IT Cannabinoid receptors
Estrogen receptors
Opioid receptors
Oxytocin receptors
Vasopressin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(modulators; treatment of male sexual dysfunction using **neutral endopeptidase** inhibitors and their combination with phosphodiesterase type 5 inhibitors and other agents in relation to inhibition of angiotensin converting enzyme)
IT Transport proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(norepinephrine-transporting, modulators; treatment of male sexual dysfunction using **neutral endopeptidase** inhibitors and their combination with phosphodiesterase type 5 inhibitors and other agents in relation to inhibition of angiotensin converting enzyme)

IT Drug delivery systems
(oral; treatment of male sexual dysfunction using **neutral endopeptidase** inhibitors and their combination with phosphodiesterase type 5 inhibitors and other agents in relation to inhibition of angiotensin converting enzyme)

IT Ion channel openers
(potassium; treatment of male sexual dysfunction using **neutral endopeptidase** inhibitors and their combination with phosphodiesterase type 5 inhibitors and other agents in relation to inhibition of angiotensin converting enzyme)

IT Sexual behavior
(premature ejaculation; treatment of male sexual dysfunction using **neutral endopeptidase** inhibitors and their combination with phosphodiesterase type 5 inhibitors and other agents in relation to inhibition of angiotensin converting enzyme)

IT Transport proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(serotonin-transporting, modulators; treatment of male sexual dysfunction using **neutral endopeptidase** inhibitors and their combination with phosphodiesterase type 5 inhibitors and other agents in relation to inhibition of angiotensin converting enzyme)

IT Drug delivery systems
(tablets; treatment of male sexual dysfunction using **neutral endopeptidase** inhibitors and their combination with phosphodiesterase type 5 inhibitors and other agents in relation to inhibition of angiotensin converting enzyme)

IT 5-HT agonists
5-HT antagonists
Angiotensin receptor antagonists
Anticoagulants
Dopamine agonists
Drug interactions
Drug screening
Opioid antagonists
Platelet aggregation inhibitors
Purinoceptor agonists
Vasodilators
(treatment of male sexual dysfunction using **neutral endopeptidase** inhibitors and their combination with phosphodiesterase type 5 inhibitors and other agents in relation to inhibition of angiotensin converting enzyme)

IT Estrogens
Opioids
Prostaglandins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment of male sexual dysfunction using **neutral endopeptidase** inhibitors and their combination with phosphodiesterase type 5 inhibitors and other agents in relation to inhibition of angiotensin converting enzyme)

IT Adrenoceptor antagonists
(.alpha.-; treatment of male sexual dysfunction using **neutral endopeptidase** inhibitors and their combination with phosphodiesterase type 5 inhibitors and other agents in relation to inhibition of angiotensin converting enzyme)

IT 57576-52-0, Thromboxane A2

RL: BSU (Biological study, unclassified); BIOL (Biological study) (agonists; treatment of male sexual dysfunction using **neutral endopeptidase** inhibitors and their combination with phosphodiesterase type 5 inhibitors and other agents in relation to inhibition of angiotensin converting enzyme)

IT 82785-45-3, Neuropeptide Y
RL: BSU (Biological study, unclassified); BIOL (Biological study) (antagonists; treatment of male sexual dysfunction using **neutral endopeptidase** inhibitors and their combination with phosphodiesterase type 5 inhibitors and other agents in relation to inhibition of angiotensin converting enzyme)

IT 10102-43-9, Nitric oxide, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study) (donors and agonists; treatment of male sexual dysfunction using **neutral endopeptidase** inhibitors and their combination with phosphodiesterase type 5 inhibitors and other agents in relation to inhibition of angiotensin converting enzyme)

IT 128908-32-7, Melanocortin
RL: BSU (Biological study, unclassified); BIOL (Biological study) (enhancers; treatment of male sexual dysfunction using **neutral endopeptidase** inhibitors and their combination with phosphodiesterase type 5 inhibitors and other agents in relation to inhibition of angiotensin converting enzyme)

IT 9028-35-7, HMG-CoA reductase
RL: BSU (Biological study, unclassified); BIOL (Biological study) (inhibitors, statins; treatment of male sexual dysfunction using **neutral endopeptidase** inhibitors and their combination with phosphodiesterase type 5 inhibitors and other agents in relation to inhibition of angiotensin converting enzyme)

IT 9000-81-1, Acetylcholinesterase 9040-59-9, Phosphodiesterase II 9068-52-4, Phosphodiesterase V **82707-54-8, Neutral endopeptidase** 138238-81-0, Endothelin converting enzyme
RL: BSU (Biological study, unclassified); BIOL (Biological study) (inhibitors; treatment of male sexual dysfunction using **neutral endopeptidase** inhibitors and their combination with phosphodiesterase type 5 inhibitors and other agents in relation to inhibition of angiotensin converting enzyme)

IT 9036-21-9, Phosphodiesterase 8
RL: BSU (Biological study, unclassified); BIOL (Biological study) (isoforms, inhibitors; treatment of male sexual dysfunction using **neutral endopeptidase** inhibitors and their combination with phosphodiesterase type 5 inhibitors and other agents in relation to inhibition of angiotensin converting enzyme)

IT 9088-07-7, Natriuretic factor 85637-73-6, Atrial natriuretic factor
RL: BSU (Biological study, unclassified); BIOL (Biological study) (modulators; treatment of male sexual dysfunction using **neutral endopeptidase** inhibitors and their combination with phosphodiesterase type 5 inhibitors and other agents in relation to inhibition of angiotensin converting enzyme)

IT 9004-10-8, Insulin, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study) (sensitizing agents; treatment of male sexual dysfunction using **neutral endopeptidase** inhibitors and their combination with phosphodiesterase type 5 inhibitors and other agents in relation to inhibition of angiotensin converting enzyme)

IT 125978-95-2, Nitric oxide synthase
RL: BSU (Biological study, unclassified); BIOL (Biological study) (substrates; treatment of male sexual dysfunction using **neutral endopeptidase** inhibitors and their combination with phosphodiesterase type 5 inhibitors and other agents in relation to inhibition of angiotensin converting enzyme)

IT 9015-82-1, Angiotensin converting enzyme
RL: BSU (Biological study, unclassified); BIOL (Biological study)

(treatment of male sexual dysfunction using **neutral endopeptidase** inhibitors and their combination with phosphodiesterase type 5 inhibitors and other agents in relation to inhibition of angiotensin converting enzyme)

IT **337962-68-2P 337962-69-3P** 337962-70-6P
337962-71-7P 337962-72-8P 337962-73-9P **337962-74-0P**
388630-36-2P 388630-55-5P
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(treatment of male sexual dysfunction using **neutral endopeptidase** inhibitors and their combination with phosphodiesterase type 5 inhibitors and other agents in relation to inhibition of angiotensin converting enzyme)

IT 58-22-0, Testosterone 71-58-9, Medroxyprogesterone acetate 520-85-4, Medroxyprogesterone 521-18-6, Dihydrotestosterone 37221-79-7, Vasoactive intestinal peptide 37221-79-7D, Vasoactive intestinal peptide, analogs 139755-83-2, Sildenafil 147676-53-7 171596-29-5, IC-351 215297-27-1 224785-90-4, Vardenafil 334826-98-1 334827-47-3 334827-59-7 335077-64-0 335077-70-8 389128-36-3
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment of male sexual dysfunction using **neutral endopeptidase** inhibitors and their combination with phosphodiesterase type 5 inhibitors and other agents in relation to inhibition of angiotensin converting enzyme)

IT 98-10-2, Benzenesulfonamide 108-33-8, 2-Amino-5-methyl-1,3,4-thiadiazole 7663-77-6, N-(3-Aminopropyl)-2-pyrrolidinone 14068-53-2, 2-Amino-5-ethyl-1,3,4-thiadiazole 59892-44-3 118755-30-9 118755-86-5 118756-03-9 118783-85-0 118786-35-9 136834-71-4 136834-85-0 136850-24-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(treatment of male sexual dysfunction using **neutral endopeptidase** inhibitors and their combination with phosphodiesterase type 5 inhibitors and other agents in relation to inhibition of angiotensin converting enzyme)

IT **337962-78-4P** 337962-79-5P **337962-80-8P**
337962-81-9P 337962-83-1P 337962-84-2P 337962-91-1P
337962-93-3P 388630-52-2P **388630-83-9P** 388631-26-3P
388631-29-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(treatment of male sexual dysfunction using **neutral endopeptidase** inhibitors and their combination with phosphodiesterase type 5 inhibitors and other agents in relation to inhibition of angiotensin converting enzyme)

IT 388630-37-3P 388630-54-4P 389083-04-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(treatment of male sexual dysfunction using **neutral endopeptidase** inhibitors and their combination with phosphodiesterase type 5 inhibitors and other agents in relation to inhibition of angiotensin converting enzyme)

IT **82707-54-8, Neutral endopeptidase**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; treatment of male sexual dysfunction using **neutral endopeptidase** inhibitors and their combination with phosphodiesterase type 5 inhibitors and other agents in relation to inhibition of angiotensin converting enzyme)

RN 82707-54-8 HCAPLUS
CN Neprilysin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L21 ANSWER 6 OF 15 HCAPLUS COPYRIGHT 2003 ACS
AN 2002:31403 HCAPLUS
DN 136:102126
TI Cyclopentyl-substituted glutaramide derivatives as inhibitors of **neutral endopeptidase**, and their preparation and use in the treatment of female sexual arousal disorder
IN Barber, Christopher Gordon; Cook, Andrew Simon; Maw, Graham Nigel; Pryde, David Cameron; Stobie, Alan
PA Pfizer Limited, UK; Pfizer Inc.
SO PCT Int. Appl., 169 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07C237-22
ICS A61K031-19; A61P015-00; C07C233-58; C07C233-60; C07C235-40; C07C275-52; C07C237-24; C07D317-58; C07D285-12; C07D207-27; C07D209-16; C07D207-14; C07D211-76; C07D213-75; C07D213-71; C07C311-18; C07C311-13; C07C311-51; C07D307-81
CC 24-4 (Alicyclic Compounds)
Section cross-reference(s): 1, 7, 28, 34
FAN.CNT 9

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002002513	A1	20020110	WO 2001-IB1205	20010702
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2002052370	A1	20020502	US 2001-893585	20010628
PRAI	GB 2000-16684	A	20000706		
	GB 2001-1584	A	20010122		
	US 2000-219100P	P	20000718		
	US 2001-274957P	P	20010312		

OS MARPAT 136:102126
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention provides compds. I [wherein: R1 = (un)substituted alkyl, cycloalkyl, aryl, heterocyclyl, alkoxy, amino deriv., or sulfonylamino deriv.; n = 0, 1, or 2; Y = (un)substituted cycloalkyl, carbamoyl, 2-indenyl, aza- or diazainden-2-yl, 5- to 7-membered heterocyclyl, or sulfonylamino; with provisos] and their pharmaceutically acceptable salts, solvates, polymorphs, or prodrugs. I are inhibitors of **neutral endopeptidase** (NEP), and as such are useful for treating a variety of conditions. In particular, the compds. are useful for treatment of female sexual dysfunction, and esp. female sexual arousal disorder (FSAD). Almost 60 synthetic examples and over 100 precursor prepns. are given. For instance, 1-[2-(tert-butoxycarbonyl)-4-pentenyl]cyclopentanecarboxylic acid was hydrogenated at the double bond (91%), amidated with piperonylamine using EDCI and HOBT, and deprotected with TFA, to give title compd. II. The example compds. inhibited NEP in vitro with IC50 < 5000 nM, with many compds. showing at least 300-fold selectivity for NEP over angiotensin converting enzyme (ACE). An animal model of human female sexual arousal was developed, using laser doppler technol. to record small

changes in vaginal and clitoral blood flow induced by pelvic nerve stimulation or vasoactive neurotransmitters in anesthetized rabbits. In this model, invention compd. III significantly enhanced pelvic nerve-stimulated increases in genital blood flow at clin. relevant doses, using both i.v. and topical (vaginal) application.

ST cyclopentyl glutaramide heterocyclic inhibitor **neutral endopeptidase**; NEP inhibitor cyclopentyl glutaramide treatment female sexual arousal disorder; animal model female sexual arousal pelvic nerve stimulation

IT Simulation and Modeling, biological
(animal, of female sexual arousal; prepn. of cyclopentyl-substituted glutaramide derivs. as **neutral endopeptidase** inhibitors, for treatment of female sexual arousal disorder)

IT Sexual behavior
(aphrodisiacs for, female; prepn. of cyclopentyl-substituted glutaramide derivs. as **neutral endopeptidase** inhibitors, for treatment of female sexual arousal disorder)

IT Behavior
(arousal, animal model for female sexual arousal; prepn. of cyclopentyl-substituted glutaramide derivs. as **neutral endopeptidase** inhibitors, for treatment of female sexual arousal disorder)

IT Reproductive organ
(clitoris, stimulation of blood flow; prepn. of cyclopentyl-substituted glutaramide derivs. as **neutral endopeptidase** inhibitors, for treatment of female sexual arousal disorder)

IT Sexual behavior
(disorder, arousal dysfunction, female, treatment; prepn. of cyclopentyl-substituted glutaramide derivs. as **neutral endopeptidase** inhibitors, for treatment of female sexual arousal disorder)

IT Circulation
(female genital, stimulation of; prepn. of cyclopentyl-substituted glutaramide derivs. as **neutral endopeptidase** inhibitors, for treatment of female sexual arousal disorder)

IT Reproductive organ
(female, stimulation of blood flow; prepn. of cyclopentyl-substituted glutaramide derivs. as **neutral endopeptidase** inhibitors, for treatment of female sexual arousal disorder)

IT Nerve
(pelvic, effect of stimulation on female sexual arousal; prepn. of cyclopentyl-substituted glutaramide derivs. as **neutral endopeptidase** inhibitors, for treatment of female sexual arousal disorder)

IT Human
X-ray spectra
(prepn. of cyclopentyl-substituted glutaramide derivs. as **neutral endopeptidase** inhibitors, for treatment of female sexual arousal disorder)

IT Vagina
(stimulation of blood flow; prepn. of cyclopentyl-substituted glutaramide derivs. as **neutral endopeptidase** inhibitors, for treatment of female sexual arousal disorder)

IT Neurotransmitters
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(vasoactive, effect on female sexual arousal; prepn. of cyclopentyl-substituted glutaramide derivs. as **neutral endopeptidase** inhibitors, for treatment of female sexual arousal disorder)

IT 136834-71-4, 2-[[1-[[[2-(Hydroxymethyl)-2,3-dihydro-1H-inden-2-yl]amino]carbonyl]cyclopentyl]methyl]pentanoic acid 136850-24-3, 2-[[1-[[[2-(Hydroxymethyl)-2,3-dihydro-1H-inden-2-yl]amino]carbonyl]cyclopentyl]methyl]-4-phenylbutanoic acid

RL: PEP (Physical, engineering or chemical process); PYP (Physical process); PROC (Process)
(chiral resoln.; prepn. of cyclopentyl-substituted glutaramide derivs. as **neutral endopeptidase** inhibitors, for treatment of female sexual arousal disorder)

IT 9015-82-1, Angiotensin Converting Enzyme
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(comparative inhibition; prepn. of cyclopentyl-substituted glutaramide derivs. as **neutral endopeptidase** inhibitors, for treatment of female sexual arousal disorder)

IT **388630-36-2P**, (-)-(2R)-2-[[1-[[(5-Ethyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]cyclopentyl]methyl]pentanoic acid
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of cyclopentyl-substituted glutaramide derivs. as **neutral endopeptidase** inhibitors, for treatment of female sexual arousal disorder)

IT **337962-93-3P**, 2-[[1-[[(5-Ethyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]cyclopentyl]methyl]pentanoic acid 388630-52-2P, 2-[[1-[[[2-(Hydroxymethyl)-2,3-dihydro-1H-inden-2-yl]amino]carbonyl]cyclopentyl]methyl]-4-methoxybutanoic acid
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(drug candidate; prepn. of cyclopentyl-substituted glutaramide derivs. as **neutral endopeptidase** inhibitors, for treatment of female sexual arousal disorder)

IT **388630-59-9P**, (-)-(2R)-2-[[1-[[(5-Ethyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]cyclopentyl]methyl]pentanoic acid sodium salt
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of cyclopentyl-substituted glutaramide derivs. as **neutral endopeptidase** inhibitors, for treatment of female sexual arousal disorder)

IT **337962-74-0P**, (+)-(2S)-2-[[1-[[(5-Ethyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]cyclopentyl]methyl]pentanoic acid 388630-54-4P, (+)-(R)-2-[[1-[[[2-(Hydroxymethyl)-2,3-dihydro-1H-inden-2-yl]amino]carbonyl]cyclopentyl]methyl]-4-methoxybutanoic acid 388630-55-5P, (-)-(S)-2-[[1-[[[2-(Hydroxymethyl)-2,3-dihydro-1H-inden-2-yl]amino]carbonyl]cyclopentyl]methyl]-4-methoxybutanoic acid
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of cyclopentyl-substituted glutaramide derivs. as **neutral endopeptidase** inhibitors, for treatment of female sexual arousal disorder)

IT 337962-70-6P, (+)-(R)-2-[[1-[[[2-(Hydroxymethyl)-2,3-dihydro-1H-inden-2-yl]amino]carbonyl]cyclopentyl]methyl]-4-phenylbutanoic acid 337962-73-9P, (+)-(R)-2-[[1-[[[2-(Hydroxymethyl)-2,3-dihydro-1H-inden-2-yl]amino]carbonyl]cyclopentyl]methyl]pentanoic acid 388630-37-3P, (-)-(S)-2-[[1-[[[2-(Hydroxymethyl)-2,3-dihydro-1H-inden-2-yl]amino]carbonyl]cyclopentyl]methyl]pentanoic acid 389083-04-9P, (S)-2-[[1-[[[2-(Hydroxymethyl)-2,3-dihydro-1H-inden-2-yl]amino]carbonyl]cyclopentyl]methyl]-4-phenylbutanoic acid
RL: PAC (Pharmacological activity); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of cyclopentyl-substituted glutaramide derivs. as **neutral endopeptidase** inhibitors, for treatment

of female sexual arousal disorder)

IT **337962-68-2P**, 2-[[1-[[(1-Benzyl-6-oxo-1,6-dihydro-3-pyridinyl)amino]carbonyl]cyclopentyl]methyl]-4-methoxybutanoic acid **337962-69-3P**, 2-[[1-[[[3-(2-Oxo-1-pyrrolidinyl)propyl]amino]carbonyl]cyclopentyl]methyl]-4-phenylbutanoic acid **337962-71-7P**, 2-[[1-[[(5-Methyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]cyclopentyl]methyl]-4-phenylbutanoic acid 337962-72-8P, cis-3-(2-Methoxyethoxy)-2-[[1-[[[4-[[(phenylsulfonyl)amino]carbonyl]cyclohexyl]amino]carbonyl]cyclopentyl]methyl]propanoic acid 337962-75-1P, 2-[[1-[(3-Benzylanilino)carbonyl]cyclopentyl]methyl]pentanoic acid **337962-76-2P**, 2-[[1-[[(1-Benzyl-6-oxo-1,6-dihydro-3-pyridinyl)amino]carbonyl]cyclopentyl]methyl]pentanoic acid 337962-77-3P, 2-[[1-[[[(1R,3S,4R)-4-(Aminocarbonyl)-3-butylcyclohexyl]amino]carbonyl]cyclopentyl]methyl]pentanoic acid **337962-89-7P**, 2-[[1-[[(1,3-Benzodioxol-5-ylmethyl)amino]carbonyl]cyclopentyl]methyl]pentanoic acid 388630-12-4P, 2-[[1-[(2-Indanylamino)carbonyl]cyclopentyl]methyl]pentanoic acid **388630-13-5P**, 2-[[1-[[(5-Methyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]cyclopentyl]methyl]pentanoic acid **388630-14-6P**, 2-[[1-[[[(5-Methyl-1,3,4-thiadiazol-2-yl)methyl]amino]carbonyl]cyclopentyl]methyl]pentanoic acid 388630-15-7P, 2-[[1-[[[-2-[(Methylamino)carbonyl]ethyl]amino]carbonyl]cyclopentyl]methyl]pentanoic acid **388630-16-8P**, 2-[[1-[[[1-Methyl-2-(2-oxopyrrolidin-1-yl)ethyl]amino]carbonyl]cyclopentyl]methyl]pentanoic acid 388630-17-9P, 2-[[1-[[[(1R,3S)-3-(Aminocarbonyl)cyclopentyl]amino]carbonyl]cyclopentyl]methyl]pentanoic acid 388630-18-0P, 2-[[1-[[[(1S,3R,4R)-4-(Aminocarbonyl)-3-butylcyclohexyl]amino]carbonyl]cyclopentyl]methyl]pentanoic acid **388630-19-1P**, 2-[[1-[[[2-(1H-Indol-3-yl)ethyl]amino]carbonyl]cyclopentyl]methyl]pentanoic acid **388630-20-4P**, 2-[[1-[[((3S)-1-Benzylpyrrolidin-3-yl)amino]carbonyl]cyclopentyl]methyl]pentanoic acid 388630-21-5P, 2-[[1-[[[1-(Hydroxymethyl)cyclopentyl]amino]carbonyl]cyclopentyl]methyl]pentanoic acid 388630-22-6P, cis-2-[[1-[[[4-(Hydroxymethyl)cyclohexyl]amino]carbonyl]cyclopentyl]methyl]pentanoic acid **388630-23-7P**, 2-[[1-[[[2-(2-Oxo-1-piperidinyl)ethyl]amino]carbonyl]cyclopentyl]methyl]pentanoic acid 388630-24-8P, 2-[[1-[[[3-[(Dimethylamino)carbonyl]cyclohexyl]amino]carbonyl]cyclopentyl]methyl]pentanoic acid 388630-25-9P, 2-[[1-[[((1R,2R)-2-Phenylcyclopropyl)amino]carbonyl]cyclopentyl]methyl]pentanoic acid **388630-26-0P**, (-)-(2R)-2-[[1-[[[5-(Cyclopropylmethyl)-1,3,4-thiadiazol-2-yl]amino]carbonyl]cyclopentyl]methyl]pentanoic acid **388630-27-1P**, (-)-(2R)-2-[[1-[[[5-(Ethoxymethyl)-1,3,4-thiadiazol-2-yl]amino]carbonyl]cyclopentyl]methyl]pentanoic acid **388630-28-2P**, 2-[[1-[(3-Pyridinylamino)carbonyl]cyclopentyl]methyl]pentanoic acid **388630-29-3P**, 2-[[1-[[(4-Butyl-2-pyridinyl)amino]carbonyl]cyclopentyl]methyl]pentanoic acid 388630-30-6P, cis-2-[[1-[[[4-[(Dimethylamino)carbonyl]cyclohexyl]amino]carbonyl]cyclopentyl]methyl]pentanoic acid 388630-31-7P, cis-2-[[1-[[[4-[(Methylamino)carbonyl]cyclohexyl]amino]carbonyl]cyclopentyl]methyl]pentanoic acid **388630-32-8P**, 2-[[1-[[(5-Benzyl-3-pyridinyl)amino]carbonyl]cyclopentyl]methyl]pentanoic acid 388630-33-9P, 2-[[1-[[[1-Benzyl-2-oxo-2-[(3-pyridinylsulfonyl)amino]ethyl]amino]carbonyl]cyclopentyl]methyl]pentanoic acid 388630-34-0P, 2-[[1-[[[2-[(Phenylsulfonyl)amino]ethyl]amino]carbonyl]cyclopentyl]methyl]pentanoic acid 388630-35-1P, 2-[[1-[[[2-[(Benzylsulfonyl)amino]ethyl]amino]carbonyl]cyclopentyl]methyl]pentanoic acid **388630-38-4P**, (-)-(2R)-2-[[1-[[(1-Benzyl-6-oxo-1,6-dihydro-3-pyridinyl)amino]carbonyl]cyclopentyl]methyl]pentanoic acid **388630-39-5P**, (-)-(2R)-2-[[1-[[(4-Butyl-2-pyridinyl)amino]carbonyl]cyclopentyl]methyl]pentanoic acid 388630-40-8P, 3-[1-[(Cyclopentylamino)carbonyl]cyclopentyl]-2-[(2-methoxyethoxy)methyl]propanoic acid **388630-41-9P**, 3-(2-Methoxyethoxy)-2-[[1-[[[3-(2-oxo-1-pyrrolidinyl)propyl]amino]carbonyl]cyclopentyl]methyl]propanoic acid 388630-42-0P, 2-[[1-[[[3-(Methylamino)-3-oxopropyl]amino]carbonyl]cyclopentyl]methyl]-4-phenylbutanoic acid **388630-43-1P**, 4-Phenyl-2-[[1-[(3-

pyridinylamino)carbonyl]cyclopentyl]methyl]butanoic acid 388630-44-2P, 2-[[1-[[[1-(Hydroxymethyl)cyclopentyl]amino]carbonyl]cyclopentyl]methyl]-4-phenylbutanoic acid 388630-45-3P, trans-3-[1-[[[2-(4-Chlorophenyl)cyclopropyl]amino]carbonyl]cyclopentyl]-2-(methoxymethyl)propanoic acid 388630-46-4P, trans-3-[1-[[[2-(4-Methoxyphenyl)cyclopropyl]amino]carbonyl]cyclopentyl]-2-(2-methoxyethyl)propanoic acid 388630-47-5P, trans-3-[1-[[(2-Pentylcyclopropyl)amino]carbonyl]cyclopentyl]-2-(2-methoxyethyl)propanoic acid **388630-48-6P**, 3-[1-[[(5-Benzyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]cyclopentyl]-2-(2-methoxyethyl)propanoic acid **388630-49-7P**, 3-[1-[[(4-Butylpyridin-2-yl)amino]carbonyl]cyclopentyl]-2-(2-methoxyethyl)propanoic acid **388630-50-0P**, 3-[1-[[(4-Phenylpyridin-2-yl)amino]carbonyl]cyclopentyl]-2-(2-methoxyethyl)propanoic acid 388630-51-1P, 3-[1-[[[1-(Hydroxymethyl)-3-phenylcyclopentyl]amino]carbonyl]cyclopentyl]-2-(2-methoxyethyl)propanoic acid 388630-53-3P, trans-3-[1-[[(2-Phenylcyclopropyl)amino]carbonyl]cyclopentyl]-2-(2-methoxyethyl)propanoic acid 388630-56-6P, 3-Methoxy-2-[[1-[[(trans-2-phenylcyclopropyl)amino]carbonyl]cyclopentyl]methyl]propanoic acid 388630-57-7P, trans-3-[1-[[((1S,2R)-2-Phenylcyclopropyl)amino]carbonyl]cyclopentyl]-2-(2-methoxyethyl)propanoic acid **388630-58-8P**, 2-[[1-[[[(2,3-Dihydrobenzofuran-2-yl)methyl]amino]carbonyl]cyclopentyl]methyl]-4-methoxybutanoic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of cyclopentyl-substituted glutaramide derivs. as **neutral endopeptidase** inhibitors, for treatment of female sexual arousal disorder)

IT **82707-54-8, Neutral Endopeptidase**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(*inhibitors; prepn. of cyclopentyl-substituted glutaramide derivs. as* **neutral endopeptidase** inhibitors, for treatment of female sexual arousal disorder)

IT 3445-12-3P, 1-(2-Hydroxyethyl)-2-piperidinone 4103-57-5P, trans-2-(4-Chlorophenyl)cyclopropanecarboxylic acid ethyl ester 4157-47-5P, trans-2-(4-Chlorophenyl)cyclopropanecarboxylic acid 5335-75-1P, 4-Butylpyridine 16502-08-2P, 5-Benzyl-1,3,4-thiadiazol-2-amine 26568-25-2P, (trans)-2-(4-Chlorophenyl)cyclopropylamine hydrochloride 27578-61-6P, 2-[2-(2-Oxo-1-piperidinyl)ethyl]amine 30134-98-6P, cis-(4-Aminocyclohexyl)methanol 34919-28-3P, trans-2-(4-Methoxyphenyl)cyclopropanecarboxylic acid 34974-00-0P, 2-Amino-4-butylpyridine 51739-61-8P, 3-Amino-N-methylpropanamide hydrochloride 55666-43-8P, tert-Butyl 3-bromopropionate 61892-90-8P, 1-(2-Oxopropyl)-2-pyrrolidinone 64145-51-3P, 3-Phenylcyclopentanone 71830-07-4P, (1S,3R)-3-Aminocyclopentanecarboxylic acid 91393-54-3P, Ethyl 2-(4-chlorophenyl)cyclopropanecarboxylate 98017-60-8P, Ethyl 2-(4-methoxyphenyl)cyclopropanecarboxylate 110826-21-6P, trans-2-(4-Methoxyphenyl)cyclopropylamine 118756-03-9P, 1-(3-tert-Butoxy-3-oxopropyl)cyclopentanecarboxylic acid 118783-78-1P, 3-(1-Carboxycyclopentyl)-2-(methoxymethyl)propanoic acid tert-butyl ester 118783-85-0P, 1-[2-(tert-Butoxycarbonyl)-4-pentenyl]cyclopentanecarboxylic acid 119427-80-4P, 7-Phenyl-1,3-diazaspiro[4.4]nonane-2,4-dione 123494-21-3P, Benzyl [3-(methylamino)-3-oxopropyl]carbamate 139084-39-2P, (R)-1-[2-(tert-Butoxycarbonyl)-4-pentenyl]cyclopentanecarboxylic acid 234111-10-5P, (5-Bromo-3-pyridinyl)(phenyl)methanol 261165-05-3P, (1S,3R)-3-[(tert-Butoxycarbonyl)amino]cyclopentanecarboxylic acid 299937-30-7P, 5-(Cyclopropylmethyl)-1,3,4-thiadiazol-2-amine 334932-13-7P, 3-[(tert-Butoxycarbonyl)amino]cyclohexanecarboxylic acid **337962-78-4P**, Benzyl 2-[[1-[[(1-benzyl-6-oxo-1,6-dihydro-3-pyridinyl)amino]carbonyl]cyclopentyl]methyl]-4-methoxybutanoate 337962-79-5P, 5-Amino-1-benzyl-2(1H)-pyridinone **337962-80-8P**,

Benzyl 2-[[1-[[[3-(2-Oxo-1-pyrrolidinyl)propyl]amino]carbonyl]cyclopentyl]methyl]-4-phenylbutanoate **337962-81-9P**, Benzyl 2-[[1-[[(5-methyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]cyclopentyl]methyl]-4-phenylbutanoate 337962-82-0P, Benzyl 2-[[1-[[[3-(methylamino)-3-oxopropyl]amino]carbonyl]cyclopentyl]methyl]-4-phenylbutanoate 337962-83-1P, cis-tert-Butyl 3-(2-methoxyethoxy)-2-[[1-[[[4-[[(phenylsulfonyl)amino]carbonyl]cyclohexyl]amino]carbonyl]cyclopentyl]methyl]propanoate 337962-84-2P, 4-[[[1-[3-tert-Butoxy-2-[(2-methoxyethoxy)methyl]-3-oxopropyl]cyclopentyl]carbonyl]amino]cyclohexanecarboxylic acid 337962-85-3P, Benzyl 2-[[1-[[(3-benzylphenyl)amino]carbonyl]cyclopentyl]methyl]pentanoate 337962-86-4P, Benzyl 2-[[1-(chlorocarbonyl)cyclopentyl]methyl]pentanoate **337962-87-5P**, Benzyl 2-[[1-[(3-pyridinylamino)carbonyl]cyclopentyl]methyl]pentanoate **337962-88-6P**, Benzyl 2-[[1-[[(1-benzyl-6-oxo-1,6-dihydro-3-pyridinyl)amino]carbonyl]cyclopentyl]methyl]pentanoate **337962-90-0P**, tert-Butyl 2-[[1-[(piperonylamino)carbonyl]cyclopentyl]methyl]pentanoate 337962-91-1P, 1-[2-(tert-Butoxycarbonyl)pentyl]cyclopentanecarboxylic acid 337962-92-2P, tert-Butyl 2-[[1-[[[1-(hydroxymethyl)cyclopentyl]amino]carbonyl]cyclopentyl]methyl]pentanoate 388630-61-3P, 1-[(2R)-2-(tert-Butoxycarbonyl)pentyl]cyclopentanecarboxylic acid 388630-62-4P, Cyclohexanaminium 1-[2-(tert-butoxycarbonyl)-4-pentenyl]cyclopentanecarboxylate 388630-63-5P, (1S,2S)-1-Hydroxy-N-methyl-1-phenyl-2-propanaminium 1-[(2R)-2-(tert-butoxycarbonyl)-4-pentenyl]cyclopentanecarboxylate 388630-64-6P, 1-[2-[(tert-Butyldimethylsilyl)oxy]ethyl]-2-piperidinone 388630-65-7P, 2-[2-(2-Oxo-1-piperidinyl)ethyl]-1H-isoindole-1,3(2H)-dione 388630-66-8P, tert-Butyl [(1R,3S)-3-(aminocarbonyl)cyclopentyl]carbamate 388630-67-9P, tert-Butyl [3-[(dimethylamino)carbonyl]cyclohexyl]carbamate 388630-68-0P, tert-Butyl [2-(2-acetylhydrazino)-2-oxoethyl]carbamate 388630-69-1P, tert-Butyl [(5-methyl-1,3,4-thiadiazol-2-yl)methyl]carbamate 388630-70-4P, N-Methoxy-N-methyl-2-(2-oxo-1-pyrrolidinyl)acetamide 388630-71-5P, 1-[2-(Hydroxyimino)propyl]-2-pyrrolidinone 388630-72-6P, tert-Butyl [1-benzyl-2-oxo-2-[(3-pyridinylsulfonyl)amino]ethyl]carbamate 388630-73-7P, (1S,3R)-3-Aminocyclopentanecarboxamide hydrochloride 388630-74-8P, 3-Amino-N,N-dimethylcyclohexanecarboxamide 388630-75-9P, [(5-Methyl-1,3,4-thiadiazol-2-yl)methyl]amine hydrochloride 388630-76-0P, 1-(2-Aminopropyl)-2-pyrrolidinone 388630-77-1P, N-(2-Amino-3-phenylpropanoyl)-3-pyridinesulfonamide dihydrochloride 388630-78-2P, (5-Amino-3-pyridinyl)(phenyl)methanol 388630-79-3P, 5-Benzyl-3-pyridinylamine 388630-80-6P, (1R,2R,4S)-4-[[[1-[2-(tert-Butoxycarbonyl)pentyl]cyclopentyl]carbonyl]amino]-2-butylcyclohexanecarboxamide 388630-81-7P, tert-Butyl 2-[[1-[(2-indanylamino)carbonyl]cyclopentyl]methyl]pentanoate **388630-82-8P**, tert-Butyl 2-[[1-[[(5-methyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]cyclopentyl]methyl]pentanoate **388630-83-9P**, tert-Butyl 2-[[1-[[(5-ethyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]cyclopentyl]methyl]pentanoate **388630-84-0P**, tert-Butyl 2-[[1-[[[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]amino]carbonyl]cyclopentyl]methyl]pentanoate 388630-85-1P, tert-Butyl 2-[[1-[[[-2-[(methylamino)carbonyl]ethyl]amino]carbonyl]cyclopentyl]methyl]pentanoate **388630-86-2P**, tert-Butyl 2-[[1-[[[1-methyl-2-(2-oxo-1-pyrrolidinyl)ethyl]amino]carbonyl]cyclopentyl]methyl]pentanoate 388630-87-3P, tert-Butyl 2-[[1-[[[(1R,3S)-3-(aminocarbonyl)cyclopentyl]amino]carbonyl]cyclopentyl]methyl]pentanoate 388630-88-4P, tert-Butyl 2-[[1-[[[3-[(dimethylamino)carbonyl]cyclohexyl]amino]carbonyl]cyclopentyl]methyl]pentanoate 388630-89-5P, (cis)-tert-Butyl 2-[[1-[[[4-(hydroxymethyl)cyclohexyl]amino]carbonyl]cyclopentyl]methyl]pentanoate **388630-90-8P**, tert-Butyl 2-[[1-[[[2-(1H-indol-3-yl)ethyl]amino]carbonyl]cyclopentyl]methyl]pentanoate 388630-91-9P, tert-Butyl 2-[[1-[((3S)-1-benzylpyrrolidin-3-yl)amino]cyclopentyl]methyl]pentanoate 388630-92-0P, tert-Butyl 2-[[1-[[((1S,2R)-2-phenylcyclopropyl)amino]carbonyl]cyclopentyl]methyl]pen

tanoate **388630-93-1P**, tert-Butyl 2-[[1-[[[2-(2-oxo-1-piperidinyl)ethyl]amino]carbonyl]cyclopentyl]methyl]pentanoate 388630-94-2P, Ethyl (1R,2R,4S)-4-[[[1-[2-(tert-butoxycarbonyl)pentyl]cyclopentyl]carbonyl]amino]-2-butylcyclohexanecarboxylate 388630-96-4P, (1R,2R,4S)-4-[[[1-[2-(tert-Butoxycarbonyl)pentyl]cyclopentyl]carbonyl]amino]-2-butylcyclohexanecarboxylic acid **388630-97-5P**, (-)-tert-Butyl (2R)-2-[[1-[[[5-(cyclopropylmethyl)-1,3,4-thiadiazol-2-yl]amino]carbonyl]cyclopentyl]methyl]pentanoate **388630-98-6P**, (-)-tert-Butyl (2R)-2-[[1-[[[5-(ethoxymethyl)-1,3,4-thiadiazol-2-yl]amino]carbonyl]cyclopentyl]methyl]pentanoate **388630-99-7P**, tert-Butyl (2R)-2-[[1-[[(5-ethyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]cyclopentyl]methyl]pentanoate **388631-00-3P**, Benzyl 2-[[1-[[(5-benzyl-3-pyridinyl)amino]carbonyl]cyclopentyl]methyl]pentanoate **388631-01-4P**, Benzyl 2-[[1-[[(4-butyl-2-pyridinyl)amino]carbonyl]cyclopentyl]methyl]pentanoate 388631-02-5P, Benzyl 2-[[1-[[[1-benzyl-2-oxo-2-[(3-pyridinylsulfonyl)amino]ethyl]amino]carbonyl]cyclopentyl]methyl]pentanoate 388631-03-6P, cis-Benzyl 2-[[1-[[[4-[(dimethylamino)carbonyl]cyclohexyl]amino]carbonyl]cyclopentyl]methyl]pentanoate 388631-05-8P, cis-Benzyl 2-[[1-[[[4-[(methylamino)carbonyl]cyclohexyl]amino]carbonyl]cyclopentyl]methyl]pentanoate 388631-06-9P, tert-Butyl 2-[[1-[[[2-[[(benzyloxy)carbonyl]amino]ethyl]amino]carbonyl]cyclopentyl]methyl]pentanoate 388631-07-0P, tert-Butyl 2-[[1-[[(2-aminoethyl)amino]carbonyl]cyclopentyl]methyl]pentanoate 388631-08-1P, tert-Butyl 3-[1-[(cyclopentylamino)carbonyl]cyclopentyl]-2-[(2-methoxyethoxy)methyl]propanoate **388631-09-2P**, tert-Butyl 3-(2-methoxyethoxy)-2-[[1-[[[3-(2-oxo-1-pyrrolidinyl)propyl]amino]carbonyl]cyclopentyl]methyl]propanoate 388631-10-5P, Benzyl 2-[[1-[[[1-(hydroxymethyl)cyclopentyl]amino]carbonyl]cyclopentyl]methyl]-4-phenylbutanoate **388631-11-6P**, Benzyl 4-phenyl-2-[[1-[(3-pyridinylamino)carbonyl]cyclopentyl]methyl]butanoate 388631-12-7P, trans-tert-Butyl 3-[1-[[[2-(4-chlorophenyl)cyclopropyl]amino]carbonyl]cyclopentyl]-2-(methoxymethyl)propanoate 388631-13-8P, trans-tert-Butyl [2-(4-chlorophenyl)cyclopropyl]carbamate 388631-14-9P, trans-tert-Butyl [2-(4-methoxyphenyl)cyclopropyl]carbamate 388631-15-0P, trans-tert-Butyl 4-methoxy-2-[[1-[[[2-(4-methoxyphenyl)cyclopropyl]amino]carbonyl]cyclopentyl]methyl]butanoate 388631-16-1P, tert-Butyl 4-methoxy-2-[[1-[[((1S,2R)-2-phenylcyclopropyl)amino]carbonyl]cyclopentyl]methyl]butanoate 388631-17-2P, tert-Butyl 3-methoxy-2-[[1-[[((1S,2R)-2-phenylcyclopropyl)amino]carbonyl]cyclopentyl]methyl]propanoate 388631-18-3P, 1-Amino-3-phenylcyclopentanecarboxylic acid 388631-19-4P, Ethyl 1-amino-3-phenylcyclopentanecarboxylate 388631-20-7P, (1-Amino-3-phenylcyclopentyl)methanol 388631-21-8P, tert-Butyl 2-[[1-[[[1-(hydroxymethyl)-3-phenylcyclopentyl]amino]carbonyl]cyclopentyl]methyl]-4-methoxybutanoate 388631-22-9P, (trans)-tert-Butyl 4-methoxy-2-[[1-[[(2-pentylcyclopropyl)amino]carbonyl]cyclopentyl]methyl]butanoate **388631-24-1P**, Benzyl 2-[[1-[[(4-butyl-2-pyridinyl)amino]carbonyl]cyclopentyl]methyl]-4-methoxybutanoate **388631-25-2P**, Benzyl 2-[[1-[[(4-phenyl-2-pyridinyl)amino]carbonyl]cyclopentyl]methyl]-4-methoxybutanoate 388631-26-3P, tert-Butyl 2-[[1-[[[2-(hydroxymethyl)-2,3-dihydro-1H-inden-2-yl]amino]carbonyl]cyclopentyl]methyl]-4-methoxybutanoate **388631-27-4P**, tert-Butyl 2-[[1-[[(5-benzyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]cyclopentyl]methyl]-4-methoxybutanoate **388631-28-5P**, tert-Butyl 2-[[1-[[[(2,3-dihydro-1-benzofuran-2-yl)methyl]amino]carbonyl]cyclopentyl]methyl]-4-methoxybutanoate 388631-29-6P, 1-[2-(tert-Butoxycarbonyl)-4-methoxybutyl]cyclopentanecarboxylic acid 388631-30-9P, (R)-Benzyl 1-[2-(tert-butoxycarbonyl)pentyl]cyclopentanecarboxylate 388631-31-0P, (R)-2-[[1-[(Benzyloxy)carbonyl]cyclopentyl]methyl]pentanoic acid 388631-32-1P, (R)-Benzyl 1-[2-[[(5-ethyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]pentyl]cyclopentanecarboxylate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)
(intermediate; prepn. of cyclopentyl-substituted glutaramide derivs. as **neutral endopeptidase** inhibitors, for treatment of female sexual arousal disorder)

IT 388630-60-2P, (2R)-1-[2-[[(5-Ethyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]pentyl]cyclopentanecarboxylic acid
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(metabolite; prepn. of cyclopentyl-substituted glutaramide derivs. as **neutral endopeptidase** inhibitors, for treatment of female sexual arousal disorder)

IT 61-54-1, Tryptamine 79-19-6, Thiosemicarbazide 85-41-6, Phthalimide 90-82-4, (1S,2S)-(+)-Pseudoephedrine 98-09-9, Benzenesulfonyl chloride 98-10-2, Benzenesulfonamide 100-39-0, Benzyl bromide 100-52-7, Benzaldehyde, reactions 100-58-3, Phenylmagnesium bromide 103-82-2, Phenylacetic acid, reactions 107-08-4, 1-Iodopropane 108-33-8, 2-Amino-5-methyl-1,3,4-thiadiazole 108-89-4, 4-Methylpyridine 115-11-7, Isobutylene, reactions 462-08-8, 3-Aminopyridine 590-92-1, 3-Bromopropionic acid 616-45-5, 2-Pyrrolidinone 623-73-4,.Ethyl diazoacetate 625-92-3, 3,5-Dibromopyridine 637-69-4, 4-Methoxystyrene 675-20-7, .delta.-Valerolactam 930-30-3, Cyclopent-2-enone 1003-03-8, Cyclopentylamine 1068-57-1, Acetic hydrazide 1073-67-2, 4-Chlorostyrene 2304-94-1, N-[(Benzyloxy)carbonyl]-.beta.-alanine 2338-18-3, 2-Aminoindan hydrochloride 2620-50-0, Piperonylamine 2922-45-4, 3-Pyridinesulfonamide 3400-45-1, Cyclopentanecarboxylic acid 3685-23-2, cis-4-Aminocyclohexanecarboxylic acid 3721-28-6, 1-(S)-Amino-2-(R)-phenylcyclopropane 4530-20-5, N-tert-Butoxycarbonylglycine 4548-34-9, 1-(S)-Amino-2-(R)-phenylcyclopropane hydrochloride 5239-82-7, Cyclopropylacetic acid 6482-24-2, 2-Bromoethyl methyl ether 7663-77-6, 1-(3-Aminopropyl)-2-pyrrolidinone 10316-79-7, 1-Amino-1-cyclopentanemethanol 13734-34-4, N-tert-Butoxycarbonyl-L-phenylalanine 14068-53-2, 2-Amino-5-ethyl-1,3,4-thiadiazole 15884-88-5, 5-(Ethoxymethyl)-1,3,4-thiadiazol-2-amine 18471-73-3, 2-Amino-4-phenylpyridine 21214-11-9, 2-Aminomethyl-2,3-dihydrobenzofuran 25912-50-9, 3-Aminocyclohexanecarboxylic acid 59892-44-3, 1-Benzyl-5-nitro-1H-pyridin-2-one 61424-26-8, 3-Benzylaniline 67442-07-3, 2-Chloro-N-methoxy-N-methylacetamide 72080-83-2, N-(Benzyloxycarbonyl)-1,2-diaminoethane 86864-60-0, (2-Bromoethoxy)(tert-butyl)dimethylsilane 114715-38-7, (3S)-1-Benzyl-3-aminopyrrolidine 118755-30-9, Benzyl 4-[[[1-[3-tert-butoxy-2-[(2-methoxyethoxy)methyl]-3-oxopropyl]cyclopentyl]carbonyl]amino]cyclohexanecarboxylate 118755-86-5, 1-[2-[(Benzyloxy)carbonyl]-4-phenylbutyl]cyclopentanecarboxylic acid 118783-83-8, 1-[3-tert-Butoxy-2-[(2-methoxyethoxy)methyl]-3-oxopropyl]cyclopentanecarboxylic acid 118786-35-9, 1-[2-[(Benzyloxy)carbonyl]-4-methoxybutyl]cyclopentanecarboxylic acid 118786-36-0, 1-[2-[(Benzyloxy)carbonyl]pentyl]cyclopentanecarboxylic acid 134003-04-6, (1R,4S)-4-Aminocyclopent-2-enecarboxylic acid 136834-85-0, 2-Amino-2-hydroxymethyl-2,3-dihydroindene 388630-95-3, (1R,2R,4S)-4-Amino-2-butylcyclohexanecarboxylic acid ethyl ester hydrochloride 388631-04-7, cis-4-[[[1-[2-[(Benzyloxy)carbonyl]pentyl]cyclopentyl]carbonyl]amino]cyclohexanecarboxylic acid 388631-23-0, (trans)-1-Amino-2-pentylcyclopropane
RL: RCT (Reactant); RACT (Reactant or reagent)
(precursor; prepn. of cyclopentyl-substituted glutaramide derivs. as **neutral endopeptidase** inhibitors, for treatment of female sexual arousal disorder)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Nexmed Holdings Inc; WO 0033825 A 2000 HCAPLUS
(2) Pfizer Ltd; WO 9110644 A 1991 HCAPLUS
(3) Pfizer Ltd; EP 1097706 A 2001 HCAPLUS
(4) Schering Corp; WO 9107386 A 1991 HCAPLUS

IT **388630-36-2P**, (-)-(2R)-2-[[1-[[(5-Ethyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]cyclopentyl]methyl]pentanoic acid
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of cyclopentyl-substituted glutaramide derivs. as **neutral endopeptidase** inhibitors, for treatment of female sexual arousal disorder)
RN 388630-36-2 HCAPLUS
CN Cyclopentanepropanoic acid, 1-[[(5-ethyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]-.alpha.-propyl-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L21 ANSWER 7 OF 15 HCAPLUS COPYRIGHT 2003 ACS
AN 2001:338075 HCAPLUS
DN 134:336238
TI NEP (**neutral endopeptidase**) inhibitors for the treatment of female sexual dysfunction
IN Maw, Graham Nigel; Wayman, Christopher Peter
PA Pfizer Limited, UK; Pfizer Inc.
SO Eur. Pat. Appl., 124 pp.
CODEN: EPXXDW
DT Patent
LA English
IC ICM A61K038-55
ICS A61K031-00; A61P015-00
CC 1-12 (Pharmacology)
Section cross-reference(s): 25, 27, 28, 63
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1097719	A1	20010509	EP 2000-309722	20001103
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	NO 2000005618	A	20010509	NO 2000-5618	20001107
	NO 2000005661	A	20010509	NO 2000-5661	20001107
	NO 2000005662	A	20010509	NO 2000-5662	20001107
	CN 1320426	A	20011107	CN 2000-137665	20001107
	CN 1322526	A	20011121	CN 2000-137671	20001107
	CN 1328824	A	20020102	CN 2000-137670	20001107
	JP 2001206855	A2	20010731	JP 2000-339905	20001108
	JP 2001213802	A2	20010807	JP 2000-339853	20001108
	JP 2001247478	A2	20010911	JP 2000-339949	20001108
	JP 2001247479	A2	20010911	JP 2000-339957	20001108
PRAI	GB 1999-26437	A	19991108		
	GB 2000-4021	A	20000218		
	GB 2000-13001	A	20000526		
	GB 2000-16563	A	20000705		
	GB 2000-17141	A	20000712		

AB A method of treating a female suffering from female sexual dysfunction, in

particular female sexual arousal dysfunction, is described. The method comprises delivering to the female an agent that is capable of potentiating cAMP in the sexual genitalia, wherein the agent is in an amt. to cause potentiation of cAMP in the sexual genitalia of the female. The agent may be admixed with a pharmaceutically acceptable carrier, diluent or excipient. The agent is an inhibitor of NEP (**neutral endopeptidase**; EC 3.4.24.11).

ST **neutral endopeptidase** inhibitor prepn female sexual dysfunction; arousal sexual dysfunction female **neutral endopeptidase** inhibitor

IT Neuropeptide Y receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(Y1; **neutral endopeptidase** inhibitors for treatment of female sexual dysfunction)

IT Animal
(animal model for sexual arousal physiol.; **neutral endopeptidase** inhibitors for treatment of female sexual dysfunction)

IT Behavior
(arousal, female sexual arousal dysfunction; **neutral endopeptidase** inhibitors for treatment of female sexual dysfunction)

IT Vagina
(blood flow; **neutral endopeptidase** inhibitors for treatment of female sexual dysfunction)

IT Resolution (separation)
(chromatog.; **neutral endopeptidase** inhibitors for treatment of female sexual dysfunction)

IT Reproductive organ
(clitoris, blood flow; **neutral endopeptidase** inhibitors for treatment of female sexual dysfunction)

IT Sexual behavior
(disorder; **neutral endopeptidase** inhibitors for treatment of female sexual dysfunction)

IT Drug delivery systems
(injections, i.v.; **neutral endopeptidase** inhibitors for treatment of female sexual dysfunction)

IT Blood pressure
Drug delivery systems
Drug screening
Heart rate
Vasodilators
(**neutral endopeptidase** inhibitors for treatment of female sexual dysfunction)

IT Drug delivery systems
(oral; **neutral endopeptidase** inhibitors for treatment of female sexual dysfunction)

IT Rabbit
(rabbit model for sexual arousal physiol.; **neutral endopeptidase** inhibitors for treatment of female sexual dysfunction)

IT Drug delivery systems
(tablets; **neutral endopeptidase** inhibitors for treatment of female sexual dysfunction)

IT Circulation
(vaginal and clitoral; **neutral endopeptidase** inhibitors for treatment of female sexual dysfunction)

IT 37221-79-7, Vasoactive intestinal peptide
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(**neutral endopeptidase** inhibitors for treatment of female sexual dysfunction)

IT 337962-70-6P 337962-73-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(**neutral endopeptidase** inhibitors for treatment of female sexual dysfunction)

IT **337962-68-2P 337962-69-3P 337962-71-7P**
337962-72-8P **337962-74-0P** 337962-75-1P **337962-76-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(**neutral endopeptidase** inhibitors for treatment of female sexual dysfunction)

IT 61413-54-5, Rolipram 78415-72-2, Milrinone 118784-21-7 118785-48-1 190666-14-9 223430-04-4
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**neutral endopeptidase** inhibitors for treatment of female sexual dysfunction)

IT 60-92-4, Cyclic AMP 9012-42-4, Adenylate cyclase 9036-21-9, Phosphodiesterase III 9040-59-9, Phosphodiesterase I 9068-52-4, Phosphodiesterase V **82707-54-8, Neprilysin**
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(**neutral endopeptidase** inhibitors for treatment of female sexual dysfunction)

IT 136834-71-4P 136850-24-3P
RL: PUR (Purification or recovery); PREP (Preparation)
(**neutral endopeptidase** inhibitors for treatment of female sexual dysfunction)

IT 337962-82-0P **337962-87-5P 337962-89-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(**neutral endopeptidase** inhibitors for treatment of female sexual dysfunction)

IT 51739-61-8P 123494-21-3P **337962-78-4P** 337962-79-5P
337962-80-8P 337962-81-9P 337962-83-1P 337962-85-3P
337962-86-4P **337962-88-6P 337962-90-0P** 337962-91-1P
337962-92-2P 338452-04-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction; **neutral endopeptidase** inhibitors for treatment of female sexual dysfunction)

IT 98-10-2, Benzenesulfonamide 108-33-8, 2-Amino-5-methyl-1,3,4-thiadiazole 593-51-1, Methylamine hydrochloride 2304-94-1, N-[(Benzyloxy)carbonyl]-.beta.-alanine 2620-50-0, Piperonylamine 7663-77-6, N-(3-Aminopropyl)-2-pyrrolidinone 10316-79-7, 1-Amino-1-cyclopentanemethanol 59892-44-3 118755-86-5 118783-85-0 118786-35-9 118786-36-0 338452-05-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction; **neutral endopeptidase** inhibitors for treatment of female sexual dysfunction)

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Berman, J; UROLOGY 1999, V54, P385 MEDLINE
(2) ErdOs, E; LABORATORY INVESTIGATION 1985, V52(4), P737
(3) Ottesen, B; AMERICAN JOURNAL OF OBSTETRICS & GYNECOLOGY 1983, V147, P208 HCAPLUS
(4) Park, K; INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH 1997, V9(1), P27 MEDLINE
(5) Smithkline Beckman Corp; EP 0274434 A 1988 HCAPLUS
(6) Suzuki, H; AMERICAN JOURNAL OF PHYSIOLOGY, Part 2 1996, V271(2), PR393

HCAPLUS

IT **337962-68-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(**neutral endopeptidase** inhibitors for treatment of female sexual dysfunction)

RN 337962-68-2 HCAPLUS

CN Cyclopentanepropanoic acid, 1-[[[1,6-dihydro-6-oxo-1-(phenylmethyl)-3-pyridinyl]amino]carbonyl]-.alpha.-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



L21 ANSWER 8 OF 15 HCAPLUS COPYRIGHT 2003 ACS

AN 2001:338074 HCAPLUS

DN 134:336237

TI Neuropeptide Y (NPY) antagonists for the treatment of female sexual dysfunction

IN Maw, Graham Nigel; Wayman, Christopher Peter

PA Pfizer Limited, UK; Pfizer Inc.

SO Eur. Pat. Appl., 165 pp.
CODEN: EPXXDW

DT Patent

LA English

IC ICM A61K038-22
ICS A61K031-00; A61P015-00

CC 1-12 (Pharmacology)
Section cross-reference(s): 25, 27, 28, 63

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1097718	A1	20010509	EP 2000-309720	20001103
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	NO 2000005618	A	20010509	NO 2000-5618	20001107
	NO 2000005661	A	20010509	NO 2000-5661	20001107
	NO 2000005662	A	20010509	NO 2000-5662	20001107
	CN 1320426	A	20011107	CN 2000-137665	20001107
	CN 1322526	A	20011121	CN 2000-137671	20001107
	CN 1328824	A	20020102	CN 2000-137670	20001107
	JP 2001206855	A2	20010731	JP 2000-339905	20001108
	JP 2001213802	A2	20010807	JP 2000-339853	20001108
	JP 2001247478	A2	20010911	JP 2000-339949	20001108
	JP 2001247479	A2	20010911	JP 2000-339957	20001108
PRAI	GB 1999-26437	A	19991108		
	GB 2000-4021	A	20000218		
	GB 2000-13001	A	20000526		
	GB 2000-16563	A	20000705		
	GB 2000-17141	A	20000712		

AB A method of treating a female suffering from female sexual dysfunction, in particular female sexual arousal dysfunction, is described. The method comprises delivering to the female an agent that is capable of potentiating cAMP in the sexual genitalia, wherein the agent is in an amt. to cause potentiation of cAMP in the sexual genitalia of the female. The

agent may be admixed with a pharmaceutically acceptable carrier, diluent or excipient. The agent is an antagonist of NPY. Prepn. of **neutral endopeptidase** inhibitors, also use for treating the above disorders, is also described.

ST neuropeptide Y antagonist female sexual dysfunction; arousal sexual dysfunction female neuropeptide Y antagonist; **neutral endopeptidase** inhibitor prepn female sexual dysfunction

IT Neuropeptide Y receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(Y1; neuropeptide Y antagonists for the treatment of female sexual dysfunction)

IT Animal
(animal model for sexual arousal physiol.; neuropeptide Y antagonists for the treatment of female sexual dysfunction)

IT Behavior
(arousal, female sexual arousal dysfunction; neuropeptide Y antagonists for the treatment of female sexual dysfunction)

IT Vagina
(blood flow; neuropeptide Y antagonists for the treatment of female sexual dysfunction)

IT Resolution (separation)
(chromatog.; neuropeptide Y antagonists for the treatment of female sexual dysfunction)

IT Reproductive organ
(clitoris, blood flow; neuropeptide Y antagonists for the treatment of female sexual dysfunction)

IT Sexual behavior
(disorder; neuropeptide Y antagonists for the treatment of female sexual dysfunction)

IT Drug delivery systems
(injections, i.v.; neuropeptide Y antagonists for the treatment of female sexual dysfunction)

IT Blood pressure
Drug delivery systems
Drug screening
Heart rate
Vasodilators
(neuropeptide Y antagonists for the treatment of female sexual dysfunction)

IT Drug delivery systems
(oral; neuropeptide Y antagonists for the treatment of female sexual dysfunction)

IT Rabbit
(rabbit model for sexual arousal physiol.; neuropeptide Y antagonists for the treatment of female sexual dysfunction)

IT Drug delivery systems
(tablets; neuropeptide Y antagonists for the treatment of female sexual dysfunction)

IT Circulation
(vaginal and clitoral; neuropeptide Y antagonists for the treatment of female sexual dysfunction)

IT 37221-79-7, Vasoactive intestinal peptide
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(neuropeptide Y antagonists for the treatment of female sexual dysfunction)

IT 337962-70-6P 337962-73-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(neuropeptide Y antagonists for the treatment of female sexual

dysfunction)

IT **337962-68-2P 337962-69-3P 337962-71-7P**
337962-72-8P **337962-74-0P** 337962-75-1P **337962-76-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(neuropeptide Y antagonists for the treatment of female sexual dysfunction)

IT 61413-54-5, Rolipram 78415-72-2, Milrinone 118784-21-7 118785-48-1
190666-14-9 223430-04-4
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(neuropeptide Y antagonists for the treatment of female sexual dysfunction)

IT 60-92-4, Cyclic AMP 9012-42-4, Adenylate cyclase 9036-21-9,
Phosphodiesterase III 9040-59-9 9068-52-4, Phosphodiesterase V
82707-54-8, Neprilysin 82785-45-3, Neuropeptide Y
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(neuropeptide Y antagonists for the treatment of female sexual dysfunction)

IT 136834-71-4P 136850-24-3P
RL: PUR (Purification or recovery); PREP (Preparation)
(neuropeptide Y antagonists for the treatment of female sexual dysfunction)

IT 337962-82-0P **337962-87-5P 337962-89-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(neuropeptide Y antagonists for the treatment of female sexual dysfunction)

IT 51739-61-8P 123494-21-3P **337962-78-4P** 337962-79-5P
337962-80-8P 337962-81-9P 337962-83-1P 337962-84-2P
337962-85-3P 337962-86-4P **337962-88-6P 337962-90-0P**
337962-91-1P 337962-92-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction; neuropeptide Y antagonists for the treatment of female sexual dysfunction)

IT 98-10-2, Benzenesulfonamide 108-33-8, 2-Amino-5-methyl-1,3,4-thiadiazole
593-51-1, Methylamine hydrochloride 2304-94-1, N-[(Benzyloxy)carbonyl]-.beta.-alanine 2620-50-0, Piperonylamine 7663-77-6,
N-(3-Aminopropyl)-2-pyrrolidinone 10316-79-7, 1-Amino-1-cyclopentanemethanol 59892-44-3 118755-30-9 118755-86-5
118783-85-0 118786-35-9 118786-36-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction; neuropeptide Y antagonists for the treatment of female sexual dysfunction)

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Berman, J; UROLOGY 1999, V54, P385 MEDLINE
(2) Ciba Geigy Ag; WO 9720821 A 1997 HCAPLUS
(3) Clark, J; ENDOCRINOLOGY 1985, V117(6), P2435 HCAPLUS
(4) Hauser-Kronberger, C; PEPTIDES 1999, V20(5), P539 HCAPLUS
(5) Hoyle, C; JOURNAL OF ANTAOMY 1996, V188(3), P633
(6) Neurogen Corp; WO 9803492 A 1998 HCAPLUS
(7) Ottesen, B; AMERICAN JOURNAL OF OBSTETRICS & GYNECOLOGY 1983, V147, P208 HCAPLUS
(8) Park, K; INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH 1997, V9(1), P27 MEDLINE

IT **337962-68-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(neuropeptide Y antagonists for the treatment of female sexual dysfunction)

RN 337962-68-2 HCAPLUS

CN Cyclopentanepropanoic acid, 1-[[[1,6-dihydro-6-oxo-1-(phenylmethyl)-3-pyridinyl]amino]carbonyl]-.alpha.-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



L21 ANSWER 9 OF 15 HCAPLUS COPYRIGHT 2003 ACS

AN 2001:338068 HCAPLUS

DN 134:348237

TI Treatment of female sexual arousal dysfunction

IN Maw, Graham Nigel; Wayman, Christopher Peter

PA Pfizer Limited, UK; Pfizer Inc.

SO Eur. Pat. Appl., 135 pp.
CODEN: EPXXDW

DT Patent

LA English

IC ICM A61K031-00
ICS A61K038-22; A61K038-55; A61P015-00

CC 1-1 (Pharmacology)
Section cross-reference(s): 63

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1097707	A1	20010509	EP 2000-309719	20001103
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	NO 2000005618	A	20010509	NO 2000-5618	20001107
	NO 2000005661	A	20010509	NO 2000-5661	20001107
	NO 2000005662	A	20010509	NO 2000-5662	20001107
	CN 1320426	A	20011107	CN 2000-137665	20001107
	CN 1322526	A	20011121	CN 2000-137671	20001107
	CN 1328824	A	20020102	CN 2000-137670	20001107
	JP 2001206855	A2	20010731	JP 2000-339905	20001108
	JP 2001213802	A2	20010807	JP 2000-339853	20001108
	JP 2001247478	A2	20010911	JP 2000-339949	20001108
	JP 2001247479	A2	20010911	JP 2000-339957	20001108
PRAI	GB 1999-26437	A	19991108		
	GB 2000-4021	A	20000218		
	GB 2000-13001	A	20000526		
	GB 2000-16563	A	20000705		
	GB 2000-17141	A	20000712		

AB A method of treating a female suffering from female sexual dysfunction (FSD), in particular female sexual arousal dysfunction (FSAD), is described. The method comprises delivering to the female an agent that is capable of potentiating cAMP in the sexual genitalia; wherein the agent is in an amt. to cause potentiation of cAMP in the sexual genitalia of the female. The agent may be admixed with a pharmaceutically acceptable carrier, diluent or excipient.

ST female sexual arousal dysfunction cAMP potentiation sequence

IT Diagnosis
(agents; treatment of female sexual arousal dysfunction)

IT Kidney

(angiotensin concerting enzyme of; treatment of female sexual arousal dysfunction)

IT Neuropeptide Y receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(antagonists; treatment of female sexual arousal dysfunction)

IT Drug delivery systems
(carriers; treatment of female sexual arousal dysfunction)

IT Reproductive organ
(clitoris, vasorelaxants for; treatment of female sexual arousal dysfunction)

IT Sexual behavior
(disorder, female; treatment of female sexual arousal dysfunction)

IT Reproductive organ
(female; treatment of female sexual arousal dysfunction)

IT Circulation
(genital; treatment of female sexual arousal dysfunction)

IT Drug delivery systems
(oral; treatment of female sexual arousal dysfunction)

IT Nerve
(pelvic, stimulation of; treatment of female sexual arousal dysfunction)

IT Swine
(renal angiotensin converting enzyme of; treatment of female sexual arousal dysfunction)

IT Diagnosis
Dog (Canis familiaris)
Drug bioavailability
Drug delivery systems
Protein sequences
Rabbit
Vasodilators
cDNA sequences
(treatment of female sexual arousal dysfunction)

IT Vagina
(vasorelaxants for; treatment of female sexual arousal dysfunction)

IT 82785-45-3, Neuropeptide y
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(antagonists; treatment of female sexual arousal dysfunction)

IT 9036-21-9, Camp phosphodiesterase
RL: ANT (Analyte); BAC (Biological activity or effector, except adverse); BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
(inhibitors; treatment of female sexual arousal dysfunction)

IT **82707-54-8, Neutral endopeptidase**
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(inhibitors; treatment of female sexual arousal dysfunction)

IT 9015-82-1, Angiotensin converting enzyme
RL: ANT (Analyte); BAC (Biological activity or effector, except adverse); BOC (Biological occurrence); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence)
(of renal cortex; treatment of female sexual arousal dysfunction)

IT 60-92-4, Camp
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence)
(potentiators of; treatment of female sexual arousal dysfunction)

IT 67482-93-3
RL: ARU (Analytical role, unclassified); BPR (Biological process); BSU (Biological study, unclassified); ANST (Analytical study); BIOL

(Biological study); PROC (Process)
(treatment of female sexual arousal dysfunction)
IT 37221-79-7, Vasoactive intestinal peptide
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(treatment of female sexual arousal dysfunction)
IT 51739-61-8P 123494-21-3P **337962-68-2P 337962-69-3P**
337962-70-6P **337962-71-7P** 337962-72-8P 337962-73-9P
337962-74-0P 337962-75-1P **337962-76-2P** 337962-77-3P
337962-78-4P 337962-79-5P **337962-80-8P**
337962-81-9P 337962-82-0P 337962-83-1P 337962-84-2P
337962-85-3P 337962-86-4P **337962-87-5P 337962-88-6P**
337962-89-7P 337962-90-0P 337962-91-1P 337962-92-2P
337962-93-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(treatment of female sexual arousal dysfunction)
IT 61413-54-5, Rolipram 78415-72-2, Milrinone 118784-21-7 118785-48-1
190666-14-9 223430-04-4
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment of female sexual arousal dysfunction)
IT 79-37-8, Oxalyl chloride 98-10-2, Benzenesulfonamide 109-02-4, 4-Methylmorpholine 504-29-0, 2-Aminopyridine 538-75-0 1122-58-3, 4-Dimethylaminopyridine 2304-94-1 10316-79-7, 1-Amino-1-cyclopentanemethanol 25952-53-8 59892-44-3 80029-43-2 118755-30-9 118755-86-5 118783-85-0 118786-35-9 118786-36-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(treatment of female sexual arousal dysfunction)
IT 140036-66-4, GenBank AX138824 140513-16-2 158375-12-3, GenBank AX138828 170671-70-2 172444-60-9 175196-86-8 190614-32-5 339210-09-2 339210-11-6 339210-12-7
RL: PRP (Properties)
(unclaimed nucleotide sequence; treatment of female sexual arousal dysfunction)
IT 87502-47-4 92307-59-0 146317-05-7 146317-08-0 147416-17-9 162996-13-6 169802-53-3 339210-08-1 339210-10-5
RL: PRP (Properties)
(unclaimed protein sequence; treatment of female sexual arousal dysfunction)
RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Bayer Ag; EP 0771799 A 1997 HCAPLUS
(2) Berman, J; UROLOGY 1999, V54, P385 MEDLINE
(3) Ciba Geigy Ag; WO 9720821 A 1997 HCAPLUS
(4) Compas B V Maschf; WO 9924333 A 1999
(5) Hauser-Kronberger, C; PEPTIDES 1999, V20(5), P539 HCAPLUS
(6) Heaton, J; WO 9739760 A 1997 HCAPLUS
(7) Neal, G; WO 9920266 A 1999 HCAPLUS
(8) Neurogen Corp; WO 9803492 A 1998 HCAPLUS
(9) Ottesen, B; AMERICAN JOURNAL OF OBSTETRICS & GYNECOLOGY 1983, V147, P208 HCAPLUS
(10) Park, K; INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH 1997, V9(1), P27 MEDLINE
(11) Pfizer Ltd; EP 0911333 A 1999 HCAPLUS
(12) Senetek Plc; WO 9104042 A 1991 HCAPLUS
(13) Smithkline Beckman Corp; EP 0274434 A 1988 HCAPLUS
(14) Vaisman, J; WO 9922731 A 1999 HCAPLUS
(15) Vivus Inc; WO 9921562 A 1999 HCAPLUS
IT **82707-54-8, Neutral endopeptidase**
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL

(Biological study); PROC (Process)
(inhibitors; treatment of female sexual arousal dysfunction)
RN 82707-54-8 HCAPLUS
CN Neprilysin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L21 ANSWER 10 OF 15 HCAPLUS COPYRIGHT 2003 ACS
AN 2001:338067 HCAPLUS
DN 134:348236
TI Phosphodiesterase inhibitors for the treatment of female sexual arousal dysfunction
IN Maw, Graham Nigel; Wayman, Christopher Peter
PA Pfizer Limited, UK; Pfizer Inc.
SO Eur. Pat. Appl., 129 pp.
CODEN: EPXXDW
DT Patent
LA English
IC ICM A61K031-00
ICS A61P015-00
CC 1-1 (Pharmacology)
Section cross-reference(s): 9, 63
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1097706	A1	20010509	EP 2000-309718	20001103
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	NO 2000005618	A	20010509	NO 2000-5618	20001107
	NO 2000005661	A	20010509	NO 2000-5661	20001107
	NO 2000005662	A	20010509	NO 2000-5662	20001107
	CN 1320426	A	20011107	CN 2000-137665	20001107
	CN 1322526	A	20011121	CN 2000-137671	20001107
	CN 1328824	A	20020102	CN 2000-137670	20001107
	JP 2001206855	A2	20010731	JP 2000-339905	20001108
	JP 2001213802	A2	20010807	JP 2000-339853	20001108
	JP 2001247478	A2	20010911	JP 2000-339949	20001108
	JP 2001247479	A2	20010911	JP 2000-339957	20001108
PRAI	GB 1999-26437	A	19991108		
	GB 2000-4021	A	20000218		
	GB 2000-13001	A	20000526		
	GB 2000-16563	A	20000705		
	GB 2000-17141	A	20000712		

AB A method of treating a female suffering from female sexual dysfunction (FSD), in particular female sexual arousal dysfunction (FSAD), is described. The method comprises delivering to the female an agent that is capable of potentiating cAMP in the sexual genitalia; wherein the agent is in an amt. to cause potentiation of cAMP in the sexual genitalia of the female. The agent may be admixed with a pharmaceutically acceptable carrier, diluent or excipient. Said agent is a phosphodiesterase (PDE) inhibitor wherein said PDE is a cAMP hydrolyzing PDE (and optionally cGMP hydroyzing).
ST female sexual dysfunction phosphodiesterase inhibitor sequence
IT Diagnosis
(agents; phosphodiesterase inhibitors for the treatment of female sexual arousal dysfunction)
IT Animal
(anesthetized female as model system; phosphodiesterase inhibitors for the treatment of female sexual arousal dysfunction)
IT Drug delivery systems
(carriers; phosphodiesterase inhibitors for the treatment of female sexual arousal dysfunction)
IT Reproductive organ

(clitoris, vasorelaxants for; phosphodiesterase inhibitors for the treatment of female sexual arousal dysfunction)
IT Sexual behavior
(disorder, female; phosphodiesterase inhibitors for the treatment of female sexual arousal dysfunction)
IT Reproductive organ
(female; phosphodiesterase inhibitors for the treatment of female sexual arousal dysfunction)
IT Circulation
(genital; phosphodiesterase inhibitors for the treatment of female sexual arousal dysfunction)
IT Anesthesia
(in female animal test system; phosphodiesterase inhibitors for the treatment of female sexual arousal dysfunction)
IT Kidney
(**neutral endopeptidase** of; phosphodiesterase inhibitors for the treatment of female sexual arousal dysfunction)
IT Hydrolysis
(of cAMP; phosphodiesterase inhibitors for the treatment of female sexual arousal dysfunction)
IT Drug delivery systems
(oral; phosphodiesterase inhibitors for the treatment of female sexual arousal dysfunction)
IT Nerve
(pelvic, stimulation of; phosphodiesterase inhibitors for the treatment of female sexual arousal dysfunction)
IT Diagnosis
Drug screening
Protein sequences
Test kits
Vasodilators
cDNA sequences
(phosphodiesterase inhibitors for the treatment of female sexual arousal dysfunction)
IT Dog (Canis familiaris)
Rabbit
Rat
(renal **neutral endopeptidase** of; phosphodiesterase inhibitors for the treatment of female sexual arousal dysfunction)
IT Vagina
(vasorelaxants for; phosphodiesterase inhibitors for the treatment of female sexual arousal dysfunction)
IT 9036-21-9, Camp phosphodiesterase 9068-52-4, Cgmp phosphodiesterase
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(inhibitors; phosphodiesterase inhibitors for the treatment of female sexual arousal dysfunction)
IT **82707-54-8P, Neutral endopeptidase**
RL: ANT (Analyte); BAC (Biological activity or effector, except adverse); BOC (Biological occurrence); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation)
(of kidney; phosphodiesterase inhibitors for the treatment of female sexual arousal dysfunction)
IT 9015-82-1, Angiotensin converting enzyme
RL: ANT (Analyte); ANST (Analytical study)
(phosphodiesterase inhibitors for the treatment of female sexual arousal dysfunction)
IT 198836-19-0
RL: ARU (Analytical role, unclassified); BPR (Biological process); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study); PROC (Process)
(phosphodiesterase inhibitors for the treatment of female sexual

arousal dysfunction)
IT 61413-54-5, Rolipram 78415-72-2, Milrinone 118784-21-7 118785-48-1
190666-14-9 223430-04-4
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(phosphodiesterase inhibitors for the treatment of female sexual arousal dysfunction)
IT 51739-61-8P 123494-21-3P **337962-68-2P 337962-69-3P**
337962-70-6P **337962-71-7P** 337962-72-8P 337962-73-9P
337962-74-0P 337962-75-1P **337962-76-2P** 337962-77-3P
337962-78-4P 337962-79-5P **337962-80-8P**
337962-81-9P 337962-82-0P 337962-83-1P 337962-84-2P
337962-85-3P 337962-86-4P **337962-87-5P 337962-88-6P**
337962-89-7P 337962-90-0P 337962-91-1P 337962-92-2P
337962-93-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(phosphodiesterase inhibitors for the treatment of female sexual arousal dysfunction)
IT 82785-45-3, Neuropeptide y
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(phosphodiesterase inhibitors for the treatment of female sexual arousal dysfunction)
IT 79-37-8, Oxalyl chloride 98-10-2, Benzenesulfonamide 109-02-4,
4-Methylmorpholine 538-75-0 1122-58-3, 4-Dimethylaminopyridine
2304-94-1 25952-53-8 59892-44-3 80029-43-2 118755-30-9
118755-86-5 118786-35-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(phosphodiesterase inhibitors for the treatment of female sexual arousal dysfunction)
IT 7665-99-8, Cgmp
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(potentiators of; phosphodiesterase inhibitors for the treatment of female sexual arousal dysfunction)
IT 60-92-4, Camp
RL: BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative)
(potentiators of; phosphodiesterase inhibitors for the treatment of female sexual arousal dysfunction)
IT 140036-66-4, GenBank AX138824 140513-16-2 158375-12-3, GenBank
AX138828 170671-70-2 175196-86-8 339210-13-8, 2: PN: EP1097706 PAGE:
95 unclaimed DNA 339210-14-9 339210-15-0
RL: PRP (Properties)
(unclaimed nucleotide sequence; phosphodiesterase inhibitors for the treatment of female sexual arousal dysfunction)
IT 87502-47-4 92307-59-0 146317-05-7 147416-17-9 162996-13-6
169802-53-3 183907-90-6 339210-08-1
RL: PRP (Properties)
(unclaimed protein sequence; phosphodiesterase inhibitors for the treatment of female sexual arousal dysfunction)
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Bayer Ag; EP 0771799 A 1997 HCAPLUS
(2) Compas B V Maschf; WO 9924333 A 1999
(3) Heaton, J; WO 9739760 A 1997 HCAPLUS
(4) Pfizer Ltd; EP 0911333 A 1999 HCAPLUS
(5) Vaisman, J; WO 9922731 A 1999 HCAPLUS
IT **82707-54-8P, Neutral endopeptidase**
RL: ANT (Analyte); BAC (Biological activity or effector, except adverse);

BOC (Biological occurrence); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation)
(of kidney; phosphodiesterase inhibitors for the treatment of female sexual arousal dysfunction)
RN 82707-54-8 HCAPLUS
CN Neprilysin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L21 ANSWER 11 OF 15 HCAPLUS COPYRIGHT 2003 ACS
AN 2001:50486 HCAPLUS
DN 134:105881
TI Pharmaceuticals with protective effects against oxidative-toxic substances, particularly against cardiotoxic substances
IN Rozsa, Zsuzsanna; Papp, Julius G.; Thormahlen, Dirk; Waldeck, Harald
PA Solvay Pharmaceuticals G.m.b.H., Germany
SO PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DT Patent
LA German
IC ICM A61K031-55
ICS A61K045-06; A61K031-70
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001003699	A1	20010118	WO 2000-EP6525	20000710
W: AU, BR, CA, CN, CZ, DZ, HU, ID, IL, IN, JP, KR, MX, NO, NZ, PL, RU, SK, TR, UA, US, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
DE 19932555	A1	20010118	DE 1999-19932555	19990713
BR 2000012442	A	20020402	BR 2000-12442	20000710
EP 1200095	A1	20020502	EP 2000-947960	20000710
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
JP 2003504336	T2	20030204	JP 2001-508979	20000710
NO 2002000132	A	20020312	NO 2002-132	20020111
PRAI DE 1999-19932555	A	19990713		
WO 2000-EP6525	W	20000710		

OS MARPAT 134:105881
AB The invention relates to the utilization of benzazepine-N-acetic acid derivs. which contain an oxo group in addn. to the nitrogen atom in the .alpha.-position and which are substituted in the third position by a 1-(carboxyalkyl)cyclopentylcarbonylamino group and to their salts and biolabile esters for the prophylaxis and/or treatment of heart damages caused by cardiotoxic doses of drugs or chems. in large mammals and particularly humans. beings. The invention particularly relates to the prophylaxis and/or treatment of heart damages, esp. myocardial damages, which may occur during cytostatic chemotherapy. The invention further relates to the utilization of these benzazepine-N-acetic acid derivs. for adjuvant treatment in therapy in which drugs, which have undesirable oxidative-toxic side effects, are used. The invention addnl. relates to the prodn. of drugs suitable for the prophylaxis and/or treatment or adjuvant treatment. Thus, tablets were prepd. from (3S,2'R)-3-(1-[2'-(ethoxycarbonyl)-4'-phenylbutyl]cyclopentane-1-carbonylamino)-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-acetic acid 20, corn starch 60, lactose 135, and gelatin (10% soln.) 6 mg/tablet.
ST pharmaceutical cytoprotectant cardiotoxicity anthracycline antibiotic; carboxyalkylcyclopentylcarbonylaminotetrahydrobenzazepine cytoprotectant; tetrahydrobenzazepine cyclopentylcarbonylamino cytoprotectant

IT Antibiotics
(anthracycline; pharmaceuticals with protective effects against cardiotoxic substances)
IT Toxicity
(cardiotoxicity; pharmaceuticals with protective effects against cardiotoxic substances)
IT Cytoprotective agents
Oxidative stress, biological
(pharmaceuticals with protective effects against cardiotoxic substances)
IT 20830-81-3, Daunorubicin 23214-92-8, Doxorubicin 25316-40-9, Adriamycin 56420-45-2, Epirubicin 65271-80-9, Mitoxanthrone
RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceuticals with protective effects against cardiotoxic substances)
IT **182560-83-4 182560-84-5 182560-85-6**
182560-86-7 182560-96-9 182560-97-0
182821-26-7 182821-27-8 182821-29-0
320387-73-3 320387-75-5
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceuticals with protective effects against cardiotoxic substances)
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Kali Chemie Pharma GMBH; DE 19510566 A 1996 HCAPLUS
(2) Snoeck, H; WO 9913871 A 1999 HCAPLUS
IT **182560-83-4**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceuticals with protective effects against cardiotoxic substances)
RN 182560-83-4 HCAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-(ethoxycarbonyl)-4-phenylbutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L21 ANSWER 12 OF 15 HCAPLUS COPYRIGHT 2003 ACS
AN 2000:574119 HCAPLUS
DN 133:172184
TI Medicament for treatment of high blood pressure
IN Wilkins, Martin R.; Thormaehlen, Dirk; Waldeck, Harald
PA Solvay Pharmaceuticals G.m.b.H., Germany
SO Ger. Offen., 8 pp.
CODEN: GWXXBX
DT Patent
LA German
IC ICM A61K031-55
CC 1-8 (Pharmacology)
Section cross-reference(s): 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19906310	A1	20000817	DE 1999-19906310	19990216
	WO 2000048601	A1	20000824	WO 2000-EP1068	20000210
	W: AU, BR, CA, CN, CZ, HU, ID, IL, IN, JP, KR, MX, NO, NZ, PL, RU, SK, TR, UA, US, ZA				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	BR 2000008260	A	20011106	BR 2000-8260	20000210
	EP 1154777	A1	20011121	EP 2000-903681	20000210
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002537258	T2	20021105	JP 2000-599393	20000210
	NO 2001003958	A	20011015	NO 2001-3958	20010815
	US 2002052361	A1	20020502	US 2001-930186	20010816
	US 6482820	B2	20021119		
PRAI	DE 1999-19906310	A	19990216		
	WO 2000-EP1068	W	20000210		

OS MARPAT 133:172184

GI



I

AB Benzazepine-N-acetic acid derivs. I [R1 = (substituted) phenylalkyl, naphthylalkyl; R2, R3 = H, biolabile ester-forming group] are useful for treatment of high blood pressure regardless of etiol., esp. certain forms of secondary hypertension assocd. with noncardiac disorders. Thus, rats with hypoxia-induced pulmonary hypertension, treated with (3S,2'R)-3-[1-(2-carboxy-4-phenylbutyl)cyclopentane-1-carbonylamino]-2,3,4,5-tetrahydro-2-oxo-(1H)-1-benzazepine-1-acetic acid (II) (40 mg/kg i.p./day by osmotic minipump), showed a redn. in pulmonary arterial pressure with no effect on the systemic blood pressure. A sterile injection soln. contained II 10, Na2HPO4.7H2O 43.24, NaH2PO4.2H2O 7.72, NaCl 30.0, and H2O 4948.0 mg.

ST benzazepineacetate antihypertensive

IT Drug delivery systems
(injections; medicament for treatment of high blood pressure)

IT Antihypertensives
(medicament for treatment of high blood pressure)

IT Antihypertensives
(pulmonary; medicament for treatment of high blood pressure)

IT Drug delivery systems
(tablets; medicament for treatment of high blood pressure)

IT **182821-27-8 182821-29-0** 288263-29-6D, 1H-1-Benzazepine-1-acetic acid, derivs.
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medicament for treatment of high blood pressure)

IT **182821-27-8**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES

(Uses)
(medicament for treatment of high blood pressure)
RN 182821-27-8 HCAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[(2R)-2-(ethoxycarbonyl)-4-phenylbutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L21 ANSWER 13 OF 15 HCAPLUS COPYRIGHT 2003 ACS
AN 1998:196303 HCAPLUS
DN 128:239479
TI Benzazepineacetic acid derivatives promoting gastrointestinal blood circulation
IN Rozsa, Susanna; Papp, Julius Gy.; Thormaehlen, Dirk; Waldeck, Harald
PA Solvay Pharmaceuticals G.m.b.H., Germany
SO Ger. Offen., 20 pp.
CODEN: GWXXBX
DT Patent
LA German
IC ICM A61K031-55
CC 1-8 (Pharmacology)
Section cross-reference(s): 27, 63
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 19638020	A1	19980319	DE 1996-19638020	19960918
EP 830863	A1	19980325	EP 1997-115603	19970909
EP 830863	B1	20000510		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
ES 2145545	T3	20000701	ES 1997-115603	19970909
US 5783573	A	19980721	US 1997-929114	19970915
JP 10101565	A2	19980421	JP 1997-251928	19970917
PRAI DE 1996-19638020	A	19960918		

OS MARPAT 128:239479
GI



AB Benzazepineacetic acid derivs. I [R1 = (substituted) phenylalkyl, naphthylalkyl; R2, R3 = H, group forming a biol. labile ester] and their

salts are useful in pharmaceutical compns. for treatment and/or prophylaxis of disorders in the gastrointestinal (mesenteric) circulation of various etiol. in humans and large mammals. Thus, in rats with streptozotocin-induced diabetes, the mesenteric arterial blood pressure was 9 mL/min; this was increased to 14 mL/min by treatment with I (substituents not specified) at 30 mg/kg/day orally for 8 wk. Tablets were prepd. contg. (3S,2R)-I (R1 = PhCH2CH2, R2 = Et, R3 = H) (II) 20, corn starch 60, lactose 135, and gelatin 6 mg. II was prepd. from di-Et malonate and phenethyl bromide via 2-carboxy-4-phenylbutyric acid and Et .alpha.-(2-phenethyl)acrylate, reaction with cyclopentanecarboxylic acid, resoln. with L(-)-.alpha.-methylbenzylamine, condensation with tert-Bu 3-amino-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-acetate, etc.

ST gastrointestinal circulation diabetes benzazepineacetate

IT Circulation
Diabetes mellitus
Digestive tract
(benzazepineacetic acid derivs. promoting gastrointestinal blood circulation)

IT **182560-83-4P 182560-84-5P 182560-85-6P**
182560-86-7P 182560-96-9P 182560-97-0P
182560-98-1P 182560-99-2P 182561-11-1P
182561-14-4P 182821-26-7P 182821-27-8P
182821-33-6P 204781-61-3P 204781-62-4P
204781-63-5P 204781-64-6P 204781-65-7P
204781-66-8P 204781-67-9P 204781-68-0P
204781-69-1P 204781-70-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(benzazepineacetic acid derivs. promoting gastrointestinal blood circulation)

IT 103-63-9, 2-Phenylethyl bromide 105-53-3, Diethyl malonate 529-34-0, .alpha.-Tetralone 1074-82-4, Potassium phthalimide 3400-45-1, Cyclopentanecarboxylic acid 5292-43-3, tert-Butyl bromoacetate 62327-21-3, tert-Butyl dimethylphosphonoacetate
RL: RCT (Reactant); RACT (Reactant or reagent)
(benzazepineacetic acid derivs. promoting gastrointestinal blood circulation)

IT 6628-68-8P 27356-87-2P 56384-59-9P 80091-07-2P 84793-30-6P 86499-26-5P 86499-96-9P 98626-45-0P 105260-10-4P 105260-11-5P 109010-60-8P 168081-19-4P 182561-15-5P 182561-16-6P 182561-25-7P 182561-27-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(benzazepineacetic acid derivs. promoting gastrointestinal blood circulation)

IT **182560-83-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(benzazepineacetic acid derivs. promoting gastrointestinal.blood circulation)

RN 182560-83-4 HCAPLUS

CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-(ethoxycarbonyl)-4-phenylbutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L21 ANSWER 14 OF 15 HCAPLUS COPYRIGHT 2003 ACS
AN 1996:646474 HCAPLUS
DN 125:301029
TI Preparation of 3-[[(1-carboxyalkyl)cyclopentyl]carbonylamino]benzazepin-1-acetates and analogs as **neutral endopeptidase** inhibitors
IN Waldeck, Harald; Hoeltje, Dagmar; Messinger, Josef; Antel, Jochen; Wurl, Michael; Thormaehlen, Dirk
PA Kali-Chemie Pharma Gmbh, Germany
SO Eur. Pat. Appl., 35 pp.
CODEN: EPXXDW
DT Patent
LA German
IC ICM C07K005-078
ICS A61K038-05
CC 28-22 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 733642	A1	19960925	EP 1996-104265	19960318
	EP 733642	B1	20001129		
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	DE 19510566	A1	19960926	DE 1995-19510566	19950323
	ZA 9601243	A	19960827	ZA 1996-1243	19960216
	IL 117265	A1	20000716	IL 1996-117265	19960226
	SK 281079	B6	20001107	SK 1996-354	19960315
	AT 197801	E	20001215	AT 1996-104265	19960318
	ES 2152444	T3	20010201	ES 1996-104265	19960318
	CN 1147506	A	19970416	CN 1996-104257	19960320
	CN 1059436	B	20001213		
	RU 2159768	C2	20001127	RU 1996-105383	19960320
	CA 2172354	AA	19960924	CA 1996-2172354	19960321
	AU 9648210	A1	19961003	AU 1996-48210	19960321
	AU 701271	B2	19990121		
	NO 9601181	A	19960924	NO 1996-1181	19960322
	JP 08269011	A2	19961015	JP 1996-66703	19960322
	US 5677297	A	19971014	US 1996-620213	19960322
	CZ 289245	B6	20011212	CZ 1996-863	19960322
	PL 184336	B1	20021031	PL 1996-313433	19960322
PRAI	DE 1995-19510566	A	19950323		

OS MARPAT 125:301029
GI



I

AB Title compds. (I; R1 = alkoxyalkoxyalkyl, phenylalkyl, phenoxyalkyl, etc.; R2,R3 = H or halo; R4,R5 = H, metab. labile ester residue; Z = CH2, O, S) were prepd. Thus, tert-Bu 3-amino-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-acetate was amidated by 1-(2-ethoxycarbonyl-4-phenylbutyl)cyclopentanecarboxylic acid (prepn. each given) to give I (R1 = CH2CH2Ph, R2 = R3 = H, R4 = Et, R5 = CMe3, Z = CH2). Data for in vitro and in vivo biol. activity of I were given.

ST benzazepinacetate carboxyalkylcyclopentylcarbonylamino prepn **neutral endopeptidase** inhibitor

IT Heart, disease
(failure, treatment; prepn. of 3-[[(1-carboxyalkyl)cyclopentyl]carbonyl amino]benzazepin-1-acetates and analogs as **neutral endopeptidase** inhibitors)

IT **182560-83-4P 182560-84-5P 182560-85-6P**
182560-86-7P 182560-89-0P 182560-90-3P
182560-91-4P 182560-92-5P 182560-93-6P
182560-94-7P 182560-95-8P 182560-96-9P
182560-97-0P 182560-98-1P 182560-99-2P
182561-00-8P 182561-01-9P 182561-02-0P
182561-03-1P 182561-04-2P 182561-05-3P
182561-06-4P 182561-07-5P 182561-08-6P
182561-09-7P 182561-10-0P 182561-11-1P
182561-12-2P 182561-13-3P 182561-14-4P
182561-29-1P 182561-30-4P 182561-31-5P
182561-32-6P 182561-33-7P 182561-34-8P
182561-35-9P 182561-36-0P 182561-38-2P
182561-39-3P 182561-40-6P 182704-04-7P
182821-26-7P 182821-27-8P 182821-28-9P
182821-29-0P 182821-30-3P 182821-31-4P
182821-32-5P 182821-33-6P 182821-36-9P
182821-37-0P 182824-17-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 3-[[(1-carboxyalkyl)cyclopentyl]carbonylamino]benzazepin-1-acetates and analogs as **neutral endopeptidase** inhibitors)

IT **82707-54-8, Neutral endopeptidase**
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(prepn. of 3-[[(1-carboxyalkyl)cyclopentyl]carbonylamino]benzazepin-1-acetates and analogs as **neutral endopeptidase** inhibitors)

IT 109010-60-8P 126671-19-0P 182821-34-7P 182821-35-8P
RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of 3-[[(1-carboxyalkyl)cyclopentyl]carbonylamino]benzazepin-1-acetates and analogs as **neutral endopeptidase** inhibitors)

IT 88-75-5, 2-Nitrophenol 103-63-9, Phenethyl bromide 105-53-3, Diethyl malonate 332-48-9, 2-(4-Fluorophenoxy)ethyl bromide 529-34-0, .alpha.-Tetralone 590-92-1, 3-Bromopropionic acid 616-91-1, N-Acetyl-L-cysteine 1074-82-4, Potassium phthalimide 1493-27-2, 1-Fluoro-2-nitrobenzene 3262-72-4 3400-45-1, Cyclopentanecarboxylic acid 3929-47-3, 3-(3,4-Dimethoxyphenyl)-1-propanol 3970-21-6, Methoxyethoxymethyl chloride 5292-43-3, tert-Butyl bromoacetate 5437-45-6, Benzyl bromoacetate 18997-19-8, Chloromethyl pivalate 62327-21-3, tert-Butyl dimethylphosphonoacetate
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of 3-[[(1-carboxyalkyl)cyclopentyl]carbonylamino]benzazepin-1-acetates and analogs as **neutral endopeptidase** inhibitors)

IT 3945-85-5P 6628-68-8P, Diethyl phenethylmalonate 27356-87-2P, Ethyl 2-phenethylacrylate 55710-80-0P 56384-59-9P 60115-45-9P 80091-07-2P, MonoEthyl phenethylmalonate 84793-30-6P, tert-Butyl 2-phenethylacrylate 86499-26-5P 86499-96-9P 91088-54-9P 95779-63-8P 95779-64-9P 95779-65-0P 95779-67-2P 98626-45-0P 99197-78-1P 99197-79-2P 99197-80-5P 99248-22-3P 100236-26-8P 105260-10-4P 105260-11-5P 105593-54-2P 118756-03-9P 118783-83-8P 168081-19-4P 182561-15-5P 182561-16-6P 182561-17-7P 182561-18-8P 182561-19-9P 182561-20-2P 182561-21-3P 182561-22-4P 182561-23-5P 182561-24-6P 182561-25-7P 182561-27-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of 3-[[(1-carboxyalkyl)cyclopentyl]carbonylamino]benzazepin-1-acetates and analogs as **neutral endopeptidase** inhibitors)

IT **182560-83-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 3-[[(1-carboxyalkyl)cyclopentyl]carbonylamino]benzazepin-1-acetates and analogs as **neutral endopeptidase** inhibitors)

RN 182560-83-4 HCAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-(ethoxycarbonyl)-4-phenylbutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L21 ANSWER 15 OF 15 HCAPLUS COPYRIGHT 2003 ACS
AN 1990:405779 HCAPLUS
DN 113:5779
TI Spiro-substituted glutaramides as diuretics
IN Danilewicz, John Christopher
PA Pfizer Ltd., UK
SO Brit. UK Pat. Appl., 49 pp.
CODEN: BAXXDU
DT Patent

LA English
IC ICM C07C103-737
ICS A61K031-00; C07D493-18
ICI C07D493-18, C07D307-00
CC 24-9 (Alicyclic Compounds)
Section cross-reference(s): 1
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI GB 2218983	A1	19891129	GB 1988-12596	19880527
PRAI GB 1988-12596		19880527		

OS CASREACT 113:5779; MARPAT 113:5779
GI For diagram(s), see printed CA Issue.
AB The title compds. [I; R = H, C1-6 alkyl, PhCH2, ester residue; R1 = H, C1-4 alkyl; R5 = substituent; A completes a 4-7-membered satd. or mono-unsatd. carbocyclic ring which may be optionally fused to a further satd. or unsatd. 5- or 6-membered carbocyclic ring, X = Q wherein R2, R3 = H, OH, C1-4 alkyl, alkoxy; R4 = H, C2-6 alkyl, PhCH2, ester residue; Y = O, CH2, CH2CH2, Q1 (wherein m, n = 1, 2; q = 3-5)], useful as diuretics in treating such cardiovascular disorders as hypertension and heart failure, are prepd. 1-Ethyl-3-(dimethylamino)propylcarbodiimide HCl was added to a stirred mixt. of ester II (prepn. given), ester salt III (prepn. give), 1-hydroxybenzotriazole, and N-methylmorpholine in CH2Cl2 under cooling and stirred at room temp. to give 85% IV. Also prepd. were 23 addnl. I and many intermediates. The suitable dose is 10-1500 mg/day for adults.
ST spiroglutaramide prepn diuretic
IT Antihypertensives
Diuretics
(spiroglutaramide derivs.)
IT Heart, disease or disorder
(failure, spiroglutaramide derivs. effect on)
IT 63427-64-5P 127283-43-6P 127283-44-7P 127283-45-8P 127283-46-9P
127283-47-0P 127283-48-1P 127283-49-2P 127283-50-5P 127283-51-6P
127283-52-7P 127283-53-8P 127283-54-9P 127283-55-0P 127283-56-1P
127283-57-2P 127283-58-3P 127283-59-4P 127283-60-7P 127283-61-8P
127283-62-9P 127379-44-6P 127379-45-7P 127379-46-8P 127379-47-9P
127379-48-0P 127379-49-1P 127379-50-4P 127379-51-5P 127379-52-6P
127379-53-7P 127380-64-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction of, in prepn. of diuretics)
IT 127283-24-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
IT 127283-25-4P 127283-26-5P 127283-27-6P 127283-28-7P 127283-29-8P
127283-30-1P 127283-31-2P 127283-32-3P **127283-33-4P**
127283-34-5P 127283-35-6P **127283-36-7P** 127283-37-8P
127283-38-9P 127283-39-0P 127283-40-3P 127283-41-4P 127283-42-5P
127313-05-7P 127313-06-8P 127313-07-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as diuretic)
IT 879-18-5, 1-Naphthalenecarbonyl chloride 4230-63-1 6715-18-0
23356-96-9 24802-65-1 63427-65-6 89364-90-9 118755-90-1
118783-83-8 118783-90-7 118786-35-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in prepn. of diuretics)
IT **127283-33-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as diuretic)

RN 127283-33-4 HCAPLUS
CN Cyclopentanepropanoic acid, 1-[[[6-(hydroxymethyl)-7-oxabicyclo[2.2.1]hept-2-yl]amino]carbonyl]-.alpha.-(2-methoxyethyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



=> fil reg
FILE 'REGISTRY' ENTERED AT 13:09:19 ON 11 FEB 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 10 FEB 2003 HIGHEST RN 488699-93-0
DICTIONARY FILE UPDATES: 10 FEB 2003 HIGHEST RN 488699-93-0

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> d reg tot l7

1	RN	465529-12-8	REGISTRY
2	RN	465529-08-2	REGISTRY
3	RN	465529-06-0	REGISTRY
4	RN	465529-05-9	REGISTRY
5	RN	465529-04-8	REGISTRY
6	RN	465529-03-7	REGISTRY
7	RN	465529-02-6	REGISTRY
8	RN	465529-01-5	REGISTRY
9	RN	465529-00-4	REGISTRY
10	RN	465528-89-6	REGISTRY
11	RN	465528-87-4	REGISTRY
12	RN	465528-71-6	REGISTRY
13	RN	465528-57-8	REGISTRY
14	RN	465528-46-5	REGISTRY
15	RN	465528-42-1	REGISTRY
16	RN	465528-40-9	REGISTRY
17	RN	465528-39-6	REGISTRY

18	RN	465528-38-5	REGISTRY
19	RN	465528-37-4	REGISTRY
20	RN	465528-36-3	REGISTRY
21	RN	465528-35-2	REGISTRY
22	RN	465528-34-1	REGISTRY
23	RN	465528-22-7	REGISTRY
24	RN	465528-20-5	REGISTRY
25	RN	465528-04-5	REGISTRY
26	RN	465527-90-6	REGISTRY
27	RN	406486-52-0	REGISTRY
28	RN	388631-28-5	REGISTRY
29	RN	388631-27-4	REGISTRY
30	RN	388631-25-2	REGISTRY
31	RN	388631-24-1	REGISTRY
32	RN	388631-11-6	REGISTRY
33	RN	388631-09-2	REGISTRY
34	RN	388631-01-4	REGISTRY
35	RN	388631-00-3	REGISTRY
36	RN	388630-99-7	REGISTRY
37	RN	388630-98-6	REGISTRY
38	RN	388630-97-5	REGISTRY
39	RN	388630-93-1	REGISTRY
40	RN	388630-90-8	REGISTRY
41	RN	388630-86-2	REGISTRY
42	RN	388630-84-0	REGISTRY
43	RN	388630-83-9	REGISTRY
44	RN	388630-82-8	REGISTRY
45	RN	388630-59-9	REGISTRY
46	RN	388630-58-8	REGISTRY
47	RN	388630-50-0	REGISTRY
48	RN	388630-49-7	REGISTRY
49	RN	388630-48-6	REGISTRY
50	RN	388630-43-1	REGISTRY
51	RN	388630-41-9	REGISTRY
52	RN	388630-39-5	REGISTRY
53	RN	388630-38-4	REGISTRY
54	RN	388630-36-2	REGISTRY
55	RN	388630-32-8	REGISTRY
56	RN	388630-29-3	REGISTRY
57	RN	388630-28-2	REGISTRY
58	RN	388630-27-1	REGISTRY
59	RN	388630-26-0	REGISTRY
60	RN	388630-23-7	REGISTRY
61	RN	388630-20-4	REGISTRY
62	RN	388630-19-1	REGISTRY
63	RN	388630-16-8	REGISTRY
64	RN	388630-14-6	REGISTRY
65	RN	388630-13-5	REGISTRY
66	RN	337962-93-3	REGISTRY
67	RN	337962-90-0	REGISTRY
68	RN	337962-89-7	REGISTRY
69	RN	337962-88-6	REGISTRY
70	RN	337962-87-5	REGISTRY
71	RN	337962-81-9	REGISTRY
72	RN	337962-80-8	REGISTRY
73	RN	337962-78-4	REGISTRY
74	RN	337962-76-2	REGISTRY
75	RN	337962-74-0	REGISTRY
76	RN	337962-71-7	REGISTRY
77	RN	337962-69-3	REGISTRY
78	RN	337962-68-2	REGISTRY
79	RN	320387-75-5	REGISTRY
80	RN	320387-73-3	REGISTRY

81	RN	204781-70-4	REGISTRY
82	RN	204781-69-1	REGISTRY
83	RN	204781-68-0	REGISTRY
84	RN	204781-67-9	REGISTRY
85	RN	204781-66-8	REGISTRY
86	RN	204781-65-7	REGISTRY
87	RN	204781-64-6	REGISTRY
88	RN	204781-63-5	REGISTRY
89	RN	204781-62-4	REGISTRY
90	RN	204781-61-3	REGISTRY
91	RN	182824-17-5	REGISTRY
92	RN	182821-37-0	REGISTRY
93	RN	182821-36-9	REGISTRY
94	RN	182821-33-6	REGISTRY
95	RN	182821-32-5	REGISTRY
96	RN	182821-31-4	REGISTRY
97	RN	182821-30-3	REGISTRY
98	RN	182821-29-0	REGISTRY
99	RN	182821-28-9	REGISTRY
100	RN	182821-27-8	REGISTRY
101	RN	182821-26-7	REGISTRY
102	RN	182704-04-7	REGISTRY
103	RN	182561-40-6	REGISTRY
104	RN	182561-39-3	REGISTRY
105	RN	182561-38-2	REGISTRY
106	RN	182561-36-0	REGISTRY
107	RN	182561-35-9	REGISTRY
108	RN	182561-34-8	REGISTRY
109	RN	182561-33-7	REGISTRY
110	RN	182561-32-6	REGISTRY
111	RN	182561-31-5	REGISTRY
112	RN	182561-30-4	REGISTRY
113	RN	182561-29-1	REGISTRY
114	RN	182561-14-4	REGISTRY
115	RN	182561-13-3	REGISTRY
116	RN	182561-12-2	REGISTRY
117	RN	182561-11-1	REGISTRY
118	RN	182561-10-0	REGISTRY
119	RN	182561-09-7	REGISTRY
120	RN	182561-08-6	REGISTRY
121	RN	182561-07-5	REGISTRY
122	RN	182561-06-4	REGISTRY
123	RN	182561-05-3	REGISTRY
124	RN	182561-04-2	REGISTRY
125	RN	182561-03-1	REGISTRY
126	RN	182561-02-0	REGISTRY
127	RN	182561-01-9	REGISTRY
128	RN	182561-00-8	REGISTRY
129	RN	182560-99-2	REGISTRY
130	RN	182560-98-1	REGISTRY
131	RN	182560-97-0	REGISTRY
132	RN	182560-96-9	REGISTRY
133	RN	182560-95-8	REGISTRY
134	RN	182560-94-7	REGISTRY
135	RN	182560-93-6	REGISTRY
136	RN	182560-92-5	REGISTRY
137	RN	182560-91-4	REGISTRY
138	RN	182560-90-3	REGISTRY
139	RN	182560-89-0	REGISTRY
140	RN	182560-86-7	REGISTRY
141	RN	182560-85-6	REGISTRY
142	RN	182560-84-5	REGISTRY
143	RN	182560-83-4	REGISTRY

144 RN 127283-36-7 REGISTRY
145 RN 127283-34-5 REGISTRY
146 RN 127283-33-4 REGISTRY

=> d l7 ide can 1 10 20 27 28 30 40 50 60 66 70 75 79 81 86 91 92 96 99 102 103 110 120 130 140 144-146

L7 ANSWER 1 OF 146 REGISTRY COPYRIGHT 2003 ACS
RN 465529-12-8 REGISTRY
CN Cyclopentanepropanoic acid, 1-[[[3-(2,3-dihydro-2-methyl-5-benzofuranyl)propyl]amino]carbonyl]-.alpha.-(2-methoxyethyl)-, 1,1-dimethylethyl ester, (.alpha.S)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN tert-Butyl (2S)-4-methoxy-2-[[1-[[[3-(2,3-dihydro-2-methylbenzofuran-5-yl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoate
FS STEREOSEARCH
MF C28 H43 N O5
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:278918

L7 ANSWER 10 OF 146 REGISTRY COPYRIGHT 2003 ACS
RN 465528-89-6 REGISTRY
CN Cyclopentanepropanoic acid, 1-[[[3-(2,3-dihydro-1,4-benzodioxin-6-yl)propyl]amino]carbonyl]-.alpha.-(2-methoxyethyl)-, 1,1-dimethylethyl ester, (.alpha.S)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN tert-Butyl (2S)-4-methoxy-2-[[1-[[[3-(3,4-(ethylenedioxy)phenyl)propyl]amino]carbonyl]cyclopentyl]methyl]butanoate
FS STEREOSEARCH
MF C27 H41 N O6
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:278918

L7 ANSWER 20 OF 146 REGISTRY COPYRIGHT 2003 ACS
RN 465528-36-3 REGISTRY
CN Cyclopentanepropanoic acid, 1-[[[3-(2,3-dihydro-5-benzofuranyl)propyl]amino]carbonyl]-.alpha.-[(2-methoxyethoxy)methyl]-, (.alpha.S)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN (2S)-2-((2-Methoxyethoxy)methyl)-3-[1-[[[3-(2,3-dihydro-5-benzofuranyl)propyl]amino]carbonyl]cyclopentyl]propanoic acid
FS STEREOSEARCH
MF C24 H35 N O6
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:278918

L7 ANSWER 27 OF 146 REGISTRY COPYRIGHT 2003 ACS
RN 406486-52-0 REGISTRY
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[(2R)-2-(ethoxycarbonyl)-4-phenylbutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, calcium salt (2:1), (3S)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C31 H38 N2 O6 . 1/2 Ca
SR CAS Registry Services

CRN (182821-27-8)

Absolute stereochemistry. Rotation (-).



●1/2 Ca

L7 ANSWER 28 OF 146 REGISTRY COPYRIGHT 2003 ACS
RN 388631-28-5 REGISTRY
CN Cyclopentanepropanoic acid, 1-[[[(2,3-dihydro-2-benzofuranyl)methyl]amino]carbonyl]-.alpha.-(2-methoxyethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)
OTHER NAMES:
CN tert-Butyl 2-[[1-[[[(2,3-dihydro-1-benzofuran-2-yl)methyl]amino]carbonyl]cyclopentyl]methyl]-4-methoxybutanoate
MF C25 H37 N O5
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:102126

L7 ANSWER 30 OF 146 REGISTRY COPYRIGHT 2003 ACS
RN 388631-25-2 REGISTRY
CN Cyclopentanepropanoic acid, .alpha.-(2-methoxyethyl)-1-[[(4-phenyl-2-pyridinyl)amino]carbonyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Benzyl 2-[[1-[[(4-phenyl-2-pyridinyl)amino]carbonyl]cyclopentyl]methyl]-4-methoxybutanoate
MF C30 H34 N2 O4
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:102126

L7 ANSWER 40 OF 146 REGISTRY COPYRIGHT 2003 ACS
RN 388630-90-8 REGISTRY
CN Cyclopentanepropanoic acid, 1-[[[2-(1H-indol-3-yl)ethyl]amino]carbonyl]-.alpha.-propyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)
OTHER NAMES:
CN tert-Butyl 2-[[1-[[[2-(1H-indol-3-yl)ethyl]amino]carbonyl]cyclopentyl]methyl]pentanoate
MF C26 H38 N2 O3
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:102126

L7 ANSWER 50 OF 146 REGISTRY COPYRIGHT 2003 ACS
RN 388630-43-1 REGISTRY
CN Benzenebutanoic acid, .alpha.-[[1-[(3-pyridinylamino)carbonyl]cyclopentyl]methyl]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 4-Phenyl-2-[[1-[(3-pyridinylamino)carbonyl]cyclopentyl]methyl]butanoic acid
MF C22 H26 N2 O3
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:102126

L7 ANSWER 60 OF 146 REGISTRY COPYRIGHT 2003 ACS
RN 388630-23-7 REGISTRY
CN Cyclopentanepropanoic acid, 1-[[[2-(2-oxo-1-piperidinyl)ethyl]amino]carbonyl]-.alpha.-propyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2-[[1-[[[2-(2-Oxo-1-piperidinyl)ethyl]amino]carbonyl]cyclopentyl]methyl]pentanoic acid
MF C19 H32 N2 O4
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:102126

L7 ANSWER 66 OF 146 REGISTRY COPYRIGHT 2003 ACS
RN 337962-93-3 REGISTRY
CN Cyclopentanepropanoic acid, 1-[[(5-ethyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]-.alpha.-propyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2-[[1-[[(5-Ethyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]cyclopentyl]methyl]pentanoic acid
MF C16 H25 N3 O3 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

REFERENCE 5: 134:336237

L7 ANSWER 75 OF 146 REGISTRY COPYRIGHT 2003 ACS
RN 337962-74-0 REGISTRY
CN Cyclopentanepropanoic acid, 1-[[(5-ethyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]-.alpha.-propyl-, (.alpha.S)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN (+)-(2S)-2-[[1-[[(5-Ethyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]cyclopentyl]methyl]pentanoic acid
FS STEREOSEARCH
MF C16 H25 N3 O3 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1962 TO DATE)
8 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:370356

REFERENCE 2: 136:395983

REFERENCE 3: 136:102126

REFERENCE 4: 136:96099

REFERENCE 5: 134:348237

REFERENCE 6: 134:348236

REFERENCE 7: 134:336238

REFERENCE 8: 134:336237

L7 ANSWER 79 OF 146 REGISTRY COPYRIGHT 2003 ACS
RN 320387-75-5 REGISTRY
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-[[(1,1-dimethylethoxy)methoxy]carbonyl]-4-phenylbutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo- (9CI) (CA INDEX NAME)
MF C34 H44 N2 O7
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 134:105881

L7 ANSWER 81 OF 146 REGISTRY COPYRIGHT 2003 ACS
RN 204781-70-4 REGISTRY
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-carboxy-3-(1-naphthalenyl)propyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo- (9CI) (CA INDEX NAME)
MF C32 H34 N2 O6
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 128:239479

L7 ANSWER 86 OF 146 REGISTRY COPYRIGHT 2003 ACS
RN 204781-65-7 REGISTRY
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-carboxy-3-(4-methylphenyl)propyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo- (9CI) (CA INDEX NAME)
MF C29 H34 N2 O6
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 128:239479

L7 ANSWER 91 OF 146 REGISTRY COPYRIGHT 2003 ACS
RN 182824-17-5 REGISTRY
CN 1,5-Benzothiazepine-5(2H)-acetic acid, 3-[[[1-[2-carboxy-4-(4-fluorophenoxy)butyl]cyclopentyl]carbonyl]amino]-ar,ar-dichloro-3,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)
MF C28 H29 Cl2 F N2 O7 S
CI IDS
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

PAGE 1-A



PAGE 2-A

2 (D1—C1)

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 125:301029

L7 ANSWER 92 OF 146 REGISTRY COPYRIGHT 2003 ACS
RN 182821-37-0 REGISTRY
CN 1,5-Benzothiazepine-5(2H)-acetic acid, 3-[[[1-[2-carboxy-5-(4-methoxyphenyl)pentyl]cyclopentyl]carbonyl]amino]-3,4-dihydro-4-oxo-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C30 H36 N2 O7 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 125:301029

L7 ANSWER 96 OF 146 REGISTRY COPYRIGHT 2003 ACS
RN 182821-31-4 REGISTRY
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-(2-carboxy-4-phenylbutyl)cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H34 N2 O6
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 125:301029

L7 ANSWER 99 OF 146 REGISTRY COPYRIGHT 2003 ACS
RN 182821-28-9 REGISTRY
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-[(1,1-dimethylethoxy)carbonyl]-4-phenylbutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, 1,1-dimethylethyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C37 H50 N2 O6
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 125:301029

L7 ANSWER 102 OF 146 REGISTRY COPYRIGHT 2003 ACS
RN 182704-04-7 REGISTRY
CN 1,5-Benzothiazepine-5(2H)-acetic acid, 3-[[[1-[2-carboxy-4-(4-fluorophenoxy)butyl]cyclopentyl]carbonyl]amino]-ar,ar-dichloro-3,4-dihydro-4-oxo-, [R-(R*,R*)]- (9CI) (CA INDEX NAME)
MF C28 H29 Cl2 F N2 O7 S
CI IDS
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

PAGE 1-A



PAGE 2-A

2 (D1—C1)

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 125:301029

L7 ANSWER 103 OF 146 REGISTRY COPYRIGHT 2003 ACS
RN 182561-40-6 REGISTRY
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-carboxy-3-(1-naphthalenyl)propyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (R*,S*)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C32 H34 N2 O6
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 125:301029

L7 ANSWER 110 OF 146 REGISTRY COPYRIGHT 2003 ACS
RN 182561-32-6 REGISTRY
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-(2-carboxy-5-phenoxypentyl)cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (R*,R*)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C30 H36 N2 O7
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 125:301029

L7 ANSWER 120 OF 146 REGISTRY COPYRIGHT 2003 ACS
RN 182561-08-6 REGISTRY
CN 1,5-Benzothiazepine-5(2H)-acetic acid, 3-[[[1-[2-carboxy-5-(4-methoxyphenyl)pentyl]cyclopentyl]carbonyl]amino]-3,4-dihydro-4-oxo-, [R-(R*,R*)]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C30 H36 N2 O7 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 125:301029

L7 ANSWER 130 OF 146 REGISTRY COPYRIGHT 2003 ACS
RN 182560-98-1 REGISTRY
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-[[(2,2-dimethyl-1-oxopropoxy)methoxy]carbonyl]-4-phenylbutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, phenylmethyl ester (9CI) (CA INDEX NAME)
MF C42 H50 N2 O8
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1962 TO DATE)
2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 128:239479

REFERENCE 2: 125:301029

L7 ANSWER 140 OF 146 REGISTRY COPYRIGHT 2003 ACS
RN 182560-86-7 REGISTRY
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-(2-carboxy-4-phenylbutyl)cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo- (9CI) (CA INDEX NAME)
MF C29 H34 N2 O6
SR CA
LC STN Files: CA, CAPLUS, SYNTHLINE, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1962 TO DATE)
3 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 134:105881

REFERENCE 2: 128:239479

REFERENCE 3: 125:301029

L7 ANSWER 144 OF 146 REGISTRY COPYRIGHT 2003 ACS
RN 127283-36-7 REGISTRY
CN 7-Oxabicyclo[2.2.1]heptane-2-carboxylic acid, 6-[[[1-(2-carboxy-4-methoxybutyl)cyclopentyl]carbonyl]amino]- (9CI) (CA INDEX NAME)
MF C19 H29 N O7
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 113:5779

L7 ANSWER 145 OF 146 REGISTRY COPYRIGHT 2003 ACS
RN 127283-34-5 REGISTRY
CN Cyclopentanepropanoic acid, 1-[[[6-(hydroxymethyl)-7-oxabicyclo[2.2.1]hept-2-yl]amino]carbonyl]-.alpha.-(2-methoxyethyl)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 7-Oxabicyclo[2.2.1]heptane, cyclopentanepropanoic acid deriv.
MF C19 H31 N O6
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 113:5779

L7 ANSWER 146 OF 146 REGISTRY COPYRIGHT 2003 ACS
RN 127283-33-4 REGISTRY
CN Cyclopentanepropanoic acid, 1-[[[6-(hydroxymethyl)-7-oxabicyclo[2.2.1]hept-2-yl]amino]carbonyl]-.alpha.-(2-methoxyethyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 7-Oxabicyclo[2.2.1]heptane, cyclopentanepropanoic acid deriv.
MF C26 H37 N O6
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 113:5779

=> d his

(FILE 'HOME' ENTERED AT 12:58:26 ON 11 FEB 2003)
SET COST OFF

FILE 'REGISTRY' ENTERED AT 12:58:36 ON 11 FEB 2003
L1 STR
L2 50 S L1
L3 STR L1
L4 45 S L3 CSS
L5 STR L3
L6 9 S L5 CSS
L7 146 S L5 CSS FUL
SAV L7 GERSTL893/A

FILE 'HCAOLD' ENTERED AT 13:03:21 ON 11 FEB 2003
L8 0 S L7

FILE 'HCAPLUS' ENTERED AT 13:03:29 ON 11 FEB 2003
L9 15 S L7
L10 6 S L9 AND (BARBER ? OR COOK ? OR MAW ? OR PRYDE ? OR STOBIE ?)/A
L11 8 S L9 AND PFIZ?/PA,CS
L12 8 S L10,L11
L13 9 S L9 AND ?ENDOPEPTIDASE?
L14 9 S L9 AND ?ENDOPEPTIDASE?(L)NEUTRAL
L15 9 S L13,L14

FILE 'REGISTRY' ENTERED AT 13:05:41 ON 11 FEB 2003
L16 1 S 82707-54-8

FILE 'HCAPLUS' ENTERED AT 13:06:42 ON 11 FEB 2003
L17 1908 S L16
L18 1688 S NEPRILYSIN OR ENKEPHALINASE OR VASOPEPTIDASE OR ATRIOPEPTIDAS
L19 10 S L9 AND L17,L18
L20 10 S L15,L19
L21 15 S L9,L20

FILE 'USPATFULL, USPAT2' ENTERED AT 13:07:53 ON 11 FEB 2003
L22 8 S L7

FILE 'REGISTRY' ENTERED AT 13:08:12 ON 11 FEB 2003

FILE 'USPATFULL, USPAT2' ENTERED AT 13:08:29 ON 11 FEB 2003

FILE 'HCAPLUS' ENTERED AT 13:08:58 ON 11 FEB 2003

FILE 'REGISTRY' ENTERED AT 13:09:19 ON 11 FEB 2003

US 0989358509P1

Creation date: 22-07-2003
Indexing Officer: NTRAN2 - NGHI TRAN
Team: OIPEBackFileIndexing
Dossier: 09893585

Legal Date: 20-02-2003

No.	Doccode	Number of pages
1	CTNF	4
2	892	1

Total number of pages: 5

Remarks:

Order of re-scan issued on .....